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Background: Cerebral small vessel disease (SVD) causes substantial cognitive, 
psychiatric and physical disabilities. Despite its common nature, SVD pathogenesis 
and molecular mechanisms remain poorly understood, and prevention and treatment 
are probably suboptimal. Identifying the genetic determinants of SVD will improve 
understanding and may help identify novel treatment targets. The aim of this thesis is 
to better understand genetic associations with SVD through investigating its 
pathological, radiological and clinical phenotypes.  
Methods: To unravel the genetic associations with SVD, I used three 
complementary approaches. First, I performed a systematic review looking at 
existing intracerebral haemorrhage (ICH) classification systems and their reliability, 
to help inform future studies of ICH genetics. Second, I performed a series of 
systematic reviews and meta-analyses, investigating associations between genetic 
polymorphisms and histopathologically confirmed cerebral amyloid angiopathy 
(CAA). Third, I performed meta-analyses of existing genome-wide datasets to 
determine associations of >1000 common single nucleotide polymorphisms (SNP) in 
the COL4A1/COL4A2 genomic region with clinico-radiological SVD phenotypes: 
ICH and its subtypes, ischaemic stroke and its subtypes, and white matter 
hyperintensities. 
  
Results:  The reliability of existing ICH classification systems appeared excellent in 
eight studies conducted in specialist centres with experienced raters, although these 
existing systems have several limitations. In my systematic evaluation of CAA 
genetics, meta-analyses of 24 studies including 3520 participants showed robust 
evidence for a dose-dependent association between APOE ɛ4 and histopathological 
CAA. There was, however, no convincing association between APOE ɛ2 and 
presence of CAA in a meta-analysis of 11 studies including 1640 participants. Meta-
analyses of five studies including 497 participants showed, contrary to an existing 
popular hypothesis, that while APOE 4 may increase the risk of developing severe 
CAA vasculopathy, there is no clear evidence to support a role of ɛ2. There were few 
data about the role of APOE in hereditary CAA, but in the three studies that had 
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looked at this, there was no evidence for an association between APOE ɛ4 and CAA 
severity. There were too few studies and participants to draw firm conclusions about 
the effect of non-APOE ε2/ε3/ε4 genetic polymorphisms on CAA, but there were 
positive associations with TGF-β1, TOMM40 and CR1 genes in four studies. Finally, 
in my meta-analyses of the COL4A1/COL4A2 genomic region, three intronic SNPs 
in COL4A2 were associated with SVD phenotypes: significantly with deep ICH, and 
suggestively with lacunar ischaemic stroke and WMH.  
 
Conclusions: I have shown that while existing ICH classification systems appear to 
have very good reliability, further research is needed to determine their performance 
in different settings. For large population-based prospective studies of ICH genetics, 
anatomical systems are likely to be more feasible, scalable and appropriate, although 
they have limitations and will need to be further developed. Using systematic 
reviews and meta-analyses, I have confirmed a dose-related association between 
APOE ɛ4 and histopathological CAA, but also demonstrated that, despite popular 
acceptance, there is insufficient data to draw firm conclusions about the association 
with APOE ɛ2. I found some positive associations with CAA in other genes, which 
merit replication in further larger studies, and showed that there is currently 
insufficient data about the role of APOE in hereditary CAA. Finally, I identified a 
novel association between a locus in a known hereditary SVD gene – COL4A2 – and 
sporadic SVD. This highlights a new and successful approach for selecting candidate 
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1. Introduction 
 Cerebral small vessel diseases (SVDs) are common and cause substantial 
cognitive and physical disability  
 Cerebral amyloid angiopathy affects mainly superficial cortical and 
leptomeningeal small vessels, while arteriolosclerosis-associated SVD 
preferentially affects the deep perforating vessels 
 SVDs are influenced by many environmental and genetic factors and interactions 
between these, but their pathogenesis remains poorly understood 
 Studying genetic associations with SVDs will improve this understanding and 
may help identify novel treatment targets 
 Systematic review and meta-analysis methods can be used to study genetic 
association data in a meaningful way, though neither is a replacement for large 
robust genetic association studies 
 The aim of my work has been to better understand genetic associations with 
SVDs through investigating their pathological, radiological and clinical 
phenotypes through systematic review and meta-analysis methods 
1.1 Cerebral small vessel diseases 
1.1.1 Importance  
In the past 15 years cerebral small vessel diseases (SVDs) have been recognised as a 
serious problem with a high cost to society. They are very common and cause certain 
subtypes of stroke, as well as contributing to a substantial proportion of dementias. 
Since their pathogenesis and molecular mechanisms remain poorly understood, 
prevention and treatment are suboptimal (Wardlaw et al. 2013a) and it is an 
important area for further study.  
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1.1.2 Definition  
The term SVDs refers to a group of pathological processes with various aetiologies 
that affect the small vessels of the brain (Pantoni 2010). The definition of a cerebral 
small vessel has not been uniform amongst neuropathologists (Pantoni et al. 2006). A 
definition recently proposed, includes all small arteries and veins, arterioles, venules, 
and capillaries located in the brain parenchyma or in the subarachnoid space (Pantoni 
2010). Current standard neuroimaging techniques used in practice do not allow the 
direct visualization of small vessels. Therefore, brain parenchyma lesions thought to 
be caused by small vessel alterations have been adopted as the marker of SVDs, and 
SVDs have become a synonym of certain brain parenchyma lesions (Pantoni 2010). 
1.1.3 Classification  
Pantoni (2010) has proposed a simplified aetiopathogenic classification of cerebral 
SVDs, including six types: 
 Cerebral amyloid angiopathies (sporadic and hereditary);  
 Arteriolosclerosis-associated SVD; 
 Hereditary SVDs distinct from cerebral amyloid angiopathies;  
 Inflammatory and immunologically mediated SVDs (vasculitis); 
 Venous collagenosis; 
 Other SVDs (e.g., post-radiation angiopathy).  
The frequency of each of these SVD types varies considerably, with SVD due to 
sporadic cerebral amyloid angiopathy (CAA) and arteriolosclerosis-associated SVD 
being the two most common forms (Pantoni 2010). These two predominant SVD 
types are the focus of this thesis. Arteriolosclerosis-associated SVD is also known as 
non-amyloidogenic SVD and hypertensive SVD, but throughout the rest of this 
thesis, only the term arteriolosclerosis-associated SVD will be employed.  
Cerebral arterial small vessels have two origins. Superficially, they stem from the 
subarachnoid circulation as the terminal vessels of medium-sized arteries, which 
originate from larger arteries. Deeper, at the base of the brain, they stem directly 
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from the large vessels as arterial perforators. These two systems converge towards 
each other and merge in the deepest areas of the subcortical white matter where there 
is a watershed area. Different underlying processes can preferentially affect either the 
superficial vessels or the deep perforating vessels (Figure 1.1) – while SVD due to 
CAA affects mainly superficial cortical and leptomeningeal small vessels, 
arteriolosclerosis-associated SVD preferentially affects the deep perforating vessels 
(please see 1.1.7.3 for more discussion on this).  
Figure 1.1 Features of the arteriolar and capillary wall 
Reprinted from The Lancet Neurology “Mechanisms of sporadic cerebral small vessel disease: 
insights from neuroimaging” 2013:12:483-497, Wardlaw JM, Smith C, Dichgans M, with permission 
from Elsevier. 
1.1.4 Pathological features  
1.1.4.1 Pathological features of sporadic CAA  
The term amyloid describes highly insoluble fibrils composed of protein polymers 
consisting of proteins rich in a β-pleated sheet secondary structure. In CAA, amyloid 
fibrils deposit in the walls of arteries and arterioles – and less frequently in veins and 
capillaries – of cortical and leptomeningeal vessels. Amyloid-β peptide is by far the 
most common amyloid subunit implicated in sporadic CAA (Revesz et al. 2009). 
CAA deposition is progressive, initially occurring in the basement membranes in the 
tunica media of the blood vessel wall. In the early stages, the vessel wall structure 
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remains intact, but as the severity of CAA increases, there is a loss of smooth muscle 
cells as amyloid-β infiltrates all layers of the wall (Keable et al. 2015). Finally, 
severe vasculopathic changes are seen: splitting or “double barrelling” of the vessel 
wall; microaneurysm formation; fibrinoid necrosis; and perivascular leakage (Attems 
2005).  
Figure 1.2 Progression of CAA 
 
Mild: amyloid-β deposition in abluminal portions of the blood vessel wall; Moderate: abundant 
amyloid-β deposition in all layers of the blood vessel wall with loss of smooth muscle cells; Severe: 
blood vessel wall replaced by amyloid-β deposition, additional double barrelling and/or dyshoric 
changes (i.e. spread of amyloid-β into the surrounding synaptically dense brain areas composed 
mostly of unmyelinated axons, dendrites and glial cell processes). Reproduced from “Sporadic 
cerebral amyloid angiopathy: pathology, clinical implications, and possible pathomechanisms” in Acta 
Neuropathol 2005:110:345-359, Attems J, with permission of Springer.  
 
Severe CAA is visible as acellular thickening of blood vessel walls on haematoxylin- 
and eosin-stained tissue sections, although this appearance is non-specific, occurring 
also with arteriolosclerosis-associated small vessel disease (Attems 2005). Stains for 
amyloid-include Thioflavin S or T and Congo Red. In recent years, 
immunohistochemical stains for amyloid-have become more widely used because 
they offer greater standardisation and increase the specificity of diagnosis (Dickson 
2005).  
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Thal et al. (2002) have proposed that there are two different types of CAA: type-1 
involves amyloid-β deposits in every type of leptomeningeal and intracortical blood 
vessel (including capillaries), and type-2, which is similar, but the capillaries are not 
involved (Thal et al. 2002).  
1.1.4.2 Pathological features of arteriolosclerosis-associated SVD 
Arteriolosclerosis-associated SVD is characterised by a loss of smooth muscle cells 
from the tunica media, fibrinoid necrosis, deposits of fibro-hyaline material, 
narrowing of the lumen, and thickening of the vessel wall (Fisher 1965, Ogata et al. 
2014, Pantoni 2010).  
Fibrinoid refers to material consisting of exudated plasma protein and necrotic 
smooth muscle cells. It deposits segmentally and commonly occupies a portion of the 
vessel. Consequently mural or occlusive thrombus formation, aneurysmal dilatation 
and leakage of blood components through the disintegrated vessel wall can appear.  
Fibrinoid necrosis may precede hyalinosis, which involves degenerated collagen, 
smooth muscle cells and unspecified amorphous structures on electron microscopy. 
Fibrohyalinosis is used to describe arteries with thickened hyalinised walls that 
contain areas of fibrosis (Ogata et al. 2014).  
Other possible pathological features of this form of microangiopathy are 
microatheroma and microaneurysms (Fisher 1965, Ogata et al. 2014, Pantoni 2010). 
Microatheroma encompasses atherosclerotic changes and deposition of cholesterol 
crystals (Ogata et al. 2014). Microaneurysms were originally described by CharcÔt 
and Bouchard (Charcot and Bouchard 1868) and later by Miller Fisher in 1971. They 
are preferentially seen in the thalamus and basal ganglia in individuals with a deep 
intracerebral haemorrhage (Fisher 1971). The wall of the aneurysm lacks muscle or 
elastic tissue and sometimes shows fibrinoid necrosis.  
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1.1.5 Neuroimaging correlates  
The consequences of SVDs on the brain parenchyma are heterogeneous and depend 
on whether superficial cortical or deep arterial perforator vessels are affected 
(Pantoni 2010). They include ischaemic and haemorrhagic manifestations.  
1.1.5.1 Neuroimaging correlates of sporadic CAA  
The neuroimaging correlates of CAA include lobar intracerebral haemorrhages 
(ICHs), brain microbleeds and white matter hyperintensities (WMH) (Charidimou et 
al. 2012a). More recently recognised potential imaging correlates of CAA are 
cortical superficial siderosis, convexity subarachnoid haemorrhage (Charidimou et 
al. 2012a, Linn et al. 2008), silent cortical ischaemic lesions (Charidimou et al. 
2012a) and enlarged perivascular spaces (Charidimou et al. 2014).  
Brain microbleeds are small hypointense foci on T2* weighted haem-sensitive MRI 
sequences, histopathologically corresponding to focal accumulations of hemosiderin 
laden macrophages (Charidimou et al. 2012a, Fazekas et al. 1999). WMH are seen on 
MRI as confluent areas in the hemispheric white matter that appear hyperintense on 
T2-weighted and fluid-attenuated inversion recovery sequences. On CT, WMH 
appear as hypodense periventricular or subcortical areas (Pantoni 2010). Superficial 
siderosis refers to cortical linear deposits of hemosiderin on T2*-weighted MRI 
images. Convexity subarachnoid haemorrhage describes localised bleeding in up to 
several adjacent sulci, without other subarachnoid bleeding at the base of the brain in 
the pattern typically associated with saccular aneurysm rupture.  
1.1.5.2 Neuroimaging correlates of arteriolosclerosis-associated SVD 
The imaging correlates of arteriolosclerosis-associated SVD include: acute lacunar 
infarcts; deep ICHs; lacunes (fluid-filled cavities thought to show old infarcts, many 
clinically silent) (Wardlaw et al. 2013a); WMH (Rost et al. 2010); enlarged 
perivascular spaces (Doubal et al. 2010); brain microbleeds (Cordonnier et al. 2007); 
and brain atrophy (Aribisala et al. 2013).  
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Terminology for imaging features of SVD and protocols for image acquisition and 
analysis vary widely. This variation inhibits cross-study comparisons and is a barrier 
to research on risk factors, pathophysiology, pathological correlations and clinical 
consequences of these lesions. To address this obstacle, an international working 
group from the Centres of Excellence in Neurodegeneration has developed 
definitions and imaging standards for markers and consequences of SVD under the 
acronym STRIVE (Standards for ReportIng Vascular changes on nEuroimaging) 
(Wardlaw et al. 2013b).  They propose the following terms for neuroimaging features 
of SVD: (1) recent small subcortical infarcts; (2) lacune of presumed vascular origin; 
(3) white matter hyperintensity of presumed vascular origin; (4) perivascular space; 
(5) cerebral microbleed; (6) brain atrophy (Wardlaw et al. 2013b).  
It has been suggested that a total SVD burden score may better capture the overall 
effects of SVD on the brain in comparison with only considering one or two 
individual features separately, but further testing of this score is required 
(Klarenbeek et al. 2013, Staals et al. 2014).   
1.1.5.3 Shared manifestations  
WMH are considered a radiological marker of arteriolosclerosis-associated SVD 
(Grinberg and Thal 2010, Rost et al. 2010, van Swieten et al. 1991). WMH are 
probably also a radiological marker of CAA (Charidimou et al. 2012a, Smith et al. 
2010), however studies that have examined the relationship between CAA and white 
matter ischaemia at the pathological level in humans are limited (Esiri et al. 2015). 
There is some evidence to suggest a more posterior WMH distribution in association 
with CAA, compared to WMH in arteriolosclerosis-associated SVD. This is possibly 
explained by the CAA vascular pathology being more abundant in posterior regions 
of the brain, but needs confirmation in larger prospective studies (Zhu et al. 2012, 
Thanprasertsuk et al. 2014).   
Enlarged perivascular spaces and brain microbleeds are other shared markers of 
different SVDs. Some evidence suggests that the location of enlarged perivascular 
spaces predominantly in the white matter and centrum semiovale region may be 
associated with CAA, while basal ganglia region enlarged perivascular spaces may 
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be a marker of arteriolosclerosis-associated SVD (Charidimou et al. 2014, 
Charidimou et al. 2013, Doubal et al. 2010, Martinez-Ramirez et al. 2013, Roher et 
al. 2003). Similarly, it has been suggested that the location of brain microbleeds may 
differ between CAA and arteriolosclerosis-associated SVD, with strictly lobar 
microbleeds being more suggestive of CAA (Charidimou et al. 2012a, Greenberg et 
al. 1999, Greenberg et al. 2009, Knudsen et al. 2001, Vernooij et al. 2008).  
Another emerging feature of SVDs visible at higher MRI field strengths includes 
microinfarcts (Smith et al. 2012, Wardlaw et al. 2013a). Microinfarcts are mainly a 
pathological finding defined as sharply delimited microscopic regions of cellular 
death or tissue necrosis, sometimes with cavitation. They are distinct from small 
infarcts and lacunes and are undetectable on gross pathological examination or 
conventional structural MRI (Smith et al. 2012). Cortical microinfarcts have been 
associated with CAA (Haglund et al. 2006), while subcortical microinfarcts have 
been suggested as a potential marker of arteriolosclerosis-associated SVD (Smith et 
al. 2012).  
1.1.6 Clinical manifestations  
Clinical manifestations of SVD range from none to discrete focal neurological 
symptoms (e.g., stroke), to insidious global neurological dysfunction and dementia. 
1.1.6.1 Ischaemic and haemorrhagic symptomatic stroke 
SVDs are associated with ischaemic strokes and ICH, reflecting the distribution of 
the underlying microangiopathy. SVD due to CAA is associated mainly with (often 
multiple) lobar ICHs preferentially affecting the occipital and temporal lobes 
(Charidimou et al. 2012a, Samarasekera et al. 2012, Wardlaw et al. 2013a), while 
arteriolosclerosis-associated SVD manifests clinically as lacunar ischaemic strokes 
and deep subcortical and infratentorial ICHs.   
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1.1.6.2 Classification of stroke subtypes 
Risk factors (including genetic risk factors), causal pathways, investigations, 
management and prognosis probably differ between stroke subtypes. Hence studies 
need to use classification systems that distinguish stroke subtypes accurately.  
Existing ischaemic stroke classification systems are ‘anatomical’ or ‘mechanistic’. 
The Oxfordshire Community Stroke Project classification (OCSP) is the most widely 
used anatomical system and predicts infarct site and size (Bamford et al. 1991). 
Mechanistic classification systems can be either ‘single cause’, assigning the single 
most likely stroke mechanism (e.g., TOAST [the Trial of Org 10172 in Acute Stroke 
Treatment] (Adams et al. 1993), CCS [Causative Classification] (Ay et al. 2005) or 
ASCO1 [Atherosclerosis-Small artery occlusion-Cardiac Embolism-Other-1] 
(Amarenco et al. 2009)), or ‘descriptive’ (e.g., the A-S-C-O or ‘phenotypic CCS’ 
systems (Arsava et al. 2010)), describing the contribution of each mechanism to the 
stroke.  
Existing intracerebral haemorrhage (ICH) classification systems are also 
‘anatomical’ or ‘mechanistic’. Anatomical systems classify haemorrhages according 
to their anatomical origin or location as lobar, deep, infratentorial, intraventricular, 
and various combinations or modifications of these. Mechanistic systems integrate 
this anatomical information with clinical symptoms, signs and investigations, to 
assign a subtype based on presumed mechanism. Commonly used categories include 
hypertension, CAA, anticoagulation and structural causes. The only clearly 
structured, published, mechanistic system for ICH is SMASH-U (Structural lesion, 
Medication, Amyloid angiopathy, Systemic/other disease, Hypertension, 
Undetermined) (Meretoja et al. 2012).  
An ideal classification system for large-scale research use, including for studies of 
stroke genetics, would assign the maximum number of cases to determined, valid 
subtypes, without sacrificing reliability or accuracy, and would be applicable in a 
range of different clinical settings. A recent systematic review explored existing 
ischaemic stroke classification systems, assessed their reliability, and made 
recommendations for future studies for classifying ischaemic stroke (Woodfield et al. 
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2013). However, to my knowledge, no such study assessing existing ICH 
classification systems exists.  
1.1.6.3 Other clinical manifestations of SVD 
Arteriolosclerosis-associated SVD causes substantial cognitive, psychiatric, and 
physical disabilities and contributes to up to 45% of dementias (Wardlaw et al. 
2013a). There is increasing evidence that CAA is also an important contributor to 
cognitive impairment. In addition, SVD due to CAA is associated with transient 
neurological episodes called “amyloid spells”, the prevalence of which in a recent 
multicentre CAA cohort (diagnosed using the Boston criteria) was 14% (Charidimou 
et al. 2012b). Finally, CAA is associated with rapidly progressive cognitive and 
neurological decline in the context of CAA-related inflammation, which typically 
affects older adults who present with acute to subacute cognitive decline, headache, 
behavioural change, seizures and focal neurological deficits (Charidimou et al. 
2012a).   
1.1.7 Pathogenesis  
The pathogenic mechanisms linking the pathology of small vessels with the 
consequent parenchymal changes are largely unknown and likely very complex. 
Pathology often shows end-stage disease which makes identification of the earliest 
stages difficult (Wardlaw et al. 2013a). It is known that there are striking changes in 
small arteries and arterioles, summarised by the loss of smooth muscle cells and the 
replacement of wall constituents by other materials (e.g. collagen, amyloid, or 
hyaline material). The vessel lumen is restricted or dilated and the general 
architecture of the vascular tree disrupted with increased vessel tortuosity, elongation 
and formation of aneurysmal sacs. The probable subsequent mechanisms leading to 
the brain parenchymal damage are:  
 reduced or dysregulated blood flow, which if focal and severe may lead to 
small infarcts; 
 some areas suffer from chronic ischaemia causing selective damage to 
certain cell populations, rather than tissue pan-necrosis; 
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 vessel walls rupture and cause parenchymal haemorrhage;  
 changes in small vessels lead to damage of the blood-brain barrier, which 
leads to extravasation of fluids and different molecules into the brain 
parenchyma.  
The precise mechanisms leading from the vessel wall damage to supposedly 
ischaemic parenchymal insults remain unknown at present, as local thrombosis has 
not been documented and other possible mechanisms such as local vasospasm or 
lumen occlusion without thrombosis are difficult to prove. It is possible that 
thrombosis is a late secondary phenomenon, triggered by the disrupted arteriolar 
endothelium. Thickened stiffened arterioles may have impaired autoregulatory 
ability, and contribute further to brain damage through reduced ability to vasodilate 
when required. Both of these late-stage consequences could be superimposed on the 
background initiating process of endothelial failure. Besides ischaemia and blood-
brain barrier dysfunction, other mechanisms to link the pathologic changes of small 
vessels to parenchymal damage have been proposed, such as venous dysfunction, 
increased arterial pulsatility and apoptosis. It is possible that these mechanisms are 
not mutually exclusive and act contemporaneously (Pantoni 2010, Wardlaw and 
Pantoni 2014, Wardlaw et al. 2013a).  
Grinberg and Thal have put forward a theory suggesting arteriolosclerosis-associated 
SVD may exacerbate CAA by impairing perivascular clearance of amyloid-β. 
Proposed mechanisms include: (a) fibrosis of the vessel wall decreases the capacity 
for drainage of amyloid along the basement membranes, (b) increasing stiffness of 
the affected vessels leads to cessation of pulsation and a less effective outward 
transport of the perivascular fluid, (c) arteriolosclerosis-associated SVD induced 
leakage of plasma proteins into the vessel wall and the perivascular space competes 
for perivascular drainage of amyloid (Grinberg and Thal 2010). 
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1.1.7.1 Pathogenesis of sporadic CAA  
Factors that initiate or promote amyloid-β deposition in sporadic CAA are not fully 
understood. However, research based on mouse models has provided valuable 
insights into its pathogenesis. It is thought that most vascular amyloid-β is derived 
from neurons (Herzig et al. 2006). CAA is likely to result from reduced amyloid-β 
clearance (rather than overproduction) through perivascular lymphatic drainage 
pathways in the brain (Weller et al. 2008). Theoretical models suggest that vessel 
pulsations supply the force for perivascular drainage of interstitial fluid and solutes. 
As arteries stiffen with age, the amplitude of pulsations is reduced and insoluble 
amyloid-β is deposited in the drainage pathways as CAA, thus further impeding the 
drainage of soluble amyloid-β (Charidimou et al. 2012a, Weller et al. 2008).  
1.1.7.2 Pathogenesis of arteriolosclerosis-associated SVD 
Though arteriolosclerosis-associated SVD is typically thought of as an age-related 
hypertensive vasculopathy, the association between vascular risk factors and SVD is 
still not completely understood (Wardlaw et al. 2013a). While exposure to vascular 
risk factors, particularly hypertension, will probably accelerate the vessel damage 
(Wardlaw and Pantoni 2014), epidemiological studies indicate that patients with 
lacunar stroke are equally likely to have a history of hypertension, diabetes, 
hypercholesterolaemia and smoking as are patients with non-lacunar ischaemic 
stroke (Jackson and Sudlow 2005, Jackson et al. 2010).   
1.1.7.3 Differing structure of cortical and deep arteries 
CAA affects mainly superficial cortical and leptomeningeal vessels (Ogata et al. 
2014) which may be at least partly explained by the differing structures of the walls 
of cortical and deep arteries. Cortical arteries have only one leptomeningeal layer, 
and therefore lack the expandable perivascular space, which may make them more 
vulnerable to deposition of amyloid-β which cannot be drained (Figure 1.1). In 
contrast, deep arteries have a double layer of leptomeninges which can function as an 
expandable perivascular space (Pollock et al. 1997, Zhang et al. 1990).  
Chapter 1. Introduction  40 
 
Arteriolosclerosis-associated vasculopathy occurs mainly in the basal grey matter, 
pons and cerebellum (Ogata et al. 2014). The endothelial tight junctions are tightest 
in capillaries, in which the barrier function is most important, and looser in arteriolar 
and venular endothelium. The hypothetical consequence of this is that the effects of 
endothelial failure are seen earlier in larger proximal perforating arterioles than in the 
smaller capillaries. This difference could lead to differential development of 
proximal arteriolar disease and lacunar infarcts in the basal ganglia before more 
diffuse white matter hyperintensities in the centrum semiovale develop (in which 
tissue is served by smaller arterioles and capillaries).  
1.1.8 Diagnosis  
The reference standard for the diagnosis of CAA is pathological confirmation using 
biopsy or autopsy specimens (Charidimou et al. 2012a). Since patients with ICH may 
not undergo surgery or autopsy, the Boston criteria have been developed for an ante-
mortem diagnosis of CAA. These criteria categorise ICH as definite, probable or 
possible CAA-related ICH by using pathological findings if available, radiographic 
features such as multiple ICHs or brain microbleeds, and clinical features such as the 
absence of coagulopathy (Knudsen et al. 2001). The Boston criteria were validated in 
a selected sample of 39 participants at a tertiary referral centre and their sensitivity 
for detection of CAA was 45% (95% confidence intervals [CI] 28-62%) and 
specificity 100% (95% CI 77-100%) (Knudsen et al. 2001). However, the number of 
neuropathological samples viewed per brain and their locations is unclear, which 
may influence the likelihood of finding other pathologies in the brain and 
determining the relative contribution of each to the ICH. More recently modified 
Boston criteria have been proposed, that include superficial siderosis in the 
radiological features, but this has not been shown to significantly increase their 
sensitivity (Linn et al. 2010). An important limitation for the use of the Boston 
criteria in population-based studies of ICH is that MRI is often unavailable or not 
tolerated.  
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To my knowledge, no specific criteria exist for the diagnosis of arteriolosclerosis-
associated SVD, and the diagnosis is made based on typical radiological and clinical 
findings.   
1.1.9 Hereditary forms  
Monogenic or hereditary SVDs are caused by highly penetrant mutations in a single 
gene. In some of these disorders cerebral SVD is the main manifestation, in others 
SVD is part of a wider phenotypic spectrum (Opherk and Dichgans 2014).  
1.1.9.1 Hereditary CAAs 
Amyloid-β peptide is by far the most common amyloid subunit implicated in 
sporadic forms of CAA and Alzheimer’s disease (AD). Amyloid-β CAA is also 
prominent in variants of familial AD due to mutations of the amyloid precursor 
protein (APP), presenilin-1 (PSEN1) or presenilin-2 (PSEN2) genes and in several 
forms of hereditary CAA (HCAA) due to mutations in the APP gene.  
A number of other proteins may also be involved in rare familial diseases in which 
CAA is a characteristic morphological feature. These latter proteins include (Revesz 
et al. 2009):  
 ABri and ADan subunits in BRI2 gene-related familial British and familial 
Danish dementia; 
 variant cystatin C in cystatin C gene-related Hereditary Cerebral 
Haemorrhage with Amyloidosis-Icelandic type; 
 variant transthyretins in TTR gene-related meningo-vascular amyloidosis; 
 disease-associated prion protein (PsPSc) in PRPN gene-related hereditary 
prion disease with premature stop codon mutations; 
 mutated gelsolin (AGel) in gelsolin gene-related familial amyloidosis of 
Finnish type. 
In the case of these rare familial diseases, in addition to the central nervous system, 
vascular deposits of the pathological protein can often be found in a variety of 
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peripheral tissues and systemic organs (Opherk and Dichgans 2014, Revesz et al. 
2009). 
1.1.9.2 Hereditary non-CAA SVDs 
Currently mutations in at least seven genes (NOTCH3, HTRA1, TREX1, CECR1, 
GLA, COL4A1 and COL4A2) are known to cause rare familial forms of non-CAA 
SVD:  
 NOTCH3 mutations cause cerebral autosomal dominant arteriopathy with 
subcortical infarcts and leukoencephalopathy (CADASIL) (Chabriat et al. 
2009);  
 HTRA1 mutations are associated with cerebral autosomal recessive 
arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) 
(Hara et al. 2009); 
 TREX1 mutations cause retinal vasculopathy with cerebral leukodystrophy 
(RVCL) (Kavanagh et al. 2008); 
 CECR1 mutations cause deficiency of adenosine deaminase 2 (DADA2) 
(Zhou et al. 2014); 
 GLA mutations cause Fabry’s disease (Opherk and Dichgans 2014); 
 COL4A1 and COL4A2 mutations cause hereditary angiopathy with 
nephropathy, aneurysms, and muscle cramps (HANAC) and other 
syndromes (Lanfranconi and Markus 2010, Opherk and Dichgans 2014).  
One emerging view is that these familial SVDs are united by similar disease 
mechanisms involving perturbation of the cerebrovascular matrisome (i.e. the 
ensemble of proteins constituting the extracellular matrix as well as the associated 
proteins), which could be a convergent pathway that drives the functional and 
structural alterations of small brain vessels and disease manifestations, and that 
similar mechanisms could also play a role in sporadic disease (Joutel et al. 2015).   
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1.2 Studying genetic associations of complex 
disease 
Common complex diseases, such as stroke and cerebral small vessel disease, are 
influenced by many environmental and genetic factors, and interactions between 
these. Studying genetic associations with complex diseases is important, because a 
substantial proportion of individual differences in disease susceptibility are known to 
be due to genetic factors. Understanding these may contribute to better prevention, 
diagnosis and treatment of the disease (Manolio et al. 2009).  
Studies of rare monogenic disorders and common complex diseases have supported 
the correlation between variant frequency and effect size, whereby rare variants tend 
to associate with large and often deleterious effects, while common variants are more 
likely to have subtle effects on disease susceptibility (Figure 1.3). The relative 
impact of common and rare variants on common complex diseases remains an 
unanswered question (Gibson 2011, Manolio et al. 2009). 
There are two principle approaches to the identification of disease genes: linkage 
analysis and association studies. Linkage analysis relies on the coinheritance of loci 
that lie near each other on the same chromosome. As a consequence, linkage studies 
require DNA and clinical information from more than one family member. This 
approach has been used successfully in monogenic disorders, but there are a number 
of challenges to its application in complex diseases (Dichgans and Markus 2005). 
These include low power of tests of linkage for genes of modest effect and 
assembling sufficient number of families (Risch and Merikangas 1996). While some 
genes of small effect could be uncovered by linkage analysis, it would be necessary 
to collect and analyse samples of 'unrealistic' size, to achieve adequate statistical 
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Figure 1.3 Feasibility of identifying genetic variants by risk allele frequency and strength of 
genetic effect (odds ratio) 
  
Most emphasis and interest lies in identifying associations with variants shown within diagonal dotted 
lines. Reprinted with permission from Macmillan Publishers Ltd: “Finding the missing heritability of 
complex diseases”, Manolio et al, Nature 2009;461:747-753.  
 
Association studies compare the frequency of specific DNA sequence variants in 
groups of individuals in a case-control design. An allele is said to be associated with 
disease if its frequency differs between cases and controls more than is expected by 
chance. For complex traits, association studies are generally considered to be more 
efficient than linkage studies because they have greater statistical power to detect 
several genes of small effect (Dichgans and Markus 2005, Risch and Merikangas 
1996).   
Association studies can use an a priori hypothesis-driven candidate-gene approach, 
or hypothesis-free genome-wide association study (GWAS), whole exome 
sequencing or whole genome sequencing approaches. Rather than relying on markers 
throughout the genome without regard to their function or context in a specific gene, 
candidate-gene studies focus on genes that are selected because of a priori 
hypotheses about their aetiological role in disease. Two important criticisms of this 
study design are the failure to replicate significant findings from many candidate-
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gene studies and its dependence on the ability to predict functional candidate genes 
and polymorphisms (Tabor et al. 2002). GWAS studies allow examination of mostly 
common single nucleotide polymorphisms (SNPs) (minor allele frequency ≥1-5%) 
across the genome, but miss rare variation. In addition, variants identified by GWAS 
are not usually the causative variants themselves, but rather in linkage disequilibrium 
with the causative variant (Hirschhorn and Daly 2005). While GWAS studies 
primarily make use of markers that are intended to represent causal variation 
indirectly, whole exome sequencing and whole genome sequencing approaches can 
directly identify the causal (rare and common) variants. This is the central advantage 
of sequencing approaches over standardised GWAS panels, especially because 
complex diseases could be influenced by fairly infrequent variants in many different 
genes. However, despite the promise of next generation sequencing, the challenge is 
in appropriately analysing and interpreting the resulting sequencing data. For GWAS 
studies, a simple single statistical threshold to report significance between a given 
polymorphism and phenotype (p <5x10
-8
) has been derived based on the principle 
that it needs to account for the number of possible independent statistical tests with 
equal prior probabilities of true association with the phenotype (Goldstein et al. 
2013). The same type of solution is not applicable to sequence data, as it reveals 
inherently different categories of variants that cannot be viewed as all having the 
same probability of influencing the disease, and treating them as such would 
constitute too great a cost in terms of power.  Exome-sequencing data are based on 
the idea that mutations influencing human disease are more likely found in the 
coding sequence than elsewhere. Nonetheless, there is currently too little information 
about the full distribution of functional consequences of different variants in the 
human genome to allow simple quantitative assumptions to be applied to the variants 
in a universal fashion (Goldstein et al. 2013).  
1.3 Systematic review and meta-analysis for studying 
genetic associations 
A systematic review attempts to collate all empirical evidence that fits pre-specified 
eligibility criteria in order to answer a specific research question. It uses systematic 
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methods selected with a view to minimizing bias, thus providing more reliable 
findings from which conclusions can be drawn (The Cochrane Collaboration 2011). 
Many systematic reviews contain meta-analyses. Meta-analysis uses quantitative 
methods for combining results of different studies on the same research question, 
thus increasing statistical strength and precision. It also measures and tries to explain 
the extent of inconsistency across the included studies. Both can be very useful tools 
in understanding the genetics of complex diseases, provided they are appropriately 
applied and interpreted.  
Genetic association studies of candidate genes have shown that a substantial 
proportion of initial positive results cannot be replicated in subsequent studies, 
suggesting possible false-positive results. Equally, results may be false-negative with 
small genetic effects remaining undetectable (Ioannidis 2003). Meta-analysis 
combining data from several candidate-gene studies may help separate true effects 
from false. Meta-analysis has also become popular for synthesis of data from GWAS 
studies, given that most genetic effects are small and require the coalition of many 
teams to generate large-scale evidence. However, like any research design, meta-
analysis has strengths but also weaknesses (Kavvoura and Ioannidis 2008).  
Ideally, meta-analysis should be prospective, including all data that fulfil pre-set 
quality criteria. However if it is retrospective, pertinent data should be retrieved in an 
unbiased way, such as by use of systematic review methods. This should include 
searching for all relevant studies from appropriate databases and considering 
including unpublished data and non-English literature where possible (Kavvoura and 
Ioannidis 2008). The validity of including unpublished data that has not passed peer-
review can be questioned, however the peer-review filter may be imperfect and there 
is some evidence to suggest that inclusion of unpublished data may lead associations 
to lose their statistical significance, suggesting that the published literature is shaped 
by selective reporting biases (Kyzas et al. 2005).  
The reliability of meta-analysis is affected by the reliability of the included data. 
Hence the data should be examined for potential errors and biases, and these should 
be carefully recorded. Biases can be broadly divided into study-specific and field-
wide biases. Study-specific biases include: selection bias (e.g. differential selection 
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of cases and controls creating unequally representative groups within study 
populations); information bias (e.g. poor quality control measures for genotyping and 
phenotype misclassification); and confounding (e.g. population stratification when 
the total population has been formed by admixture between subpopulations and 
admixture proportions vary between cases and controls). Field-wide biases include 
publication bias (preference to publish studies with “positive” findings i.e. 
statistically significant results) and reporting bias (when investigators publish only a 
subset of the analyses they have conducted with preference to most impressive 
results) (Kavvoura and Ioannidis 2008). 
Some of the heterogeneity across studies may be explained by the errors and biases 
mentioned above, however there may also be genuine diversity in the genetic effects 
across studies. It is important to explore this and to use appropriate statistical 




). The chi-squared (
2
) 
test assesses whether observed differences in results are compatible with chance 
alone. A low p value of the 
2 
test or a large 
2 
statistic relative to its degree of 
freedom provides evidence of heterogeneity. It has low power when there are few 
studies and/or studies have a small sample size. Hence while a statistically significant 
result may indicate a problem with heterogeneity, a non-significant result must not be 
taken as evidence of no heterogeneity (The Cochrane Collaboration 2011). Some 
argue that since clinical and methodological diversity always occur in a meta-
analysis, heterogeneity will always exist whether or not it can be detected using a 
statistical test (Higgins et al. 2003). Methods have been developed for quantifying 
inconsistency across studies that move the focus away from testing whether 
heterogeneity is present to assessing its impact on the meta-analysis. A useful 






percentage of the 
variability in effect estimates that is due to heterogeneity rather than chance (The 
Cochrane Collaboration 2011). 
The fixed- and/or random-effects model should be chosen as appropriate (Kavvoura 
and Ioannidis 2008). It is generally recommended to use the fixed-effects method 
when the underlying assumption is that the true allele effect is the same in all studies 
included in the meta-analysis, and to use the random-effects method when the 
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underlying assumption is that the true allele effect is different in the included studies 
(Borenstein et al. 2010). When no heterogeneity exists, both models show similar 
effect sizes. 
A number of diagnostics have been proposed to try and assess the robustness of 
summary results and explore heterogeneity. Sensitivity analyses (excluding specific 
studies) are a simple way of examining if the summary results and estimated 
heterogeneity depend on specific studies with possible errors, biases or special 
features. Meta-regression relates the effect size to one or more characteristics of the 
studies that may explain heterogeneity, but the covariates should be pre-specified and 
few (Thompson and Higgins 2002). There are several tests to explore potential 
publication bias (e.g. funnel plot asymmetry, “trim and fill”), however researchers 
need to be careful not to over-interpret and over-simplify their results. For example, 
significant results in asymmetry tests do not mean that publication bias is certain, 
because there are many other reasons why small studies may yield different results 
from larger ones. Equally, non-statistically significant results or a symmetrical funnel 
plot on visual inspection do not exclude publication bias. However, demonstration of 
small-study effects should lead to caution in interpreting summary results (Kavvoura 
and Ioannidis 2008). Finally, the potential effect of unpublished negative studies or 
studies not reporting the data required for meta-analysis (i.e. publication and 
reporting biases) can be assessed using a modified ‘failsafe N’ method. This method 
involves determining the size of a notional study with a null result required to bring 
any significant result to a just non-significant level (Rosenthal 1979).  
Overall, while systematic reviews and meta-analyses are not suitable replacements 
for large robust genetic association studies, they provide useful additional tools to 
allow examination of data in a way that is both meaningful and less susceptible to 
bias than narrative reviews.  
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1.4 Known genetic associations with sporadic 
cerebral small vessel disease 
Heritability is a measure indicating the proportion of variation in phenotype in a 
population explained by genetic factors. Traditionally, heritability has been assessed 
by studying related individuals. Family-based studies have demonstrated that WMH 
are highly heritable, with heritability measures ranging from 50% to 80% (Haffner et 
al. 2015, Opherk and Dichgans 2014). In clinically evident stroke, however, family-
based studies are difficult to apply because of the relatively late age of onset and high 
case fatality. Therefore an alternative way of measuring heritability by using 
genome-wide complex trait analysis of GWAS data has been applied. This method 
allows calculation of the proportion of phenotypic variance explained by common 
genetic variants present on GWAS genotyping arrays. Using genome-wide complex 
trait analysis, the heritability of WMH volume in ischaemic stroke cases is estimated 
to be 21% (Adib-Samii et al. 2015). Lacunar ischaemic stroke heritability ranges 
from 16% to 25%, depending on the exact method used to measure heritability and 
the definition of lacunar stroke (TOAST classification versus MRI-defined) (Bevan 
et al. 2012, Traylor et al. 2015). Lobar ICH heritability is 73% (48% for non-APOE 
loci) and the respective deep ICH heritability is 34% (30% for non-APOE loci) 
(Devan et al. 2013). The discrepancy between high heritability estimates for WMH 
obtained in twin and family history studies and relatively low estimates derived from 
genome-wide complex trait analysis might indicate that much of the genetic 
contribution to SVD is because of rare genetic variants (Haffner et al. 2015). Also, 
this narrow-sense heritability does not capture gene-environment interactions or 
gene-gene interactions (denoted as broad-sense heritability).  
Most genetic studies of SVD rely on either its radiological or clinical markers, or 
both, and none of these are specific for SVD. Also, the majority of studies have 
focused on individual markers of SVD rather than considering multiple markers in 
aggregate. In practice, large sample sizes are often used to “compensate” for the 
limited specificity of individual disease markers (Haffner et al. 2015). 
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So far, data about SVD genetic associations come from candidate-gene and GWAS 
studies, as no large whole exome or whole genome sequencing studies have been 
conducted.  
White matter hyperintensities 
GWAS of WMH burden in stroke-free individuals from the Cohorts for Heart and 
Aging Research in Genomic Epidemiology consortium (CHARGE) revealed a risk 
locus on chromosome 17q25, where two lead SNPs belong to a cluster containing 
several genes (TRIM65, TRIM 47, WBP2, MRPL38, FBF1, ACOX1) (Fornage et al. 
2011). A more recent multi-ethnic GWAS in stroke-free individuals replicated this 
locus and identified four novel loci associated with WMH burden: chromosome 
10q24 (PDCD11, NEURL, SH3PXD2A, TAF5, CALHM1); chromosome 2p21 
(HAAO, THADA); chromosome 1q22 (PMF1); and chromosome 2p16 (EFEMP1) 
(Verhaaren et al. 2015).  The 17q25 locus was also associated with WMH burden in 
ischaemic stroke cases but not with lacunar stroke, indicating that it acts through 
mechanisms more specific for the pathogenesis of WMH rather than SVD in general 
(Adib-Samii et al. 2013). 
In a more recent GWAS of WMH burden in ischaemic stroke cases, there were no 
associations at genome-wide significance (Traylor et al. 2016). However in a 
subsequent meta-analysis including both stroke-free individuals and ischaemic stroke 
cases, six independent loci were significantly associated with WMH burden, four of 
these novel associations: rs72934505 (NBEAL1), rs941898 (EVL), rs962888 
(C1QL1), rs9515201 (COL4A2) (Traylor et al. 2016). This suggests that some 
genetic associations with WMH burden are shared in stroke-free individuals and 
patients with stroke. 
Many candidate-gene studies have attempted to find associations with WMH. These 
have been summarised in a systematic review and series of meta-analyses, which 
concluded that while numerous genes have been evaluated, there was no convincing 
evidence for an association with WMH. There did appear to be an association with 
an insertion/deletion polymorphism in the ACE gene, but this may have been due to 
small-study and other biases (Paternoster et al. 2009). A more recent systematic 
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review and meta-analysis specifically looking at the APOE gene demonstrated that 
both APOE ɛ4 and ɛ2 are associated with WMH burden (Schilling et al. 2013). 
Finally, variants in the NOTCH3 gene were reported to be associated with WMH 
burden in a community-dwelling elderly cohort (Schmidt et al. 2011), but a more 
recent study in ischaemic stroke cases has not replicated this signal (Rutten-Jacobs et 
al. 2015).  
Lacunar stroke 
Although GWAS studies in ischaemic stroke patients have identified several loci for 
large artery and cardioembolic stroke, until recently, no GWAS significant loci for 
lacunar stroke have been demonstrated. This may be at least partly explained by 
insufficient sample size, sample heterogeneity and lack of robust standards for 
classifying patients as having a lacunar stroke. In the more recently published 
ischaemic stroke GWAS performed by the International Stroke Genetics Consortium 
and NINDS Stroke Genetics Network (SiGN), the 12q24.12 locus near ALDH2, 
which has been associated with all ischaemic stroke previously, exceeded genome-
wide significance in the meta-analysis of lacunar stroke (NINDS Stroke Genetics 
Network (SiGN) and International Stroke Genetics Consortium (ISGC) 2015).  
Candidate-gene studies have provided some evidence to suggest that a SNP in 
PRKCH, which is monomorphic in the European population, may be a risk locus for 
lacunar stroke exclusively in the Asian population (Kubo et al. 2007).  The PRKCH 
locus has also been associated with subcortical silent brain infarcts and cerebral 
haemorrhage in the Chinese (Wu et al. 2009) (Haffner et al. 2015, Serizawa et al. 
2008).   
Brain microbleeds 
To my knowledge, no GWAS of brain microbleeds has been published. A systematic 
review looking at genetic associations with brain microbleeds found that only the 
APOE ε2/ε3/ε4 polymorphism had been studied in >100 people. Meta-analyses 
showed a significant association between the ε4 allele and presence of brain 
microbleeds, especially in a strictly lobar location (Maxwell et al. 2011). This has 
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been confirmed by a more recent systematic review and meta-analysis (Schilling et 
al. 2013).  
Intracerebral haemorrhage 
ICH GWAS has identified a susceptibility locus for non-lobar ICH on chromosome 
1q22 (lead SNP rs2984613), that overlaps with the SLC25A44 and PMF1 genes 
(Woo et al. 2014). Although not GWAS significant, the same 1q22 locus showed a 
trend towards association with WMH in stroke-free individuals (Fornage et al. 2011).  
Candidate-gene studies have shown that APOE ε2 and ε4 alleles are associated with 
lobar ICH (Biffi et al. 2010). In addition, rare mutations in COL4A1 and COL4A2 
have recently been shown to be associated with sporadic ICH (Jeanne et al. 2012, 
Schmidt et al. 2011, Weng et al. 2012). Finally, several variants within a larger set of 
oxidative phosphorylation genes were collectively associated with increased risk of 
both lacunar stroke and deep ICH (Anderson et al. 2013).  
1.5 Aims of the thesis 
Cerebral small vessel disease is very common, causing substantial cognitive, 
psychiatric and physical disabilities, and its cost to society is huge. Although 
substantial progress has been made in elucidating the molecular, cellular, and 
physiologic mechanisms underlying SVD, its pathogenesis still remains largely 
unknown. Understanding genetic associations with SVD may contribute to better 
understanding of its pathogenesis, and ultimately to prevention, diagnosis and 
treatment (Haffner et al. 2015, Wardlaw et al. 2013a). The aim of my work has been 
to better understand genetic associations with SVD phenotypes. In pursuit of this 
aim, the objectives of the work described in this thesis are:  
 To perform a systematic review looking at the inter- and intra-rater 
reliability of existing ICH classification systems, to inform ICH subtyping in 
future large-scale prospective studies of ICH, including of ICH genetics 
(Chapter 2). 
Chapter 1. Introduction  53 
 
 To perform a systematic review and series of meta-analyses to assess the 
evidence for an association between the APOE ɛ2/ɛ3/ɛ4 polymorphism and 
histopathologically confirmed CAA (Chapter 3).  
 To perform a systematic review and series of meta-analyses to assess the 
evidence for an association between the APOE ɛ2/ɛ3/ɛ4 polymorphism and 
progression to severe CAA vasculopathy (Chapter 4).  
 To perform a systematic review to assess the evidence for an association 
between the APOE ɛ2/ɛ3/ɛ4 polymorphism and CAA severity in brain 
pathology samples of cases with genetically proven hereditary CAA 
(Chapter 5).  
 To perform a systematic review to assess the evidence for an association 
between any (non-APOE ɛ2/ɛ3/ɛ4) genetic polymorphism and 
histopathologically confirmed CAA (Chapter 6).  
 To conduct meta-analyses of existing GWAS data to determine if there is an 
association between common SNPs in the COL4A1/COL4A2 genomic region 
and clinical / radiological manifestations of SVD (Chapter 7).  
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2. Reliability of intracerebral haemorrhage 
classification systems 
 Accurately distinguishing  ICH subtypes is important since they may have 
different risk factors, causal pathways, management and prognosis 
 Existing ICH classification systems are ‘anatomical’ or ‘mechanistic’ 
 An ideal classification system for sub-classifying ICH in large, population-based, 
prospective studies (including studies of ICH genetics) would assign the 
maximum number of cases to determined, valid subtypes without sacrificing 
reliability or accuracy, and be applicable in different clinical settings 
 In this chapter I present my systematic review looking at existing ICH 
classification systems and their inter- and intra-rater reliability  
 I used a comprehensive search strategy, critically appraised study quality, and 
assessed potential bias and factors affecting reliability 
 I conclude that the reliability of existing classification systems appears excellent, 
but is unknown outside specialist centres with experienced raters 
2.1 Introduction 
Non-traumatic intracerebral haemorrhage (referred to in this chapter as ICH) 
accounts for 10-20% of strokes worldwide. Although age-standardized mortality 
rates for haemorrhagic stroke have decreased in the past two decades, the absolute 
number of those affected, of related deaths and of disability-adjusted life-years lost, 
is increasing (Krishnamurthi et al. 2013). Risk factors, causal pathways, 
investigations, management and prognosis may differ between ICH subtypes, and 
stratified approaches to treatment may be appropriate (Al-Shahi Salman et al. 2009). 
For example, some genetic associations differ between anatomical ICH subtypes, 
with APOE ɛ2/ɛ3/ɛ4 polymorphism being associated with lobar ICH (Biffi et al. 
2010, Falcone et al. 2014) and a locus on chromosome 1q22 being associated with 
non-lobar ICH (Woo et al. 2014). Hence studies of ICH need to use classification 
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systems that distinguish subtypes accurately. Such studies also need to be very large 
for adequate statistical power and misclassification of subtypes would further reduce 
statistical power to detect differences between them (Burton et al. 2009). 
Existing ICH classification systems are ‘anatomical’ or ‘mechanistic’. Anatomical 
systems classify haemorrhages according to their anatomical origin or location on 
brain imaging (CT and/or MRI), or rarely, based on autopsy results as lobar, deep, 
infratentorial, intraventricular, and various combinations, or modifications of these. 
Mechanistic systems integrate this anatomical information with clinical symptoms, 
signs and investigations to assign a subtype based on presumed mechanism. 
Commonly used categories include hypertension, cerebral amyloid angiopathy 
(CAA), anticoagulation and structural causes.  
The work described in this chapter was part of an initiative to develop scalable 
methods for sub-classifying ICH in large, population-based, prospective studies, 
including studies of ICH genetics. An ideal classification system for large-scale use 
would assign the maximum number of cases to determined, valid subtypes without 
sacrificing reliability or accuracy, and would be applicable in a range of different 
clinical settings.  
Reliability and agreement (terms often used interchangeably) are ways of 
demonstrating reproducibility: the degree to which repeated measurements in stable 
study objects provide similar results. Reliability measures how well objects can be 
distinguished from each other despite measurement errors, while agreement assesses 
exactly how close the scores for repeated measurements are (de Vet et al. 2006). 
There are various measures of reliability depending on the data format and nature: 
the kappa statistic (measure of “true agreement” i.e. proportion of agreement beyond 
that expected by chance) used for nominal and ordinal data; ranked intra-class 
correlation used for ordinal data; and intraclass correlation coefficient used for 
continuous data (Kottner et al. 2011). Results of reliability and agreement studies 
provide information about the amount of error inherent in a classification which in 
turn may affect its validity (Kottner et al. 2011).   
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In this chapter, I aim to identify existing ICH classification systems, and assess 
their inter- and intra-rater reliability by performing a systematic review, 
incorporating a comprehensive search strategy and critical appraisal of reporting 
quality and potential bias. I also assess the proportion of cases assigned to each 
subtype to ensure that the included studies offer an appropriately representative 
sample.  
2.2 Methods 
2.2.1 Search strategy 
I searched Ovid Medline (1946 - October 2014) and Embase (1980 - October 2014) 
for studies that assessed the inter- and/or intra-rater reliability of ICH classification 
systems in human adults, using a combination of search terms for haemorrhagic 
stroke, classification systems, and reliability (Appendix 1). I included conference 
abstracts and foreign language articles (obtaining translations where necessary), 
checked the bibliographies of all relevant studies and reviews identified, searched 
Google Scholar for studies citing relevant studies, and contacted researchers in the 
field for information about ongoing and unpublished studies. I assessed eligibility by 
reviewing all titles, abstracts and, where necessary, the full texts of potentially 
relevant articles. I resolved uncertainties through discussion and mutual consensus 
with a second, more senior researcher (Professor Cathie Sudlow). 
2.2.2 Inclusion/exclusion criteria and contact with authors 
I included all studies identified by October 2014, which reported inter- and/or intra-
rater reliability of any anatomical or mechanistic ICH classification system. I also 
included studies identified by July 2013, which had not reported reliability, but had 
used an anatomical or mechanistic ICH classification system and reported the 
proportion of cases classified into mutually exclusive categories.   
I excluded studies that used a classification system based on features other than 
anatomical or mechanistic (e.g. based on ICH severity or prognosis). I also excluded 
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studies conducted in highly selected patient populations (e.g. ICH limited to one 
anatomical territory), among cases with selected clinical features (e.g. study 
including only ICH cases with an epileptic seizure at onset) and studies that had sub-
classified one mechanistic subgroup of ICH cases only (i.e. sub-classification of 
cases with ICH due to vascular malformations). 
I contacted the authors of all included studies to obtain additional unpublished 
information about study characteristics that may affect reliability. To minimize 
publication and reporting bias (whereby positive results are more likely to be 
published or reported than negative ones), I also invited authors of studies which had 
used an anatomical or mechanistic classification system and reported the proportion 
of cases classified into mutually exclusive categories, but not reported reliability, to 
provide any unpublished reliability data. I created a structured data extraction form 
for all studies and pre-filled it as far as possible by entering data from the original 
publication (Appendix 2). I then asked the authors to complete the missing fields and 
where possible to provide additional unpublished reliability data or alternatively 
information that would enable me to calculate the reliability of the classification 
system myself.  
2.2.3 Data extraction 
I divided the included studies into those that had used either an anatomical or a 
mechanistic classification system.  
From each study, I extracted data on:  
 study characteristics: first author, publication year, study inclusion/exclusion 
criteria, country where study population recruited from, whether it was a 
population- or a hospital-based study; 
 study population characteristics: number, mean age, ethnicity, gender, which 
investigations they had performed to enable classification; 
 classification system used: categories, their definitions and classification 
rules; 
 raters classifying the cases: number and qualifications; 
Chapter 2. Reliability of intracerebral haemorrhage classification systems  60 
 
 number of cases classified into each category; 
For studies reporting on system reliability I also extracted data on: 
 methods of reliability assessment: timing of classification in relation to 
symptom onset; raters’ institutions; blinding of raters to being assessed; 
blinding of raters to other raters’ and their own previous decisions; blinding 
of raters to patient’s clinical history (for anatomical systems only) and 
outcome; data and data format presented to the raters; 
 results of reliability assessment: kappa statistic with 95% confidence 
intervals (CI) and/or any other measure available. 
2.2.4 Inter- and intra-rater reliability 
I extracted data about any reliability measure reported for an anatomical or a 
mechanistic classification system. I displayed the most commonly reported inter- and 
intra-rater reliability measure (kappa [κ] statistics and 95% CI) of the more 
commonly reported classifications on a forest plot for visual inspection: 
 lobar versus other location ICH; 
 lobar versus deep versus cerebellar versus brainstem ± multiple location 
ICH; 
 SMASH-U (Structural lesion, Medication, Amyloid angiopathy, 
Systemic/other disease, Hypertension, Undetermined) (Meretoja et al. 2012) 
and its modifications. 
I considered kappa to indicate slight- (κ= 0.01–0.20), fair- (κ =0.21-0.40), moderate- 
(κ=0.41–0.60), substantial- (κ=0.61–0.80) or almost perfect reliability (κ=0.81–0.99) 
(Viera and Garrett 2005). 
I assessed the quality of reliability reporting of included studies, using criteria based 
on the Guidelines for Reporting Reliability and Agreement Studies (GRRAS) 
(Kottner et al. 2011). I assessed the potential risk of bias, using criteria developed 
specifically for this study, relating to study design features that I considered might 
influence the reliability results, such as: 
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 study investigators’ independence of classification system development; 
 raters conducting the rating independently or together; 
 rater blinding to each other’s classification / their own previous 
classification; 
 raters’ institutions same or different;  
 single rater decisions or consensus opinions compared; 
 rater blinding to being assessed;  
 rater blinding to clinical information for anatomical systems and to patient 
outcome for mechanistic systems. 
I explored factors that may affect the kappa statistic, that were available from all 
studies, such as the number of categories in the classification system and the number 
of raters.   
2.2.5 Meta-analyses of ICH subtype proportions 
I performed random-effects proportion meta-analyses for the more commonly used 
categories for anatomical classifications of ICH: 
 supratentorial versus infratentorial location; 
 lobar versus any other location; 
 intraventricular haemorrhage (IVH) present versus absent; 
and mechanistic classifications – ICH attributed versus not to:  
 hypertension; 
 CAA; 
 anticoagulant use; 
 vascular structural cause; 
 undetermined cause. 
I chose to use the DerSimonian and Laird random-effects method because of the 
substantial variability between the characteristics and settings of the individual 
studies contributing data, leading to the assumption that there is significant 
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heterogeneity and hence the true proportions may be different in the included studies 
(Borenstein et al. 2010).  I assessed heterogeneity with I
2
 statistics, interpreting the I
2 
as follows (The Cochrane Collaboration 2011):  
 I2 = 0% to 40%: might not be important; 
 I2 = 30% to 60%: may represent moderate heterogeneity; 
 I2 = 50% to 90%: may represent substantial heterogeneity; 
 I2 = 75% to 100%: considerable heterogeneity; 
I performed an additional sensitivity analysis of the proportions of ICH subtypes, 
including only those studies that also provided data for reliability, to ensure that 
results were consistent for this group of studies with the more inclusive analysis.  
I also performed subgroup analyses by study mean age (≥70 versus <70 years, cut-
off chosen based on spread of ages in included studies), country 
(Europe/USA/Australia versus Asia) and hospital- versus population-based study 
design. I chose to perform these subgroup analyses because data were available for 
these study characteristics from most included studies. I used the Q-test for 
heterogeneity, with a p-value of 0.1 indicating significant between-group difference, 
since heterogeneity tests are typically applied conservatively for meta-analysis 
(Petitti 2001). I performed all analyses with StatsDirect 
(http://www.statsdirect.com/). 
2.3 Results 
2.3.1 Included studies 
From 2152 publications screened, I identified 20 eligible studies, 16 through 
electronic database searches (Anderson et al. 1994, Barton and Hemphill 2007, 
Chiewvit et al. 2009, Díaz-Guzmán et al. 2009, Labovitz et al. 2001, Lee et al. 2004, 
Lovelock et al. 2009, Mayda-Domaç et al. 2010, Meretoja et al. 2012, Nilsson et al. 
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2002, Rost et al. 2008, Zahuranec et al. 2012, Ziai et al. 2011, Takahashi et al. 2006, 
Wijman et al. 2010, Yeh et al. 2014) and four through other methods (hand search, 
bibliography screening, personal contact with researchers) (Bhattathiri et al. 2003, 
Charidimou et al. 2015b, Palm et al. 2013, Wermer et al. 2002) (Figure 2.1). One 
study was available in the form of an abstract only (Ziai et al. 2011) and one study 
was published in Spanish (Díaz-Guzmán et al. 2009).  
2.3.2 Reliability of classification systems 
Six studies provided data about the reliability of an anatomical classification system 
(Bhattathiri et al. 2003, Charidimou et al. 2015b, Chiewvit et al. 2009, Palm et al. 
2013, Ziai et al. 2011, Wermer et al. 2002) and three about the reliability of a 
mechanistic classification system (Meretoja et al. 2012, Palm et al. 2013, Yeh et al. 
2014) (Table 2.1, Figure 2.2). Authors from six studies provided additional 
unpublished information about classification system reliability and/or study 
characteristics (Charidimou et al. 2015b, Chiewvit et al. 2009, Meretoja et al. 2012, 
Palm et al. 2013, Wermer et al. 2002, Yeh et al. 2014). 
2.3.2.1 Study characteristics  
Most studies were hospital- rather than population-based (5/6 anatomical and 2/3 
mechanistic system studies). The median number of cases was 76 for anatomical and 
142 for mechanistic studies. Mean age of cases ranged from 57-75 years for 
anatomical and 61-71 years for mechanistic studies. The proportion of males ranged 
from 48-66%. Studies were conducted in Europe (4/6 anatomical, 2/3 mechanistic), 
Asia (1/6 anatomical, 1/3 mechanistic) and the USA (1/6 anatomical). Classifications 
were performed retrospectively in most studies (4/6 anatomical and 3/3 mechanistic). 
Where intra-rater reliability was assessed, the time interval between the two ratings 
ranged from 2-6 months in anatomical and 15 months to two years in mechanistic 
studies. There were 2-6 raters for anatomical and 2-3 for mechanistic studies. Raters 
in the anatomical studies included neuroradiologists, neurologists (some with special 
experience in stroke) and neurosurgeons; in the mechanistic studies they were all 
stroke neurologists. In 5/6 anatomical studies, CT scans were available to each rater, 
while this was not reported for one study. Access to medical records and imaging 
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reports was available to the raters in all mechanistic studies. Completeness of 
investigation varied across mechanistic studies, but in all studies most cases had had 
a CT brain scan, 15-20% of cases an MRI brain scan and 25-30% intracranial blood 
vessel imaging (CT angiography, MR angiography or digital subtraction 
angiography) (Table 2.2). 
2.3.2.2 Quality of reporting and measures used to reduce bias 
No study satisfied all the GRRAS criteria (Kottner et al. 2011) (Table 2.3). More 
than half of the studies lacked details in the original publication about the rater 
population of interest, rationale for the study, sampling method, measurement / rating 
process, statistical analysis and software used and about raters’ and subjects’ sample 
characteristics. 
No study had used all possible measures to reduce potential bias when assessing 
reliability (Table 2.4). However reassuringly all studies but one, where the 
information was missing as it was only available as an abstract, reported that ratings 
were conducted independently, were single rater decisions and that the raters were 
blinded to their own previous decisions and to the decisions of other raters. Also, in 
the majority of the studies, the raters were blinded to clinical information that may 
have introduced bias. Common potential sources of bias were that the raters came 
from the same institution and that they were not blinded to the fact that they were 
being compared to other raters. The latter is important in order to remove the 
possibility of a Hawthorne effect i.e. ensuring that the rater’s behaviour is not altered 
because of an awareness being observed
 
(Kottner et al. 2011).  
2.3.2.3 Inter-rater and intra-rater reliability 
Anatomical classification systems 
Six studies provided data about inter-rater reliability (Bhattathiri et al. 2003, 
Charidimou et al. 2015b, Chiewvit et al. 2009, Palm et al. 2013, Ziai et al. 2011, 
Wermer et al. 2002), three of these also had data about intra-rater reliability 
(Bhattathiri et al. 2003, Charidimou et al. 2015b, Wermer et al. 2002) (Table 2.1, 
Figure 2.2). This included unpublished reliability data from two studies (Charidimou 
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et al. 2015b, Palm et al. 2013). All studies had used the unweighted kappa statistic to 
measure reliability. Inter-rater reliability was substantial to almost perfect for 
classifying ICH as lobar versus any other location in four studies, (κ = 0.78 to 0.97) 
(Bhattathiri et al. 2003, Palm et al. 2013, Ziai et al. 2011, Wermer et al. 2002), and 
for classifying ICH into 4-5 categories (lobar, deep, cerebellar, brainstem ± multiple 
location categories) in two studies (κ = 0.81 to 0.87) (Charidimou et al. 2015b, 
Chiewvit et al. 2009). Intra-rater reliability for lobar versus any other ICH was 
almost perfect in two studies (κ = 0.85 to 1) (Bhattathiri et al. 2003, Wermer et al. 
2002), and substantial in one study of ICH classified into four categories (lobar, 
deep, cerebellar, brainstem) (ĸ = 0.8) (Charidimou et al. 2015b).  
Mechanistic classification systems  
Three studies provided data about inter-rater reliability (Meretoja et al. 2012, Palm et 
al. 2013, Yeh et al. 2014) and two of these (Meretoja et al. 2012, Yeh et al. 2014) 
about intra-rater reliability of a mechanistic classification system (Table 2.1, Figure 
2.2). The systems assessed were SMASH-U (Meretoja et al. 2012) and modifications 
of this. All studies provided additional unpublished data about study characteristics 
and reliability. All studies had used the unweighted kappa statistic to measure 
reliability. One study also reported the absolute agreement (Meretoja et al. 2012). 
Inter-rater reliability was almost perfect (κ = 0.89 to 0.93; absolute agreement 
92/100), as was intra-rater reliability (κ = 0.92 to 0.93).   
2.3.2.4 Factors affecting reliability 
Although reliability generally appeared somewhat lower with a larger number of 
raters or categories, there were insufficient data to draw reliable conclusions about 
these or other factors potentially affecting reliability (Figure 2.2).  
2.3.3 Proportions of ICH subtypes 
These meta-analyses included 14 studies that used an anatomical classification 
system (Anderson et al. 1994, Charidimou et al. 2015b, Chiewvit et al. 2009, Díaz-
Guzmán et al. 2009, Labovitz et al. 2001, Lee et al. 2004, Lovelock et al. 2009, 
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Mayda-Domaç et al. 2010, Nilsson et al. 2002, Palm et al. 2013, Rost et al. 2008, 
Zahuranec et al. 2012, Takahashi et al. 2006, Wijman et al. 2010) and seven that 
used a mechanistic system (Barton and Hemphill 2007, Chiewvit et al. 2009, Díaz-
Guzmán et al. 2009, Meretoja et al. 2012, Palm et al. 2013, Wijman et al. 2010, Yeh 
et al. 2014). The number of studies included in different parts of meta-analyses 
varied, depending on availability of required data.  
2.3.3.1 Study characteristics  
Study characteristics were incompletely reported and inclusion criteria varied (Table 
2.5, Table 2.6). 7/14 of the anatomical and 5/7 of the mechanistic classification 
studies were hospital-based, the remainder being population-based. There was a 
median of 115 cases per study for anatomical and 142 for mechanistic classifications. 
The mean age in each study ranged from 57-76 years for anatomical and 57-71 years 
for mechanistic classifications. 48-63% of cases were male. Studies recruited cases 
from Asia (4/14 anatomical, 2/7 mechanistic), Europe (5/14 anatomical, 3/7 
mechanistic), the USA (4/14 anatomical, 2/7 mechanistic) and Australia (1/14 
anatomical). The number of raters per study was 1-3 for anatomical and 1-2 for 
mechanistic studies. Rater expertise ranged from trainee to specialist neurologist or 
radiologist. To classify ICHs, 11/14 anatomical classification studies used CT brain 
scans, 3/14 used MRI brain scans and one also included autopsy data. Of the 
mechanistic classification studies, 5/7 provided raters with access to medical records 
and results of CT, MRI, and/or vascular imaging, while information about the 
investigations informing classification was unavailable for 2/7.  
2.3.3.2 Classification system categories 
Terminology varied across anatomical classification studies (e.g., the term “deep 
ICH” could include or exclude infratentorial ICH, or be replaced by “central ICH”; 
lobar ICH could include or exclude cerebellar cortical areas) (Table 2.7). Studies 
reported variable levels of detail about the rules used to define ICH location. 10/14 
studies reported classifying based on “location of ICH”, 2/14 reported classifying 
based on “origin of ICH” and criteria were not clear for 2/14. Only two studies 
reported a category for multiple ICHs (Chiewvit et al. 2009, Wijman et al. 2010) and 
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only one (Anderson et al. 1994) for uncertain location. Clear definitions of 
classification categories were not available for all studies. Furthermore, except for 
studies using the SMASH-U system or its modifications, it was not clear how studies 
dealt with cases with more than one possible mechanistic cause (Table 2.7).  
2.3.3.3 Results of proportion meta-analysis  
Anatomical classification systems  
The pooled proportion of ICH cases classified as supratentorial among ten studies 
was 0.88 (95% CI 0.86 to 0.89), with no detectable heterogeneity between studies 
(I
2
=0%). The pooled proportion classified as lobar among 13 studies was 0.35 (95% 
CI 0.29 to 0.41), with substantial heterogeneity between studies (I
2
=88%). Finally, 
the pooled proportion with IVH present among three studies was 0.47 (95% CI 0.41 
to 0.52), with moderate heterogeneity between studies (I
2
=50%) (Figure 2.3).  
The pooled proportion estimates were very similar when only those studies 
contributing reliability data were analysed separately. The pooled proportion of ICH 
cases classified as supratentorial among two studies was 0.90 (95% CI 0.84 to 0.94), 
pooled proportion classified as lobar among three studies was 0.32 (95% CI 0.24 to 
0.41) and the proportion with IVH present in one study was 0.42 (95% CI 0.34 to 
0.50). There was substantial heterogeneity between studies in the lobar ICH category 
(I
2
=60%). Heterogeneity could not be assessed in other categories, because there 
were too few studies.  
Subgroup analyses showed that the proportion of cases classified as lobar was 
significantly higher in studies based in Europe, USA and Australia (0.41, 95% CI 
0.36 to 0.45), compared to studies from Asia (0.24, 95% CI 0.21 to 0.27) (p<0.0001) 
and in population-based (0.41, 95% CI 0.33 to 0.49), compared to hospital-based 
studies (0.31, 95% CI 0.23 to 0.39) (p=0.09) (Table 2.8, Figure 2.4). There were no 
other significant subgroup differences (Table 2.8, Figure 2.5, Figure 2.6). Subgroup 
differences remained significant for lobar ICH and non-significant for supratentorial 
ICH when the Mayda-Domaç
 
study conducted in Turkey was excluded from the 
Asian subgroup. 
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Mechanistic classification systems 
Among seven studies, the pooled proportion of ICH cases classified as hypertensive 
was 0.51 (95% CI 0.40 to 0.61) with considerable heterogeneity between the studies 
(I
2
=97%). The pooled proportion of ICH due to a vascular structural cause across 
seven studies was 0.06 (95% CI 0.05 to 0.08) with substantial heterogeneity 
(I
2
=65%). Among five studies, the pooled proportion classified as CAA-related ICH 
was 0.16 (95% CI 0.10 to 0.23), as ICH due to anticoagulant use was 0.08 (95% CI 
0.02 to 0.16) and as ICH of undetermined cause was 0.13 (95% CI 0.07 to 0.21) with 
considerable heterogeneity (I
2
=95%, 97% and 96% respectively) (Figure 2.7).  
The pooled proportion estimates were very similar when only those studies 
contributing reliability data were analysed separately. The pooled proportion of ICH 
cases classified as hypertensive among three studies was 0.47 (95% CI 0.32 to 0.62), 
as CAA-related was 0.20 (95% CI 0.12 to 0.29), as undetermined was 0.11 (95% CI 
0.04 to 0.20), as due anticoagulant use was 0.09 (95% CI 0.02 to 0.20) and as due to 
vascular structural cause was 0.06 (95% CI 0.03 to 0.08). There was considerable 
heterogeneity between the studies in all categories (I
2
= 87%-98.7%).  
Subgroup analyses showed that studies with a higher mean age of cases (≥70 years), 
compared to a lower mean age of cases (<70 years), attributed a higher proportion to 
CAA (0.31, 95% CI 0.24 to 0.39 versus 0.13, 95% CI 0.08 to 0.19; p=0.0007), and a 
lower proportion to an undetermined cause (0.04, 95% CI 0.01 to 0.08 versus 0.16, 
95% CI 0.09 to 0.25; p=0.06) (Table 2.8, Figure 2.8, Figure 2.9). Studies recruiting 
cases from Asia, compared to studies recruiting from Europe/USA/Australia, 
attributed a higher proportion to a vascular structural cause (0.08, 95% CI 0.07 to 
0.09 versus 0.06, 95% CI 0.04 to 0.07; p=0.05) and a lower proportion to 
anticoagulant use (0.03, 95% CI 0.02 to 0.05 versus 0.14, 95% CI 0.12 to 0.16; 
p<0.0001) (Table 2.8, Figure 2.10, Figure 2.11). Population-based (versus hospital-
based) studies attributed a higher proportion of cases to CAA (0.31, 95% CI 0.24 to 
0.39 versus 0.13, 95% CI 0.08 to 0.19; p=0.0007) and a lower proportion to 
undetermined cause (0.04, 95% CI 0.01 to 0.08 versus 0.16, 95% CI 0.09 to 0.25; 
p=0.006) (Table 2.8, Figure 2.8, Figure 2.9). There were no other significant 
subgroup differences (Table 2.8, Figure 2.12). 
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2.4 Discussion 
2.4.1 Main findings 
My review found that both the inter- and intra-rater reliabilities of existing 
anatomical and mechanistic classification systems appear to be substantial to almost 
perfect. Although there was a suggestion that smaller numbers of raters or categories 
improved reliability, as would be expected (Sim and Wright 2005), there were 
insufficient data to formally assess factors that could influence reliability. The 
quality of reliability reporting was variable with no study completely following the 
GRRAS guidelines (Kottner et al. 2011), probably because measuring reliability was 
not the primary aim for all studies and also because these guidelines were published 
only recently. Furthermore, since no study had used all possible measures to reduce 
potential bias, reliability may have been over-estimated. Finally, all raters in these 
studies were experts in their field, limiting the generalisability of the results to less 
expert raters who might usefully contribute to large-scale research studies. 
The proportions of ICH subtypes in anatomical categories were largely consistent 
with previous reports (Hanley 2009, Warlow et al. 2008), suggesting that the 
included studies are appropriately representative. Subgroup analyses suggested that 
the considerable heterogeneity between proportion of lobar ICH cases across studies 
was partly explained by study design and country. Substantial to considerable 
heterogeneity between proportions of mechanistic subtypes in included studies was 
partly explained by variation in mean age of cases, country and study design. I could 
not formally assess other potential contributing factors (including differences 
between diagnostic criteria and completeness of investigations). Contrary to previous 
findings (Shen et al. 2007), my meta-analyses found that ICH attributed to 
anticoagulant use was less frequent in Asian studies. 
Existing classification systems have some limitations. For anatomical systems, these 
include:  
 classification based on presumed site of ICH origin in some studies and on 
ICH location in others; 
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 lack of clarity and/or variation between studies in category definitions; 
 surprisingly few classification systems with a separate category for bleeds in 
either multiple or uncertain locations.  
For mechanistic systems, limitations include:  
 assumptions about causal pathways (e.g., hypertension is commonly 
considered to be causally associated with deep ICH location and CAA with 
lobar ICH, despite doubts about the nature and/or strength of these 
associations) (Jackson and Sudlow 2006, Samarasekera et al. 2012); 
 variable clarity of category definitions; 
 the dependence on investigations undertaken to identify the potential cause 
(which vary considerably among specialties and countries, and with age, 
ICH location and blood pressure) (Cordonnier et al. 2010); 
 varying definitions of primary and spontaneous ICH, with some studies 
excluding specific mechanistic categories; 
 inability to assign a proportion of cases to a determined subtype; 
 most cases do not have a single cause, but several interacting contributory 
factors (Warlow et al. 2008); 
 classification systems do not always explain clearly how competing causes 
are dealt with. 
2.4.2 Strengths and limitations 
To my knowledge, no prior published systematic reviews of the reliability of ICH 
classification systems exist and thus this study is the first to summarise the total body 
of evidence. Other strengths of this study include a thorough search strategy and 
rigorous assessment of study characteristics, quality and bias indicators to inform the 
interpretation of the results. In addition, although I found relatively few relevant 
published studies, through contacting authors and establishing a collaborative group, 
I was able to include additional unpublished reliability results from four of the eight 
studies assessing reliability.  Finally, this study has highlighted the limitations of 
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existing classification systems, which should help ensure their further refinement 
where needed and their appropriate use in diverse clinical and research settings. 
This study has some limitations. I may have missed some publications where 
reliability was assessed but buried in a few words within the body of the text. I 
attempted to address this by manually searching through relevant review papers and 
reading full texts of all identified studies using an anatomical or mechanistic 
classification system. It is also important to emphasize that the pooled analyses of 
ICH subtype proportions was not the primary aim of this study, but a secondary 
analysis of eligible studies identified from a search which targeted studies of 
reliability. These analyses do not therefore include all published studies of the 
distribution of ICH subtypes. Furthermore, limited available data mean that 
conclusions about potential factors affecting the reliability and proportions of ICH 
subtypes are also inherently limited. In addition to bias, number of categories and 
raters, kappa can also be affected by disease prevalence, pattern of disagreement, 
time interval between ratings and other factors (Sim and Wright 2005). Finally, 
although reliability is an important feature of a classification system, it does not 
necessarily correlate with diagnostic accuracy or validity, which would require 
reference to a ‘gold’ standard. 
2.4.3 Outstanding issues 
While both anatomical and mechanistic systems appear to have excellent reliability, 
for large population-based, prospective epidemiological studies, anatomical 
classification systems are likely to be:  
 more feasible, since less information from investigations is required for all 
cases to be classified; 
 more scalable, since automated or semi-automated classification may be 
possible with a combination of International Classification of Diseases-
coded hospital episodes and automated processing of brain imaging reports; 
 more appropriate since they are free of assumptions about causal pathways. 
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The development of such methods for use at scale will require clear definitions, 
classification protocols, and the availability of categories for multiple or uncertain 
locations.  
Mechanistic systems such as the SMASH-U and its modifications have the advantage 
of already having a very clear set of rules and excellent reliability (consistent with 
findings from ischemic stroke sub-classification studies showing that reliability 
increases with clear rules or protocols) (Woodfield et al. 2013). However, 
mechanistic systems could be further improved by integrating categories for cases 
with an uncertain and multiple overlapping mechanisms. Such systems are likely to 
be appropriate for: 
 stratifying patients for clinical trials; 
 some case-control studies, where stroke specialists collect the more detailed 
information required at the time of presentation with ICH;  
 clinical practice to encourage a more systematic mechanistic work-up.  
The feasibility of collecting this additional, more detailed information in large, 
prospective, population-based studies also needs further assessment, since it would 
complement the more basic information required for anatomical sub-classification 
and – potentially – allow nested case-control studies, based on not only anatomical, 
but also mechanistic information.  
Reliability is unknown outside highly specialised centres with experienced readers. 
Future comparisons of reliability studies will be facilitated by studies following 
published GRRAS reporting guidelines. This should provide the detailed information 
necessary to understand how the study was designed and conducted, and how the 
results were obtained. Reliability is not a fixed property of the measurement tool but 
rather the product of interactions between the measurement tool, the objects, and the 
context of the assessment, affected by various sources of variability. Therefore study 
results are better interpretable when the study conditions are sufficiently described 
(Kottner et al. 2011).  
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2.4.4 Conclusions 
To conclude, existing classification systems appear to have very good reliability in 
the settings in which they have been tested, but their reliability is unknown outside 
highly specialised centres with experienced readers. Future comparisons of reliability 
studies will be facilitated by studies following published GRRAS reporting 
guidelines (Kottner et al. 2011).  
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ANATOMICAL CLASSIFICATION SYSTEMS 
Chiewvit Unweighted kappa 5 0.866 - - - - - 
Wermer Unweighted kappa 2 
Mean across 3 ratings: 0.92 - - 
1.00 - - 
Rater I vs II: 0.88 0.75 1.00 
Rater I vs III: 0.96 0.88 1.00 




2 (thalamus or basal ganglia / other) 0.85 
- - 
Mean kappa across six raters: 0.85 
- - 
Range: 0.699 – 13 
Unweighted 
subtype kappa  
2 (lobar / other) 0.78 
Mean kappa across six raters: 0.85 
Range: 0.720 – 14 
Unweighted kappa  4 (frontal / temporal / parietal / occipital) Range 0.61-0.8 - 
Palm 
Unweighted 
Cohen´s kappa  
2 0.94 0.88 1 - - - 
Charidimou Unweighted kappa 4 
Combined across 3 ratings: 0.808 0.672 0.892 
0.804 0.76 0.971 Rater I vs II: 0.791 0.753 0.853 
Rater II vs III: 0.845 0.787 0.874 




6 (lobar / caudate / globus pallidus / 
putamen / thalamus / IVH) 
0.76 0.7 0.82 - - - 
Subtype kappa5 
2 (subtype kappa for each location vs all 
other locations) 
Caudate:0.56; Globus pallidus:0.03; 
Putamen:0.72; Thalamus:0.85; 
Lobar:0.97; Primary IVH:0.74 
- - - - - 




6 0.89 0.82 0.96 0.93 0.89 0.97 




6 0.89 0.84 0.94 0.92 0.86 0.99 




If categories not defined in brackets then categories used as described in Table 2.7 (please see Table 2.7 for further information about category 
definitions); 
2
Bhattathiri: it is not entirely clear from the article how the kappa has been calculated. The information in the table reflects my best guess; 
3
Rater I: 
0.950; Rater II: 0.898; Rater III: 0.779; Rater IV: 1; Rater V: 0.779; Rater VI:  0.699; 
4
 Rater I: 0.9; Rater II: 0.755; Rater III: 0.801; Rater IV: 1; Rater V: 0.720; 
Rater VI: 0.905; 
5
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?: unknown; Y: yes; N: no; NR: neuroradiologist; NS: neurosurgeon; NE: neurologist; SN: neurologist specialised in stroke; RF: research fellow; CIL: central 
imaging laboratory for a multicentre trial; DSA: digital subtraction angiography; 
1
Definitions of classification system categories can be found in Table 2.7.  
2
Number of ICH cases classified for reliability assessment; 
3
Method: R (retrospective): cases were classified after initial presentation, usually through retrieving 
and reviewing medical records; P (prospective): patients were classified at the time of or shortly after presenting and being recruited to the study; 
4
Timing: time 
from symptom onset to classification for inter-rater reliability; time between two ratings for intra-rater reliability;
 5
Expertise: Predefined categories were: Expert = 
qualified doctors at specialist level (trainee, research fellow or consultant); Less expert = physicians 1-4 years post registration, general practitioners, nurses or 
medical students (NB: no studies had less expert raters); 
6
Blinding: 1: rater unaware of other raters’ decisions and/or their own previous decision; 2: rater unaware 
of being compared to other raters; 
7
Institutions: raters from single or multiple institutions; 
8
Blinding: raters blind to each patient’s clinical history (Hx) and/or 
outcome; 
9
Same: same information available to each rater; 
10
Information available: information available to the rater for classification purposes; 
11
Classification 
system modified from SMASH-U locally; 
Comments about specific studies: Chiewvit: mean age applies to a larger sample of 131 cases (including cases with subarachnoid haemorrhage, subdural 
haemorrhage and intraventricular haemorrhage [IVH]); Wermer: included only supratentorial cases; 50 cases rated by 3 raters to assess inter-rater agreement, 25/50 
cases rated twice by one rater to assess intra-rater agreement, not specified how the 25 cases were chosen from amongst the 50 for intra-rater agreement; 
Bhattathiri: included only supratentorial ICH cases; classification assumed retrospective, though not specifically mentioned in the publication; Ziai: not stated 
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 explicitly in the abstract but assumed to include only supratentorial ICH cases; not stated explicitly in the abstract but “CIL” assumed to use expert rater(s). Palm: 
% male, mean age and investigations performed applies to a larger sample of 152 non-traumatic ICH cases; Meretoja: each case classified by 2 of 3 raters, with 2 
raters classifying 50 cases each and one rater classifying 100 cases; Investigations performed apply to larger sample of 1013 ICH cases; 100 cases for reliability 
selected at random from the whole sample of 1013 patients, but weighted to ensure appropriate representation of all SMASH-U classifications (the raters did not 
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Table 2.3 Reporting quality of ICH classification system reliability studies based on the GRRAS guidelines 


































1. Identify in title or abstract that inter-rater/intra-rater reliability or agreement was investigated ● ● ● ● ○ 
INTRODUCTION  
2. Name and describe the diagnostic or measurement device of interest explicitly ○ ● ● ● ● 
3. Specify the subject population of interest ● ● ● ● ● 
4. Specify the rater population of interest ○ ● ● ○  
5. Describe what is already known about reliability and agreement and provide a rationale for the study ○  ● ● ○ 
METHODS  
6. Explain how the sample size was chosen. State the determined number of raters, subjects/objects, and replicate 
observations 
● ●   ● 
7. Describe the sampling method ●      ○ ● 
8. Describe the measurement / rating 
process 
 
Data presented to adjudicators ● ● ● ● ● 
Time since index ICH ○ ○ ○ ○ ○ 
Blinding between observers  ○ ○ ● ○ ○ 
Blinding to study of reliability ○ ○ ○ ○ ○ 
Time interval between successive ratings  ○   ○ ○ 
Single or consensus ratings ● ● ● ● ● 
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9. State whether the measurements/ratings were conducted independently (at the same time or not) ○ ●   ● ● ○ 
10. Describe the statistical analysis and software used     ● 
RESULTS  
11. State the actual number of raters and subjects which were included and the number of replicate observations 
which were conducted 
○ ● ● ● ● 
12. Describe raters’ and subjects’ sample 
characteristics  
Subject population, general characteristics including age   ○    
% Investigations performed in subject population (mechanistic 
systems) 
     
Rater expertise
4 
● ● ●   ●
 
○ 
Rater experience with the classification system (mechanistic 
systems) 
   ○ ○ 
13. Report estimates of reliability and agreement including measures of statistical uncertainty ○ ●  ● ● 
DISCUSSION  
14. Discuss the practical relevance of the results  ●  ● ○ 
SUPPLEMENTARY MATERIAL  
15. Provide detailed results if possible (eg., online) ○ ○ ○ ○ ○ 
Assessed only based on information available in the original publication, for some studies further information became available upon direct contact with authors; 
●Criteria fulfilled in the original publication ○Criteria not fulfilled in the original publication; Criteria partly fulfilled in the original publication; 
1
Wermer: do not 
explain how the 25 scans that were assessed for intra-rater agreement were chosen from amongst the 50 scans originally assessed; 
2
Bhattathiri: in “results” section 
state that measurements conducted independently; 
3
Meretoja: rater expertise described in “methods” section; 
4
“Rater expertise” includes rater training and 
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Table 2.4 Risk of bias assessment for ICH classification system reliability studies 
Measures to reduce bias Charidimou Wermer















1. Were the study 
investigators independent 
of classification system 
development? 
● ● ●  ○ ● ? ●  
2. Was rating conducted 
independently? 
● ● ● ● ● ● ? ● ● 




● ● ● ● ● ● ? ● ● 
4. Did raters come from 
multiple institutions 
(versus a single 
institution)? 
● ● ○ ○ ○ ○ ? ? ○ 
5. Were answers compared 
single rater decisions 
(versus consensus 
opinions compared)? 
● ● ● ● ● ● ● ● ● 
6. Were the raters blinded to 
being assessed? 
○ ○ ○ ○ ○ ○ ? ? ○ 
7. Were the raters blinded to 
clinical information (for 
mechanistic  systems 
blinded to patient 
outcome)? 
● ● ● ? ● ● ? ● ● 
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Table 2.5 Characteristics of studies using an anatomical ICH classification system 






















CT MRI HT 
of 
IS 
















P 150 63.7 ? 
Multi-
ethnic  










56 ? - - - -  AVM related ICH   -  






H 83 66±11 60 ? ? - ? - 
 Multiple ICHs 
 AVM/cavernous 
angioma-related ICH 
 Cases with known 
bleeding disorders  
 Cases with prior 
neurosurgery 





H 347 72±12 49 ? ? ? - -    -  2 raters 
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CT MRI HT 
of 
IS 




H 629 72±12 54 
≥80% 
Caucasian 




 Preceding trauma or 
ischemic stroke 
 Vasculitis 
 Blood dyscrasia 
 INR >3 due to 
anticoagulation 
 No outcome data 









P 15 ? 53 ? ? ? ? ?  ? ? 





P 74 76 56 ? - - - -   ? ?  
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CT MRI HT 
of 
IS 










 Cases with chronic 
medical problems  
 Cases with missing 
outcome data or 
admitted >24 h of onset  




H 58 62 60 
27% Asian 
66% White 
7% other   
  ? - 
 Prior known cause 
for ICH (i.e. vascular 
malformation)  
No MRI or performed 
>30 days post ICH  
 ? 
One or all of: 





















51 Caucasian - - ? -  Previous IS or ICH  Some 












- - - - 
 Known underlying 
structural cause 
  -  NR  
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1
Country: country where study cases recruited from; 
2
Study population characteristics: P: population-based study, H: hospital-based study. No. of cases: number of 
ICH cases classified and included in the proportion meta-analyses; 
3
Imaging used for rating: results reflect what was felt most likely based on publications, but it 
was often difficult to be certain; 
4
Rater(s): number and qualification(s) of person (people) classifying cases;?: unknown; HT of IS = haemorrhagic transformation of 
ischemic stroke; Tu = intracranial tumour-related ICH; An = aneurysmal ICH; Tr = traumatic ICH; NR = neuroradiologist; R = radiologist; SN = neurologist 
specialised in stroke; SS = stroke specialist; Med. Records = medical records; Path. Data = pathology data; Comments about specific studies: Anderson: mean age 
and % male applies to a larger sample of 60 case presentations (including the 13 cases of large haemorrhage where impossible to distinguish between deep and 
lobar regions as site of origin); Chiewvit: mean age applies to a larger sample of 131 cases and % male applies to a larger sample of 84 cases (including cases with 
subarachnoid haemorrhage, subdural haemorrhage and intraventricular haemorrhage [IVH]); Mayda-Domaç: mean age and % male applies to a larger sample of 
208 cases (including 6 cases with IVH); Wijman: mean age, % male and ethnicity applies to a larger sample of 70 cases (including 7 cases with multiple ICHs and 
5 cases with IVH); Palm: mean age and % male applies for a larger sample of 152 non-traumatic ICH cases; Lovelock: mean age and % male applies to a larger 
sample of 78 cases (including the 4 cases of haemorrhagic transformation of an infarct); Rost: ethnicity is based on overall Massachusetts General Hospital ICH 
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 7% other 
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 Prior known 
cause for ICH 
i.e. vascular 
malformation 
 MRI not 
performed or 
performed >30 
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H 1013 67 57 
96% 
Caucasian 
4% other  













P 142 71±14 51 Caucasian - - ? - 
 Previous IS 
or ICH 







H 3785 59±17 63 
Majority 
Chinese 














Country: country where study cases recruited from; 
2
Study population characteristics: P: population-based study, H: hospital-based study. No. of cases: number of 
ICH cases classified and included in the proportion meta-analyses; 
3
Imaging used for rating: results reflect what was felt most likely based on publications, but it 
was often difficult to be certain; 
4
Rater(s): number and qualification(s) of person (people) classifying cases; 
5
Definition of classification categories: HT: 
hypertension-related ICH; VSC: vascular structural cause for ICH; C: anticoagulant use-related ICH; CAA: cerebral amyloid angiopathy-related ICH; ?: unknown; 
HT of IS = haemorrhagic transformation of ischemic stroke; Tu = intracranial tumour-related ICH; An = aneurysmal ICH; Tr = traumatic ICH; NR = 
neuroradiologist; R = radiologist; SN = neurologist specialised in stroke; SS = stroke specialist; Med. Records = medical records; Path. Data = pathology data; 
Comments about specific studies: Chiewvit: mean age applies to a larger sample of 131 cases and % male applies to a larger sample of 84 cases (including cases 
with subarachnoid haemorrhage, subdural haemorrhage and intraventricular haemorrhage [IVH]); Wijman: mean age, % male and ethnicity applies to a larger 
sample of 70 cases (including 7 cases with multiple ICHs and 5 cases with IVH); Palm: mean age and % male applies for a larger sample of 152 non-traumatic ICH 
cases;  
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Table 2.7 Anatomical and mechanistic classification system categories and their definitions 
ANATOMICAL CLASSIFICATION SYSTEM CATEGORIES AND THEIR 
DEFINITIONS 
(I) Anatomical category assigned based on origin of ICH  
Wermer  Included only supratentorial ICH cases: 
1) lobar (origin was in one of the cerebral lobes) 
2) deep (origin was in the basal ganglia) 
Anderson  1) lobar (frontal, parietal, occipital, temporal, corona radiata) 
2) deep (caudate, putamen, globus pallidus, thalamus, internal 
capsule, deep periventricular white matter)       
3) cerebellar                       
4) brainstem                        
5) massive cortical or subcortical (cases of large haemorrhage where 
impossible to distinguish between deep and lobar regions as site of 
origin or localize to a lobe)  
Rost  1) lobar (origin of haemorrhage appeared to be in cerebral 
hemispheres of the frontal, parietal, temporal, or occipital lobes 
superficial to the deep grey matter structures)                
2) deep (haemorrhages originating in the thalamus, basal ganglia)                                      
3) infratentorial 
(II) Anatomical category assigned based on location of ICH 
Bhattathiri
1 
Included only supratentorial ICH cases: 
1) lobar (frontal, temporal, parietal or occipital lobes involved)  
2) basal ganglia, thalamus or its components  
3) internal capsule 
Chiewvit
2 
1) lobar (frontal, parietal, temporal, occipital)   
2) thalamic-ganglionic (caudate, putaminal and thalamic)                                      
3) cerebellum               
4) brainstem 




Assume included only supratentorial ICH cases: 
1) lobar  
2) globus pallidus 
3) putamen 
4) caudate  
5) thalamus 
6) primary IVH 
Palm
 
1) lobar (cortical or subcortical)  
2) deep (basal ganglia, infratentorial) 
Recorded presence versus absence of IVH 
Labovitz
 
1) lobar (defined as ICH involving the frontal, parietal, temporal, or 
occipital lobes or insular cortex)               
2) deep 




1) lobar (cortical or subcortical)   
2) central (basal ganglia, thalamus, internal capsule, deep 
periventricular white matter or purely intraventricular)            




1) corticosubcortical area   
2) deep grey matter (basal ganglia and thalamus)            
3) infratentorial area (brainstem and cerebellum) 
Takahashi
 
1) lobar               
2) central (basal ganglia and thalamus)         
3) cerebellum                                           
4) brainstem                                                   
Recorded presence versus absence of IVH 
Lovelock
 
1) lobar                          





1) lobar                                                           
2) putaminal         
3) nucleus caudatus             
4) thalamic             
5) cerebellar           




1) lobar                
2) basal ganglia         
3) thalamus           
4) cerebellum 
5) brainstem       
6) isolated IVH              





Recorded presence versus absence of IVH 
 
(III) Not clear whether anatomical category assigned based on origin or location 
of ICH 
Charidimou 
1) lobar (cortical-subcortical not extending into deep structures)  
2) deep (basal ganglia, thalamus) 
3) cerebellar  
4) brainstem  
Díaz-
Guzmán
 1) lobar                       
2) deep (basal ganglia)  
3) cerebellar 
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MECHANISTIC CLASSIFICATION SYSTEMS CATEGORIES AND THEIR 
DEFINITIONS 
(I) Potentially competing causes clearly dealt with (The SMASH-U system 
            and its modifications) 
Meretoja
 
SMASH-U system based on a flowchart principle:  
1) structural lesion: imaging or pathology confirmed structural 
vascular malformation diagnosed at ICH site     
2) systemic /other disease: systemic or other determined cause for 
ICH except for anticoagulation, hypertension or CAA (liver cirrhosis 
when known liver disease combined with spontaneously elevated 
INR or LFTs >3x upper limit; thrombocytopenia if PLT<50)                  
3) Medication: warfarin with INR >2, use of novel oral 
anticoagulants within 3 days, full dose heparin or non-ischemic 
stroke systemic thrombolysis              
4) CAA: Boston criteria, lobar, cortical or subcortical haemorrhage 
and age ≥55   
5) hypertension: deep or infratentorial ICH with pre-ICH 
hypertension (most recent pre-ICH BP ≥160/100 mmHg or if BP n/k, 




Modified SMASH-U system, also based on a flowchart principle:  
1) structural lesion: AVM or cavernoma                                                                                                         
2) medication: on warfarin with INR >2         
3) CAA: older than 54 years with lobar haematoma       
4) hypertension: deep ICH with pre-ICH hypertension diagnosis or 
on medication or BP >140/90 on 2 or more measurements > 3 days 




Modified SMASH-U system based on a flowchart principle, with 
renal failure (defined as chronic kidney disease stage 5 or requiring 
regular dialysis) added under the “systemic/other disease” category 
 
(II) Unclear how potentially competing causes dealt with 
Barton
 
Cause of haemorrhage divided into following categories (not 
specified based on which criteria the categories were determined):                
1) CAA                                      
2) coagulopathy                      
3) hypertension                      
4) illicit drugs                             
5) vascular (AVM, aneurysm)      
6) other lesion (tumour, abscess)         
7) other   




Based on risk factors classified into one of the following categories:       
 1) hypertension     
 2) aneurysm            
 3) AVM                    
 4) anticoagulants/thrombolytic therapy         
 5) alcohol abuse                                      





2) vascular malformation               
3) anticoagulants                         
4) CAA                                       
5) other 
No further definitions of categories provided.  
Wijman
 
Aetiology of spontaneous ICH classified as follows:                                                       
1) hypertension (patient considered to have hypertension [HT] if 1 of 
the 3 criteria met: well documented history of HT; on treatment for 
HT as an outpatient; LVH on ECG or ECHO; study neurologists 
were also instructed to look for BMBs in deep grey nuclei or 
brainstem)                      
2) CAA (neurologists also instructed to look for BMBs in subcortical 
white matter in an elderly patient with lobar ICH)                             
3) vascular malformation     
4) neoplasm                            
5) haemorrhagic transformation of ischemic stroke (neurologists 
instructed to consider if areas of restricted diffusion substantially 
exceed commonly seen perihaemorrhagic diffusion artefacts, or 
additional areas of diffusion restriction in someone with considerable 
risk factors for ischemic stroke)  
6) illicit drug use                        
7) coagulopathy (PLT <50; INR >3; APTT >80s)         
8) other identified cause                     
9) unknown cause 
1
Bhattathiri: separately recorded “site of primary involvement” and “site of secondary involvement”; 
2
Chiewvit: location of ICH based on the location of the largest blood clot.  
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PROPORTION: MECHANISTIC CATEGORIES 
Supratentorial 
ICH 







≥70  0.88 (0.86-0.90) 0.35 (0.26-0.45) n/a 0.51 (0.43-0.60) 0.31 (0.24-0.39) 0.04 (0.01-0.08) 0.11 (0.07-0.18) 0.03 (0.01-0.07) 
<70 0.86 (0.82-0.89) 0.31 (0.25-0.36) n/a 0.51 (0.39-0.64) 0.13 (0.08-0.19) 0.16 (0.09-0.25) 0.07 (0.01-0.17) 0.07 (0.05-0.09) 







0.87 (0.84-0.90) 0.41 (0.36-0.45) 0.47 (0.37-0.58) 0.47 (0.30-0.65) 0.17 (0.08-0.28) 0.11 (0.02-0.26) 0.14 (0.12-0.16) 0.06 (0.04-0.07) 
Asia 0.88 (0.85-0.90) 0.24 (0.21-0.27) 0.46 (0.40-0.51) 0.55 (0.53-0.57) 0.12 (0.11-0.13) 0.16 (0.05-0.33) 0.03 (0.02-0.05) 0.08 (0.07-0.09) 
p-value 0.78
 





0.88 (0.86-0.90) 0.31 (0.23-0.39) 0.46 (0.40-0.51) 0.52 (0.39-0.64) 0.13 (0.08-0.19) 0.16 (0.09-0.25) 0.07 (0.01-0.17) 0.07 (0.05-0.09) 
Population-
based 
0.84 (0.77-0.90) 0.41 (0.33-0.49) 0.47 (0.37-0.58) 0.50 (0.43-0.58) 0.31 (0.24-0.39) 0.04 (0.01-0.08) 0.11 (0.07-0.17) 0.04 (0.01-0.07) 
p-value 0.26 0.09 0.77 0.87 <0.01 <0.01 0.52 0.18 
Numbers in the table represent pooled proportion (and 95% confidence interval) of cases in a category across all studies in a particular subgroup; p-value shows 
whether there is a significant difference between the pooled results of the two subgroups under comparison. Significant results (p<0.1) in bold; n/a: not applicable.  
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Four studies had used both anatomical and mechanistic classification systems (Chiewvit et al. 2009, 
Díaz-Guzmán et al. 2009, Palm et al. 2013, Wijman et al. 2010); One study was in the form of an 
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Figure 2.2 Inter- and intra-rater reliability of ICH classification systems 
 
Squares represent individual study reliability estimates, and associated horizontal lines represent 95% 
confidence intervals; All kappas are unweighted; Wermer, Bhattathiri, Ziai: included only 
supratentorial ICH cases; Palm: included infratentorial as well as supratentorial ICH cases; Wermer: 
mean kappa based on 3 sets of ratings between 2 raters (different combination of raters from amongst 
3 raters); Bhattathiri and Ziai: subtype kappa for lobar location versus any other location; Bhattathiri: 
Intra-rater reliability based on mean kappa for 6 raters all classifying each case twice; Meretoja: each 
case was classified by 2 raters, but there were 3 raters in total with 2 raters classifying 50 cases each, 





0.00 0.50 0.75 1.00 
Yeh 0.92 (0.86, 0.99) 
Meretoja 0.93 (0.89, 0.97) 
Mechanistic 
Charidimou 0.80 (0.76, 0.97) 
Bhattathiri 0.85  
Wermer 1.00  
Anatomical 
INTRA-RATER RELIABILITY 
Yeh 0.89 (0.84, 0.94) 
Meretoja 0.89 (0.82, 0.96) 
Palm 0.93 (0.89, 0.99) 
Mechanistic 
Chiewvit 0.87  
Charidimou 0.81 (0.67, 0.89) 
Lobar vs deep vs cerebellar vs brainstem  
(± multiple location) ICH (4-5 categories) 
Palm 0.94 (0.88, 1.00) 
Ziai 0.97 
Bhattathiri 0.78  
Wermer 0.92 (0.81, 1.00) 
Lobar vs other ICH (2 categories) 
Anatomical 
INTER-RATER RELIABILITY 
SMASH-U and modifications (5-6 categories) 
SMASH-U and modifications (5-6 categories) 
Lobar vs deep vs cerebellar vs    
brainstem ICH (4 categories) 
Lobar vs other ICH (2 categories) 

















Chapter 2. Reliability of intracerebral haemorrhage classification systems  99 
 
Figure 2.3 Proportions of ICH subtypes in anatomical categories 
 
Random-effects method; Squares represent individual study proportion estimates, and associated 
horizontal lines represent 95% confidence intervals; Unfilled diamonds represent overall pooled 
proportion estimates; Studies contributing reliability data in grey; P: population-based; H: hospital-
based; Y: yes; N: no; Country: country where study population recruited from; E: Europe (Spain, 
Finland, Germany, UK, Sweden); A: Asia (Thailand, Taiwan, South Korea, Turkey, Japan); AUS: 
Australia; Age: mean age of relevant study population; IVH: intraventricular haemorrhage. Where 
possible I excluded cases with multiple ICHs, cases in the uncertain ICH category, and cases with 
isolated IVH: Anderson: excluded 13 cases of large haemorrhage where impossible to distinguish 
between deep and lobar regions as site of origin; Chiewvit: excluded 2 cases with multiple ICHs and 4 
cases with IVH; Wijman: excluded 7 cases with multiple ICHs and 5 cases with IVH; Mayda-Domaç: 
excluded 6 cases with IVH; Charidimou: excluded one case with IVH. Three studies that had used an 
anatomical classification system did not include sufficient data to be included in the meta-analysis 
(Bhattathiri et al. 2003, Ziai et al. 2011, Wermer et al. 2002). I
2 
= within subgroup heterogeneity; 
 
0.2 0.4 0.6 0.8 1.0 




0.42 (0.34, 0.50) 
0.53 (0.45, 0.60) 
0.46 (0.40, 0.51) 
0.35 (0.29, 0.41) 
       I
2
=88% 
0.36 (0.28, 0.44) 
0.38 (0.26, 0.50) 
0.52 (0.46, 0.57) 
0.42 (0.31, 0.54) 
0.33 (0.25, 0.41) 
0.40 (0.27, 0.53) 
0.22 (0.18, 0.27) 
0.41 (0.38, 0.45) 
0.25 (0.19, 0.31) 
0.29 (0.19, 0.40) 
0.23 (0.15, 0.34) 
0.40 (0.26, 0.56) 
0.40 (0.16, 0.68) 
0.0 










































































0.88 (0.82, 0.92) 
0.93 (0.84, 0.98) 
0.84 (0.73, 0.93) 
0.88 (0.84, 0.91) 
 0.88 (0.85, 0.91) 
0.90 (0.85, 0.93) 
0.83 (0.73, 0.90) 
0.88 (0.79, 0.94) 
0.79 (0.64, 0.89) 








































a.  Anatomical categories 
SUPRATENTORIAL 
Díaz-Guzmán 




Chapter 2. Reliability of intracerebral haemorrhage classification systems  100 
 
 
Figure 2.4 Lobar ICH proportion meta-analysis subgroups 
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Random-effects method; Squares represent individual study proportion estimates, and associated 
horizontal lines represent 95% confidence intervals; Unfilled diamonds represent pooled proportion 
estimates for each subgroup; I
2
: within subgroup heterogeneity; n/a: not possible to assess; Subgroup 
diff p: p-value showing whether there is a significant difference (p<0.1) between the pooled results of 
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Figure 2.5 Supratentorial ICH proportion meta-analysis subgroups 
 
Random-effects method; Squares represent individual study proportion estimates, and associated 
horizontal lines represent 95% confidence intervals; Unfilled diamonds represent pooled proportion 
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estimates for each subgroup; I
2
: within subgroup heterogeneity; n/a: not possible to assess; Subgroup 
diff p: p-value showing whether there is a significant difference (p<0.1) between the pooled results of 
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Figure 2.6 ICH with IVH present proportion meta-analysis subgroups 
 
Random-effects method; Squares represent individual study proportion estimates, and associated 
horizontal lines represent 95% confidence intervals; Unfilled diamonds represent pooled proportion 
estimates for each subgroup; I
2
: within subgroup heterogeneity; n/a: not possible to assess; Subgroup 
diff p: p-value showing whether there is a significant difference (p<0.1) between the pooled results of 
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Figure 2.7 Proportions of ICH subtypes in mechanistic categories 
 
Random-effects method; Squares represent individual study proportion estimates, and associated 
horizontal lines represent 95% confidence intervals; Unfilled diamonds represent overall pooled 
proportion estimates; Studies contributing reliability data in grey; P: population-based; H: hospital-
based; Y: yes; N: no; Country: country where study population recruited from; E: Europe (Spain, 
Finland, Germany, UK, Sweden); A: Asia (Thailand, Taiwan, South Korea, Turkey, Japan); AUS: 
Australia; Age: mean age of relevant study population; I
2
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Figure 2.8 Undetermined ICH proportion meta-analysis subgroups 
 
Random-effects method; Squares represent individual study proportion estimates, and associated 
horizontal lines represent 95% confidence intervals; Unfilled diamonds represent pooled proportion 
estimates for each subgroup; I
2
: within subgroup heterogeneity; n/a: not possible to assess; Subgroup 
diff p: p-value showing whether there is a significant difference (p<0.1) between the pooled results of 
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Figure 2.9 CAA-related ICH proportion meta-analysis subgroups 
 
Random-effects method; Squares represent individual study proportion estimates, and associated 
horizontal lines represent 95% confidence intervals; Unfilled diamonds represent pooled proportion 
estimates for each subgroup; I
2
: within subgroup heterogeneity; n/a: not possible to assess; Subgroup 
diff p: p-value showing whether there is a significant difference (p<0.1) between the pooled results of 
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Figure 2.10 Vascular structural cause ICH proportion meta-analysis subgroups 
 
Random-effects method; Squares represent individual study proportion estimates, and associated 
horizontal lines represent 95% confidence intervals; Unfilled diamonds represent pooled proportion 
estimates for each subgroup; I
2
: within subgroup heterogeneity; n/a: not possible to assess; Subgroup 
diff p: p-value showing whether there is a significant difference (p<0.1) between the pooled results of 
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Figure 2.11 Anticoagulant use-related ICH proportion meta-analysis subgroups 
 
Random-effects method; Squares represent individual study proportion estimates, and associated 
horizontal lines represent 95% confidence intervals; Unfilled diamonds represent pooled proportion 
estimates for each subgroup; I
2
: within subgroup heterogeneity; n/a: not possible to assess; Subgroup 
diff p: p-value showing whether there is a significant difference (p<0.1) between the pooled results of 







0.00 0.25 0.50 0.75 1.00 
Population- based 0.113 (0.069, 0.166) 
Palm 0.113 (0.066, 0.177) 
Díaz-Guzmán 0.067 (0.002, 0.319) 
Hospital- based 0.068 (0.009, 0.175) 
Yeh 0.029 (0.024, 0.035) 
Meretoja 0.141 (0.120, 0.164) 
Chiewvit 0.048 (0.013, 0.117) 
Asia 0.031 (0.020, 0.045) 
Yeh 0.029 (0.024, 0.035) 
Chiewvit 0.048 (0.013, 0.117) 
Eur/USA/Australia 0.137 (0.118, 0.158) 
Palm 0.113 (0.066, 0.177) 
Meretoja 0.141 (0.120, 0.164) 
Díaz-Guzmán 0.067 (0.002, 0.319) 
Mean age <70 years 0.068 (0.009, 0.175) 
Yeh 0.029 (0.024, 0.035) 
Meretoja 0.141 (0.120, 0.164) 
Chiewvit 0.048 (0.013, 0.117) 
Mean age ≥70 years 0.113 (0.066, 0.177) 
Palm 0.113 (0.066, 0.177) 



















 Subgroup diff p=0.52 
 Subgroup diff p<0.01 
 Subgroup diff p=0.52 
Chapter 2. Reliability of intracerebral haemorrhage classification systems  110 
 
Figure 2.12 Hypertension-related ICH proportion meta-analysis subgroups 
 
Random-effects method; Squares represent individual study proportion estimates, and associated 
horizontal lines represent 95% confidence intervals; Unfilled diamonds represent pooled proportion 
estimates for each subgroup; I
2
: within subgroup heterogeneity; n/a: not possible to assess; Subgroup 
diff p: p-value showing whether there is a significant difference (p<0.1) between the pooled results of 
the two subgroups under comparison. 
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3. APOE ɛ2/ɛ3/ɛ4 polymorphism associations 
with sporadic CAA  
 CAA, common in the ageing brain, is associated with dementia and lobar ICH 
 APOE ɛ2/ɛ3/ɛ4 polymorphism is associated with many conditions in which CAA 
is involved, including ICH attributed to CAA based on clinical criteria 
 An association between APOE and histopathologically confirmed CAA would 
explain these associations and increase understanding of underlying mechanisms  
 In this chapter, I present my systematic review and series of meta-analyses 
looking at the association between APOE ɛ2/ɛ3/ɛ4 polymorphism and 
histopathologically confirmed presence of CAA   
 I used a comprehensive search strategy, critically appraised study quality and 
assessed small-study biases, publication-, and reporting-biases  
 I conclude that there is robust evidence for a dose-dependent association between 
APOE ɛ4 and histopathologically confirmed CAA, but there is no convincing 
association with APOE ɛ2   
3.1 Introduction 
Sporadic cerebral amyloid angiopathy (CAA) is characterised by deposition of 
amyloid- protein in leptomeningeal and cortical blood vessels, with a prevalence in 
population-based autopsy studies of 20-40% in non-demented and 50-60% in 
demented elderly people (Charidimou et al. 2012a). 
CAA is associated with increasing age, dementia, lobar intracerebral haemorrhage 
(ICH), lobar brain microbleeds, white matter hyperintensities, small cortical infarcts 
and superficial siderosis (Linn et al. 2010, Masuda et al. 1988, Neuropathology 
Group MRC CFAS 2001, Samarasekera et al. 2012). ICH is usually attributed to 
CAA when pathological examination reveals extensive CAA deposition and related 
vasculopathic changes (Vonsattel et al. 1991). The most commonly used criteria for 
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CAA diagnosis are the Boston criteria, which enables  diagnosis of probable and 
possible CAA based on clinical and radiological criteria only, but require a full post-
mortem examination for a definite diagnosis (Knudsen et al. 2001). Knudsen et al 
reported the Boston criteria to have a specificity of 100% and a sensitivity of 45%, 
however the number of participants included was only 39 (Knudsen et al. 2001). 
More recently, the modified Boston criteria have been shown to increase sensitivity, 
though not significantly (Linn et al. 2010). No specific treatment for CAA currently 
exists (Charidimou et al. 2012a).  
Identifying genetic polymorphisms associated with histopathologically confirmed 
CAA should increase understanding of the mechanisms leading to CAA and 
associated diseases. The apolipoprotein E gene (APOE) on chromosome 19 codes for 
a protein of the same name, which is expressed in several organs including the brain. 
Single base changes in the gene determine the three common alleles ɛ2, ɛ3 and ɛ4, 
lead to differences in the amino acid sequence at two sites and changes in the 
function of the resulting protein isoforms. ApoE-3 is the most frequent (wild-type) 
isoform (Takeda et al. 2010). Polymorphisms in the APOE gene are associated with 
many conditions in which CAA may be involved, including subarachnoid 
haemorrhage, ICH, lobar brain microbleeds, and Alzheimer´s disease (AD) (Bertram 
et al. 2007, Biffi et al. 2011, Biffi et al. 2010, Linn et al. 2010, Maxwell et al. 2011, 
Paternoster et al. 2009, Sudlow et al. 2006). The best known function of the 
apolipoprotein E protein is the regulation of lipid metabolism, however in addition it 
may be involved in many other physiological and pathological processes. In vitro 
studies have shown that apolipoprotein E influences amyloid- protein conformation, 
fibril formation and toxicity (Lambert et al. 1998, Wood et al. 1996), while in vivo 
mouse studies have confirmed a critical role for apolipoprotein E in amyloid- 
protein deposition, toxicity and possibly clearance (Holtzman et al. 2000, Holtzman 
et al. 1999). The currently favoured view is that APOE ε4 enhances deposition of 
amyloid-β in cerebral blood vessel walls, while ε2 promotes haemorrhage from 
amyloid-laden blood vessels by increasing specific CAA-related vasculopathic 
changes (Greenberg et al. 1998, McCarron and Nicoll 2000, McCarron et al. 1999).  
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A clear association between APOE and histopathologically confirmed CAA would 
explain many of the observed associations between APOE and clinical outcomes. 
There is robust, large-scale evidence for an association of APOE with ICH attributed 
to CAA on the basis of clinical and radiological criteria. However, studies suggesting 
an association of APOE with histopathologically confirmed CAA have been limited 
by various methodological shortcomings, including small size. Furthermore, the 
possibly contrasting effects of the different APOE alleles on CAA have remained 
unclear.  
In this chapter, I aim to assess the evidence for associations between the APOE 
ɛ2/ɛ3/ɛ4 genetic polymorphism and histopathologically confirmed CAA by carrying 
out a systematic review, incorporating a comprehensive search strategy, a thorough 
assessment of study quality, a series of meta-analyses, and an evaluation of the 
robustness of any positive findings to small-study and other methodological biases. 
3.2 Methods  
3.2.1 Search strategy  
I sought all studies of adult humans published in any language, in which participants 
had been genotyped for any genetic polymorphism and had CAA assessed 
pathologically (using autopsy or biopsy), regardless of whether any association 
between the polymorphism and CAA was reported on.  
I designed a search strategy aimed at picking up a broader range of studies than those 
included in this chapter, searching OVID Medline (1950 to March 2012) and Embase 
(1980 to March 2012), using a combination of search terms for APOE, genes and 
CAA (Appendix 3). I also checked the bibliographies of all relevant studies and 
reviews identified, and searched Google Scholar for studies citing relevant studies.  
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3.2.2 Inclusion/exclusion criteria  
For the analyses reported in this chapter, I included studies looking at the APOE 
ɛ2/ɛ3/ɛ4 genetic polymorphism and:  
 presence versus absence of sporadic CAA pathology;  
 more versus less severe sporadic CAA pathology;  
 or average CAA score on pathology.  
I excluded studies that assessed genetic associations with CAA-related ICH versus 
CAA-free controls, because these would not be able to distinguish a genetic 
association with CAA from an association with ICH. However, I included studies 
that had recruited participants with CAA-related ICH as an unselected part of the 
spectrum of CAA severity. A clinical research fellow colleague (Dr Neshika 
Samarasekera) and I independently selected eligible studies, resolving disagreements 
by discussion and mutual consensus.  
When two or more studies included overlapping sets of participants, I included only 
the study providing most data about the association among the largest number of 
participants. To avoid undue effort on relatively small studies, I further excluded 
studies with <35 participants, thus excluding <3% of the total participants in eligible 
studies.  
3.2.3 Data extraction  
For each study included, I extracted information on:  
 first author;  
 publication year;  
 country in which the study was conducted;  
 participant source and description;  
 study size;  
 participants’ age, ethnicity and gender.   
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To assess the quality of reporting of genotyping based on the STREGA 
(Strengthening the Reporting of Genetic Association Studies) and MOOSE (Meta-
analysis of Observational Studies in Epidemiology) recommendations (Little et al. 
2009, Stroup et al. 2000), I extracted information on:  
 source and storage of DNA;  
 where genotyping was undertaken;  
 whether genotypes were assigned using all data simultaneously or in batches; 
 number of participants in whom genotyping was attempted and in whom it 
was successful;  
 genotyping method;  
 whether genotypes were in Hardy-Weinberg equilibrium (HWE);  
 blinding of genotyping staff to pathology data. 
To assess the quality and characteristics of CAA pathology assessment based on 
criteria I developed specifically for this study, I extracted data on:  
 method and consistency of CAA assessment; 
 qualification of CAA rater(s); 
 brain locations examined;  
 rating system used and its intra- and inter-rater reliability;  
 blinding of CAA raters to genotyping results and relevant clinical 
information. 
Where possible, I extracted data on the numbers of participants with ε4 or ε2 allele-
containing (ε4+ or ε2+) genotypes and their CAA status, in a dichotomous (present 
or absent) or a continuous (mean severity score and its standard deviation [SD]) 
format. In studies without such data available, I recorded any qualitative statement 
about the association between APOE ɛ2/ɛ3/ɛ4 polymorphism and CAA. For each 
study, another researcher (one of Dr Neshika Samarasekera, Professor Rustam Al-
Shahi Salman or Professor Cathie Sudlow) and I extracted these data, resolving 
disagreements by discussion and mutual consensus.  
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3.2.4 Assessment of study quality  
I devised a system to assign the studies included in the meta-analyses an overall 
quality score (ranging from 0-9 points) based on the following:  
 study size 0-2 points, considering larger studies to be superior (cut-offs were 
chosen to divide the total number of participants in all included studies into 
three roughly equal groups); 
 blinding 0-2 points, considering studies using blinding to be superior; 
 participant recruitment method 0-1 points, considering prospective studies 
superior to retrospective; 
 format in which genotype-phenotype association data were provided 0-1 
points, considering continuous data superior due to potential bias in selecting 
cut-offs for dichotomous data; 
 quality of pathology assessment 0-2 points, based on the study reporting the 
method for assessing CAA, the rater qualification and number of brain 
locations examined for CAA; 
 quality of genotyping reporting 0-1 points, based on whether the source of 
DNA and genotyping method were reported.  
3.2.5 Meta-analyses 
I used Cochrane Review Manager (version 5) for undertaking the meta-analyses. For 
studies presenting data in a dichotomous format, I calculated an unadjusted odds 
ratio (OR) with 95% confidence intervals (CIs) for presence versus absence of CAA 
among those with ε4+ versus ε4-, and ε2+ versus ε2- genotypes. I used the Mantel-
Haenszel method which is the default method for fixed-effects meta-analysis in 
Review Manager and is considered to have better statistical properties than other 
methods when there are few events (The Cochrane Collaboration 2011). For studies 
presenting continuous data, I calculated standardized mean differences (SMD) with 
95% CIs in CAA scores and I used the inverse variance fixed-effects method. I used 
SMDs because while the studies all assessed the same outcome (CAA burden), they 
measured it using a variety of scales and SMDs express the size of the intervention 
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effect in each study relative to the variability observed in that study, thus 
standardizing the results of the studies to a uniform scale before they are combined 
(Borenstein et al. 2010). 
    
                                                       
                        
  
Then, to analyse the data from dichotomous and continuous studies together, I used 
the generic inverse variance fixed-effects method, that calculates pooled ORs for all 
studies, after inputting the natural logarithm of the OR (logOR) and its standard error 
[SE(logOR)].  
I used Microsoft Excel to calculate the logOR and SE (logOR) for dichotomous 
studies, using the “LN” function and the equation below:    
 
Number of participants with an 
APOE ɛ4 or ɛ2 allele present 
Number of participants with an 
APOE ɛ4 or ɛ2 allele absent 
Number of participants 
with CAA present 
a c 
Number of participants 
with CAA absent 
b d 
 













I used Microsoft Excel and the method described by Chinn to convert SMDs and 
95% CIs to logORs and SE(logOR) (Chinn 2000) as per equations: 
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I repeated the analyses, comparing the ε4+ and ε2+ genotypes with the wild-type ε3/ 
ε3 genotype only, to confirm that any significant associations were robust and not 
driven by the ε2/ε3 and ε2/ε2 genotypes in the ε4- group, or by the ε4/ε3 and ε4/ε4 
genotypes in the ε2- group. I also compared participants’ CAA status by ε4 





statistics, interpreting the I
2 
as follows (The Cochrane Collaboration 2011):  
 I2 = 0% to 40%: might not be important; 
 I2 = 30% to 60%: may represent moderate heterogeneity; 
 I2 = 50% to 90%: may represent substantial heterogeneity; 
 I2 = 75% to 100%: considerable heterogeneity. 
I considered p<0.05 to imply statistical significance. I repeated all analyses using a 
random-effects method (DerSimonian and Laird method for studies presenting data 
in a dichotomous format, inverse-variance random-effects method for studies 
presenting data in a continuous format and for combined analyses of dichotomous 
and continuous data) (The Cochrane Collaboration 2011). 
3.2.6 Subgroup analyses 
For presence versus absence of CAA among those with ε4+ versus ε4- genotypes, I 
conducted pre-specified subgroup analyses based on:  
 participants’ clinical dementia status: studies with clinically demented 
participants versus those with clinically non-demented participants versus 
studies with both demented and non-demented participants (or where 
dementia status was not specified); 
 neuropathologically confirmed AD status: studies of neuropathologically 
confirmed AD participants versus those with clinically non-demented 
participants versus studies with both demented and non-demented 
participants (or where dementia status was not specified); 
 ethnicity: studies with Asian versus studies with Caucasian participants; 
 study quality score: studies with up to 2 points versus those with 3-4 points 
versus studies with 5-9 points; 
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 each quality criterion included in the overall study quality score: study size, 
blinding, design, data format, pathology assessment and genotyping 
reporting quality.  
I assessed the subgroup differences based on analyses results from Review Manager 
that undertakes a standard test for heterogeneity across subgroup results, considering 
p<0.1 to imply statistical significance (Petitti 2001).  
3.2.7 Assessment of potential publication and reporting bias  
For any statistically significant result for the association between APOE genotype 
and CAA, I assessed the potential effect of unpublished negative studies or studies 
not reporting the data required for meta-analysis (i.e. publication and reporting 
biases), using a modified ‘failsafe N’ method: I determined the size of a notional 
study with a null result (OR=1) required to bring any significant result (p<0.05) to a 
just non-significant level (p=0.05), assuming the overall prevalence of CAA and 
distribution of genotypes to be the average of these for the studies included 
(Rosenthal 1979). I did this by calculating the logOR and SE(logOR) for a 
hypothetical study with n participants in Microsoft Excel, and then including the data 
in the relevant Review Manager meta-analysis to investigate the effect of the 
hypothetical study on the overall OR and p-value. I increased the size (n) of the 
hypothetical study gradually until the overall p-value increased to 0.05. I used the 
size of this notional study as a guide to whether there might plausibly be enough 
participants in unpublished, unreported or otherwise unretrieved null studies to make 
an apparently significant result non-significant, if data from such studies were 
available for inclusion in my meta-analyses.  
I also visually inspected funnel plots for the ɛ4+ versus ɛ4-, and ɛ2+ versus ɛ2- 
analysis.  
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3.3 Results   
3.3.1 Included studies  
Of 1754 publications identified for screening, 107 were relevant to my analyses of 
APOE genotype and sporadic CAA (Figure 3.1). From these 107, I excluded 61 (49 
because they included participants overlapping with other included studies, and 12 
because of very small size [< 35 participants]), leaving 46 studies, including 6645 
participants in total (Figure 3.1) (Alafuzoff et al. 2009, Alafuzoff et al. 1999, Attems 
et al. 2005, Attems et al. 2008, Berg et al. 1998, Caselli et al. 2010, Chalmers et al. 
2003, Christoforidis et al. 2005, Chui et al. 2006, Cruz-Sánchez et al. 2000, 
Davidson et al. 2006, Durany et al. 2000, Etiene et al. 1998, Greenberg et al. 1995, 
Greenberg et al. 1998, Honig et al. 2005, Jicha et al. 2008, Lashley et al. 2008, 
Leclercq et al. 2005, Lewis et al. 2006, Love et al. 2003, Mortimer et al. 2009, 
Nelson et al. 2010, Nicoll et al. 2011, Olichney et al. 2000, Oyama et al. 1995, 
Pahnke et al. 2003, Petrovitch et al. 2008, Peuralinna et al. 2011, Pfeifer et al. 2002, 
Premkumar et al. 1996, Roher et al. 2003, Schneider et al. 2005, Sonnen et al. 2010, 
Stopa et al. 2008, Zarow et al. 1999, Zipser et al. 2007, Zubenko et al. 1994, 
Tanskanen et al. 2005, Thal et al. 2002, Thomas et al. 2000, Tiraboschi et al. 2004, 
Walker et al. 2000, Yamada 2002, Yamaguchi et al. 2001, Yip et al. 2005).  
3.3.2 Study characteristics  
All studies used autopsy brains from a brain bank, clinical autopsies, or brain 
pathological material (mainly autopsy, some biopsy) arising during the course of a 
population-based prospective study. The median number of participants per study 
who were both genotyped and assessed pathologically was 100. Mean age was 70 to 
85 years in most studies. About half of all participants were male. 19 studies (2660 
participants) were conducted in white populations in Europe, 21 (3225 participants) 
in whites in the USA, five (714 participants) in Asian populations (three in Japan, 
two in Japanese-Americans in the USA) and for one study this information was 
unavailable. About 30% of participants had clinical dementia (mainly AD), about 
Chapter 3. APOE ɛ2/ɛ3/ɛ4 polymorphism associations with sporadic CAA  122 
 
10% were known not to be demented and dementia status was not specified for about 
60% (Table 3.1).  
Genotyping reporting quality was generally limited when assessed against current 
reporting standards (Little et al. 2009, Stroup et al. 2000) (Table 3.2). 10 studies 
(1723 participants) did not report the source of DNA, 25 (2993 participants) used 
brain tissue, seven (1040 participants) used blood samples, three (632 participants) 
used both, and one used brain tissue or buccal cells. No study described how DNA 
was stored or how data were used to assign genotypes. Only two studies (350 
participants) reported where genotyping had been done and two (294 participants) 
reported on the number of participants in whom genotyping had been attempted and 
in whom it had been successful. Six studies (1380 participants) did not report on the 
method of genotyping, while the rest used PCR-based techniques. In 22 studies 
(2884 participants) genotypes were either stated or calculated to be in HWE, for 
three (326 participants) they were not in HWE, 19 (3328 participants) provided no 
information on HWE and for two studies (117 participants) it was not applicable 
because included participants were chosen to provide a mixture of APOE genotypes 
or CAA severity. Only two studies (333 participants) reported that genotypers were 
blind to pathology data.  
Methods for pathological assessment were very variable (Table 3.3). With regard to 
CAA assessment, 34 studies (4570 participants) used immunohistochemistry (IHC) 
in all or some samples, 10 (1291 participants) used an alternative (Congo Red ± 
polarized light, Hematoxylin & Eosin, or Thioflavin S) and two (794 participants) 
did not report on staining method. Pathological assessment methods were used 
consistently in 44 studies, meaning that the same method was used throughout the 
study and did not vary with time, recruiting centre etc. 14 studies (2231 participants) 
specified that a neuropathologist rated CAA, but most did not report on this. A 
variety of CAA rating scales were used: 10 studies used scales devised by Olichney 
(Olichney et al. 1995), Vonsattel (Vonsattel et al. 1991), and/or Attems (Attems 
2005); 28 studies used an alternative severity rating measure or scale; five did not 
report the scale or severity measure used; and three did not rate CAA severity. Only 
two studies reported the inter- and intra-rater reliability of the scale used (or 
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referenced a study of these). 31 studies (4600 participants) assessed CAA in occipital 
and/or parietal cortex, frequently in addition to other areas. Only eight studies (890 
participants) reported that pathology raters were blind to genotyping results and six 
(1096 participants) that they were blind to relevant clinical information. 
3.3.3 Assessment of study quality  
For the studies in the meta-analysis, I calculated quality scores (ranging from 0 to 9) 
based on my pre-set criteria. There was substantial variation in overall study quality. 
No study fulfilled all criteria, but larger studies tended to have higher quality scores 
(Table 3.4).  
3.3.4 Meta-analyses results  
3.3.4.1 Association between APOE ε4 and CAA 
24 studies out of 46 (3520 of 6645 participants) provided sufficient quantitative data 
for meta-analyses (14 in a dichotomous and 10 in a continuous format) (Figure 3.2, 
Figure 3.3) (Alafuzoff et al. 1999, Attems et al. 2005, Caselli et al. 2010, Chalmers et 
al. 2003, Christoforidis et al. 2005, Chui et al. 2006, Cruz-Sánchez et al. 2000, 
Davidson et al. 2006, Greenberg et al. 1995, Leclercq et al. 2005, Mortimer et al. 
2009, Nicoll et al. 2011, Olichney et al. 2000, Pfeifer et al. 2002, Premkumar et al. 
1996, Schneider et al. 2005, Zarow et al. 1999, Zubenko et al. 1994, Tanskanen et al. 
2005, Thal et al. 2002, Walker et al. 2000, Yamada 2002, Yamaguchi et al. 2001, 
Yip et al. 2005). 22 studies could not be included in my meta-analysis: six (443 
participants) of these made a qualitative statement (Berg et al. 1998, Jicha et al. 
2008, Oyama et al. 1995, Roher et al. 2003, Stopa et al. 2008, Thomas et al. 2000), 
while 16 (2682 participants) provided no data about the association (Alafuzoff et al. 
2009, Attems et al. 2008, Durany et al. 2000, Etiene et al. 1998, Greenberg et al. 
1998, Honig et al. 2005, Lashley et al. 2008, Lewis et al. 2006, Love et al. 2003, 
Nelson et al. 2010, Pahnke et al. 2003, Petrovitch et al. 2008, Peuralinna et al. 2011, 
Sonnen et al. 2010, Tiraboschi et al. 2004, Zipser et al. 2007).  
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Figure 3.2 shows study specific and pooled ORs for ε4+ versus ε4- genotypes based 
on the fixed-effects method. The pooled OR showed a significantly increased odds of 
having CAA for ε4+ genotypes (OR 2.89, 95% CI 2.51 to 3.33; p<0.00001), with 





p<0.00001). When I meta-analysed studies providing continuous and dichotomous 
data separately, pooled results were in the same direction as the overall pooled OR 
and were separately significant (continuous studies: SMD 0.50, 95% CI 0.40 to 0.60; 
p<0.00001; dichotomous studies: OR 4.25, 95% CI 3.33 to 5.43; p<0.00001). The 
association was of similar magnitude and remained significant when I used the 
random-effects method (OR 3.08, 95% CI 2.32 to 4.09; p<0.00001) (Figure 3.3) and 
when I compared the ε4+ versus ε3/ε3 genotypes (OR 2.68, 95% CI 2.15 to 3.32; 
p<0.00001) (Figure 3.4, Table 3.5).   





2df=1.91; p=0.38) (Figure 3.5), with similar results when I 





2df=2.75; p=0.25) (Figure 3.6, Figure 3.7, Table 3.6). I detected no 





1df=2.33; p=0.13) (Figure 3.6, Figure 3.8). The association did not vary 




2df=3.44; p=0.18) (Figure 3.6, 
Figure 3.9). Nor did I detect significant subgroup differences based on the individual 














1df=2.30; p=0.13) (Figure 3.6, Figure 3.12). The 
association was slightly larger in studies with prospective recruitment of participants 
compared to retrospective studies (OR 3.66, 95% CI 2.87 to 4.68 versus OR 2.56, 





(Figure 3.6, Figure 3.13), in studies presenting data in dichotomous versus 
continuous format (OR 3.64, 95% CI 2.91 to 4.55 versus OR 2.48, 95% CI 2.06 to 




1df=6.77; p=0.009) (Figure 3.6, 
Figure 3.14) and in studies with higher quality of pathology assessment (studies with 
2 points: OR 4.20, 95% CI 3.37 to 5.24 versus studies with 1 point: OR 2.22, 95% CI 
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1df=18.91; p<0.0001) (Figure 
3.6, Figure 3.15). The subgroup differences were similar when I used the random-
effects method, although no longer statistically significant by study design (p=0.18) 
and data format (p=0.11) (Table 3.7).   
Studies providing only qualitative data reported either no significant association or a 
trend towards association with APOE ε4 (Berg et al. 1998, Jicha et al. 2008, Oyama 
et al. 1995, Roher et al. 2003, Stopa et al. 2008, Thomas et al. 2000) (Table 3.8). 
12 studies provided quantitative data for meta-analysis of the association of APOE ε4 
allele dose with CAA, showing a significant increase in the odds of having CAA 
with increasing dose of the ε4 allele (Attems et al. 2005, Chalmers et al. 2003, Cruz-
Sánchez et al. 2000, Davidson et al. 2006, Leclercq et al. 2005, Nicoll et al. 2011, 
Olichney et al. 2000, Premkumar et al. 1996, Zarow et al. 1999, Zubenko et al. 1994, 
Thal et al. 2002, Walker et al. 2000). The OR for participants with one ε4 allele 
versus no ε4 allele was 2.09 (95% CI 1.69 to 2.58; p<0.00001), for ε4 homozygotes 
versus ε4 heterozygotes was 3.38 (95% CI 2.34 to 4.88; p=0.04) and for the ε4 
homozygotes versus  participants with no ε4 allele was 7.04 (95% CI 4.81 to 10.29; 
p=0.0003) (Figure 3.16). Two studies (117 participants) providing a qualitative 
statement about the association supported this result (Greenberg et al. 1995, Roher et 
al. 2003) (Table 3.8). 
3.3.4.2 Association between APOE ε2 and CAA  
11 studies (1640 participants) provided quantitative data for meta-analysis of APOE 
ε2+ versus ε2- genotypes with CAA (Attems et al. 2005, Christoforidis et al. 2005, 
Cruz-Sánchez et al. 2000, Davidson et al. 2006, Leclercq et al. 2005, Nicoll et al. 
2011, Olichney et al. 2000, Premkumar et al. 1996, Tanskanen et al. 2005, Thal et al. 
2002, Walker et al. 2000). Figure 3.17 shows study specific and pooled ORs for ε2+ 
versus ε2- genotypes based on the fixed-effects method. The pooled OR showed 
significantly decreased odds of having CAA for ε2+ genotypes (OR 0.64, 95% CI 
0.47 to 0.86, p=0.003). When I meta-analysed studies providing continuous and 
dichotomous data separately, pooled results were in the same direction as the overall 
pooled OR (continuous studies: SMD -0.27, 95% CI -0.5 to -0.03; p=0.03; 
Chapter 3. APOE ɛ2/ɛ3/ɛ4 polymorphism associations with sporadic CAA  126 
 
dichotomous studies: OR 0.63, 95% CI 0.43 to 0.94; p=0.03). There was moderate 




10df=18.57; p=0.05). However 
the association was no longer significant when I used the random-effects method 
(OR 0.68, 95% CI 0.42 to 1.08; p=0.1) (Figure 3.18) or when I compared the ɛ2+ 
genotypes with ɛ3/ɛ3 genotypes (OR 0.90, 95% CI 0.65 to 1.26; p=0.55) (Table 3.5, 
Figure 3.19).  
Two studies (213 participants)
 
provided a qualitative statement; neither reported a 
significant association (Chalmers et al. 2003, Greenberg et al. 1995) (Table 3.8). 
3.3.4.3 Bias assessment 
Failsafe N calculations showed that a null study of >177,000 participants would be 
required to bring the association of ε4+ genotypes with CAA to a just statistically 
non-significant level (i.e. p=0.05). It would require a null study of >7600 participants 
to bring the stronger association with CAA of ε4 homozygous versus heterozygous 
genotypes to a just non-significant level.  
The funnel plots for the ε4+ versus ε4- analysis and for the ε2+ versus ε2- analysis 
were only slightly asymmetrical (Figure 3.20, Figure 3.21).  
3.4 Discussion 
3.4.1 Main findings 
I found a highly significant, dose-dependent association between APOE ε4 and 
pathologically proven CAA. The association remained robust when using both fixed-
effects and random-effects methods, and when using both the ɛ4- genotypes and the 
ɛ3/ɛ3 genotypes as the comparison group. The association did not vary significantly 
with dementia status, ethnicity, or study quality. I found no overall robust association 
between APOE ε2 and presence of pathological CAA (Rannikmäe et al. 2013) 
(Appendix 4). While analysis using the fixed-effects method suggested a significant 
protective effect of ɛ2, this was not confirmed by analysis using the random-effects 
method, and by analyses using the ɛ3/ɛ3 genotypes (rather than the ɛ2- genotypes) as 
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the comparison group. The latter would suggest that the apparent protective effect of 
ɛ2 could be driven by the ɛ4/ɛ3 and the ɛ4/ɛ4 genotypes in the ɛ2- group. 
To my knowledge, this is the first systematic review and meta-analysis of 
associations between APOE ɛ2/ɛ3/ɛ4 genetic polymorphisms and pathologically 
proven CAA, although there have been meta-analyses of APOE genetic associations 
with deep and lobar ICH, ICH severity and outcome, and brain microbleeds (Biffi et 
al. 2011, Biffi et al. 2010, Maxwell et al. 2011). The ɛ4 may influence the risk of 
CAA by increasing the amyloid-β 40:42 ratio, shifting amyloid deposition to the 
vessels instead of brain parenchyma (Fryer et al. 2005), and may reduce the 
efficiency of efflux of amyloid-β along perivascular channels (Thal et al. 2007) 
(Charidimou et al. 2012a).  
The prevalence of CAA in AD is over 70% but the relationship between CAA and 
AD is still poorly understood. Although the diagnostic criteria for dementia and the 
participant inclusion criteria varied between studies (with some excluding cases with 
severe dementia), the demonstration of a similar association in those with and 
without clinical dementia suggests that the association of APOE ε4 with CAA is 
independent of its known association with dementia (mainly AD). This is further 
supported by similar results when I limited the dementia subgroup to 
neuropathologically verified AD cases only. Relative to other apoE isoforms, apoE4 
is thought to increase aggregation or impair clearance of amyloid-, or both. While 
this mechanistic pathway is probably common to both CAA and AD, specific 
mechanisms might also occur. For example, apoE isoform-specific neurotoxic effects 
may contribute to neurodegeneration in AD, independent of interactions with 
amyloid- (Verghese et al. 2011).  
I performed the analyses using the fixed-effects method and then repeated all 
analyses using the random-effects method to confirm robustness of any significant 
results. It is generally recommended to use the fixed-effects method when the 
underlying assumption is that the true allele effect is the same in all studies included 
in the meta-analysis, and to use the random-effects method when the underlying 
assumption is that the true allele effect is different in the included studies (Borenstein 
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et al. 2010). I chose to use both methods to confirm robustness of any significant 
results and also because there was moderate to substantial heterogeneity between the 
studies. This approach is supported by the Cochrane Collaboration, which 
recommends comparing the fixed- and random-effects estimates if one is concerned 
about the influence of small-study effects on the results of meta-analysis in which 
there is evidence of between-study heterogeneity (The Cochrane Collaboration 
2011). If the estimates are similar, then any small-study effects have little effect on 
the effect estimate.  
Since this systematic review, at least one further study looking at the association 
between APOE ɛ2/ɛ3/ɛ4 polymorphism and neuropathological CAA in 1062 subjects 
has been published (Yu et al. 2015). Yu et al study confirms a significant association 
between ɛ4 and CAA, though there is some overlap with the cases included in my 
systematic review. Interestingly, Yu et al also show a significant association between 
CAA severity and ɛ2, but only after adjusting for Alzheimer’s pathology. There is no 
data available about proportion of cases with an intracerebral haemorrhage in this 
cohort. There was not sufficient data to perform a meaningful subgroup analysis for 
ɛ2 based on participants’ dementia status in my systematic review. However when 
including data from Yu et al (2015) to the overall meta-analysis of APOE ɛ2 
association with CAA, the association remains non-significant (fixed-effects analysis 
OR 1.25, 95% CI 0.99 to 1.57; p=0.06; random-effects analysis OR 1.11, 95% CI 
0.71 to 1.74; p=0.63). Further studies are needed to investigate if there is an 
association of ɛ2 with neuropathological CAA when adjusted for AD pathology.  
3.4.2 Strengths and limitations 
My study benefited from thorough ascertainment and critical appraisal of pertinent 
studies including a large number of participants. Lack of variation in the effect of 
APOE ε4 by study size and the very large failsafe N strongly suggest that this 
association could not plausibly be explained by publication, reporting or any other 
small-study bias. This is despite the fact that the failsafe N method assumes that the 
mean effect size in the hidden studies is zero, when in fact it could be negative, 
which would require fewer studies to nullify the effect (Borenstein et al. 2009). In 
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addition, although study quality was generally limited when assessed against current 
reporting standards (Little et al. 2009, Stroup et al. 2000), there were – reassuringly – 
no significant subgroup differences by overall study quality score.  
There were some limitations. Pathological assessment was very variable. CAA 
assessment location varied widely, possibly influencing the rate of CAA detection, 
since a greater burden of CAA is generally reported in the occipital or parietal lobes, 
albeit with a higher frequency of frontal lobe involvement reported in studies from 
China and Japan (Attems 2005, Chen et al. 2010). Indeed, at the time these studies 
were conducted, there was no widely accepted, standardized histopathological 
grading system for CAA (Chen et al. 2010), and no comparative studies to determine 
the most accurate method for assessing CAA. Recently, a new consensus protocol 
and scoring scheme for the assessment of CAA and associated vasculopathic 
abnormalities in post-mortem brain tissue has been developed (Love et al. 2014). 
Most included studies did not address the issue of potential confounding due to 
population stratification. However, such confounding is unlikely because these were 
not case-control studies but cross-sectional studies across a range of CAA severities. 
Finally, there were a large number of studies that I could not include in the meta-
analysis because they did not report the necessary quantitative data about the 
association between the genetic polymorphism and CAA. However, my systematic 
review is strengthened by the identification and detailed characterisation of these 
studies. By contrast, many meta-analyses do not account for otherwise relevant 
studies without the necessary data within their publications and so risk undetected 
reporting bias, since many studies report only significant findings and fail to mention 
non-significant ones. I have shown that my findings are robust to these missing data, 
since the large failsafe N (>177,000) greatly exceeded the total number of 
participants excluded due to lack of available data (3,125).  
3.4.3 Outstanding issues 
Since APOE effects on ICH may vary with ethnicity, there may be ethnic variation in 
genetic associations with CAA, but these have not been widely studied in non-white 
populations (Tzourio et al. 2008). Genetic associations may also differ by CAA 
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location and subtype. For example, there is preliminary evidence that APOE ε4 may 
be associated with CAA type 1 (where CAA is found in cortical capillaries), and ε2 
with CAA type 2 (where amyloid is deposited in leptomeningeal and cortical vessels 
with the exception of cortical capillaries) (Thal et al. 2002). Finally, the suggestion 
of different genetic influences on amyloid deposition in the vessel wall and 
progression to advanced vasculopathic changes leading to ICH requires further 
investigation, in particular the proposed differential effects of ε4 and ε2 alleles.  
3.4.4 Conclusions 
In conclusion, despite study quality issues, a large body of evidence supports an 
association of APOE ε4 with the presence and severity of histopathologically 
confirmed CAA, at least in white populations. There is no convincing robust 
association of histopathologically confirmed CAA with APOE ɛ2. Future research 
efforts require methodologically robust studies adhering to a standardised CAA 
assessment protocol (Love et al. 2014) and current reporting standards, facilitating 
comparisons between studies and collaborative data pooling efforts. These should 
focus on the differential effects of APOE ε2 and ε4, variation in genetic effects by 
ethnicity and CAA location, and on the potential influence of other polymorphisms 
on this clinically important but as yet incompletely understood phenotype. 
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Attems 2005 Austria 








Caselli 2010 USA 
Cognitively healthy adults mainly from 
retirement communities enrolled in the Sun 






Chalmers 2003 UK 
Clinically diagnosed AD and 34 elderly normal 







Christoforidis 2005 Germany Routine autopsy brains 118 74 Caucasian - 
Chui 2006 USA 
People from the Ischemic Vascular Dementia 
Programme (longitudinal study of subcortical 
ischemic vascular dementia, AD and cognitively 






Cruz-Sánchez 2000 - 
Cases with clinically diagnosed dementia & 







Davidson 2006 UK Neuropathologically confirmed AD cases 146 - Caucasian - 
Greenberg 1995 USA 
Brains selected from a brain tissue resource 









Mortimer 2009 USA Participants from the Nun Study (prospective 267 91 Caucasian
4 
0 


















study which recruited members of the School 
Sisters of Notre Dame congregation 1991-1992) 
Nicoll 2011 UK 
Participants from MRC CFAS neuropathology 
cohort of 456 participants (UK population-based 
study that started in early 1990s, and recruited 














Pfeifer 2002 USA 
Men from the Honolulu-Asia Aging Study 
(prospective study recruiting Japanese-American 





Premkumar 1996 USA People from an AD research programme 240 







Schneider 2005 USA 
People from the Religious Orders Study 
(prospective study in older Catholic nuns, 






Tanskanen 2005 Finland 
People aged ≥ 95 years from the Vantaa 85+ 
study (Finnish population-based study recruiting 
people from the community born before 1906,  







Thal 2002 - Cases with CAA & controls without 56 77 - 52 
Walker 2000 Germany Routine autopsy brains 244 67 Caucasian
4 
55 


















Yamada 2002 Japan 
Brains from autopsy series of a large geriatric 
hospital in Japan, excluding brains with 
neurodegenerative diseases except AD 
201 86 Asian 40 
Yamaguchi 2001 Japan People who died from cancer 101 65 Asian
4 
- 












Zubenko 1994 USA Neuropathologically confirmed AD cases 91 76 Caucasian
4 
39 
Berg 1998 USA 
Brains from a consecutive autopsy series of 
prospectively studied probable AD or incipient 







Jicha 2008 USA 





Oyama 1995 Japan 
Consecutive autopsy brains from a geriatric 




Roher 2003 USA Brains from a brain donation programme 24 82 Caucasian
4 
54 
Stopa 2008 USA Brains from a brain bank and AD research centre 75 78 Caucasian 38 
Thomas 2000 - Elderly Norwegian AD patients 50 86 Caucasian
4 
28 

















Durany 2000 - 
AD patients, CAA cases without other AD 
























Etiene 1998 USA AD cases from an AD research centre brain bank 100 80 Caucasian
4 
36 
Greenberg 1998 USA 
Autopsy brains with moderate or severe CAA 









Lashley 2008 UK 
PD cases and normal control participants 







Lewis 2006 UK 
AD cases, vascular dementia cases, and controls 




Love 2003 UK 


















Petrovitch 2008 USA 
Men from the Honolulu-Asia Aging Study 
(prospective study recruiting Japanese-American 








People from the Vantaa 85+ study (Finnish 
population-based study that recruited people 
from the community born before 1906 and living 







Sonnen 2010 USA Participants from the Adult Changes in Thought 256 93 participants≤75 Majority 42
5 


















Study (prospective study enrolling 3392 
cognitively intact community-dwelling 






Tiraboschi 2004 USA Brains with a neuropathological diagnosis of AD 48 80 Caucasian
4 
42 







Dark grey shading: studies providing data for the meta-analyses; light grey shading: studies providing a qualitative statement about the ε4 allele association with CAA; 
no shading: studies known to have APOE genotype and CAA data but providing no data about association between APOE genotype and CAA; “-“: data not available; 
AD: Alzheimer’s disease; PD: Parkinson’s disease; CAA: cerebral amyloid angiopathy;
 1 
Country: country where study conducted (if not stated explicitly, then it was 
assumed from authors’ affiliations); 
2 
All studies included autopsy brains; 
3 
Study size: number of non-overlapping participants genotyped for the APOE polymorphism 
and assessed for CAA; 
4 
Ethnicity not explicitly stated, but assumed from context; 
5 
Data provided for a larger or smaller group of participants, not just those genotyped 
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or in batches 
No. genotyping 











blood - - - - PCR-based - - 
Attems 2005 Brain - - - - PCR-based Yes - 
Caselli 2010 - - - - - PCR-based Yes - 
Chalmers 2003 Brain - - - - PCR-based - - 
Christoforidis 2005 Brain - - - 118/125 PCR-based Yes - 
Chui 2006 Blood - - - - - - - 
Cruz-Sánchez 2000 Brain - - - - PCR-based Yes - 
Davidson 2006 Brain - - - - PCR-based Yes - 
Greenberg 1995 Brain - - - - PCR-based n/a Yes 





- - - - PCR-based - - 
Nicoll 2011 Brain - - - - PCR-based Yes - 
Olichney 2000 
Brain or 
blood - - - - PCR-based Yes - 
Pfeifer 2002 Blood - - - - PCR-based - - 
Premkumar 1996 Brain - - - - PCR-based Yes Yes 
Schneider 2005 Blood - - - - PCR-based Yes - 
Tanskanen 2005 Blood - - - - PCR-based Yes - 













or in batches 
No. genotyping 









Thal 2002 Brain - - - - PCR-based Yes - 
Walker 2000 Brain - - - - PCR-based No - 
Yamada 2002 Brain - - - - PCR-based Yes - 
Yamaguchi 2001 - - - - - - - - 
Yip 2005 - - - - - - - - 
Zarow 1999 Brain - - - - PCR-based Yes - 
Zubenko 1994 Brain - - - - PCR-based Yes - 
Berg 1998 
Brain or 
blood - Stated - 176/199 PCR-based Yes - 
Jicha 2008 Blood - - - - PCR-based - - 
Oyama 1995 - - - - - PCR-based Yes - 
Roher 2003 Brain - - - - PCR-based n/a - 
Stopa 2008 - - - - - PCR-based No - 
Thomas 2000 Brain - - - - PCR-based Yes - 
Alafuzoff 2009 Brain - - - - PCR-based - - 
Attems 2008 Brain - - - - PCR-based Yes - 
Durany 2000 Brain - - - - PCR-based - - 
Etiene 1998 Brain - - - - PCR-based Yes - 
Greenberg 1998 Brain - - - - PCR-based - - 
Honig 2005 - - - - - - - - 













or in batches 
No. genotyping 









Lashley 2008 Brain - - - - PCR-based - - 
Lewis 2006 Brain - - - - PCR-based - - 
Love 2003 - - - - - PCR-based - - 
Nelson 2010 - - - - - - - - 
Pahnke
 
2003 Brain - - - - PCR-based Yes - 
Petrovitch 2008 Blood - Stated - - PCR-based - - 
Peuralinna 2011 Blood - - - - PCR-based Yes - 
Sonnen
 
2010 Blood - - - - PCR-based - - 
Tiraboschi 2004 Brain - - - - PCR-based - - 
Zipser 2007 - - - - - PCR-based No - 
 
Dark grey shading: studies providing data for the meta-analyses; light grey shading: studies providing a qualitative statement about the ε4 allele association with CAA; 
no shading: studies known to have APOE genotype and CAA data but providing no data about association between APOE genotype and CAA; “-“: data not available; 
n/a: not applicable; HWE: Hardy-Weinberg equilibrium; PCR: polymerase chain reaction; 
1 
Number of participants in whom genotyping was attempted and number in 
whom it was successful; 
2 
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Table 3.3 Pathology assessment characteristics of studies included in the systematic review of APOE genotype associations with CAA  
First author, 
publication year 


















IHC CR HE ThS        
Alafuzoff 1999     Yes - P; LM; Other - - - 
Attems 2005     Yes - F; Ot; O; LM; 
Olichney 
Attems 
- - - 
Caselli 2010   some some Yes - F; T; P; O; Other - - - 
Chalmers 2003     Yes 
Neuro-
pathologist 
F; T; P; LM; Olichney - - - 
Christoforidis
 
2005     Yes - T; O; LM; Other - - - 
Chui 2006 some    Yes 
Neuro-
pathologist 
F; T; P; O; Ot; Vonsattel - Yes Yes 
Cruz-Sánchez 2000     Yes - Ot; O; T; n/a n/a - - 
Davidson 2006     Yes - F Other “Good”8 - - 
Greenberg 1995     Yes 
Neuro-
pathologist 
F; P; T; Ot; O; C; Vonsattel - Yes - 
Leclercq 2005     Yes - F; T; LM; Other - Yes9 Yes9 
Mortimer 2009     Yes 
Neuro-
pathologist 
F; P; T; O; Ot; LM; Other - - Yes 
Nicoll 2011     Yes 
Neuro-
pathologist 
F; T; P; O; Ot; LM; Other - - Yes 
Olichney 2000     Yes - Ot; F; P; T; LM; Olichney - - - 
Pfeifer 2002     Yes 
Neuro-
pathologist 
F; T; P; O; LM; 
After 
Vinters 
- - Yes 
Premkumar 1996  some  some Yes 
Neuro-
pathologist
10 F; T; P; O; Other - Yes - 






















IHC CR HE ThS        
Schneider 2005     Yes 
Neuro-
pathologist 
F; O; LM; 
After 
Attems 
- - - 
Tanskanen 2005 some    
Yes 
 
- F; T; P; Ot; C; LM; Other - - - 
Thal 2002     Yes - T; O; LM Other - - - 
Walker 2000     Yes - Ot; T; LM; Other - Yes - 
Yamada 2002 some    Yes - O; LM; Other - - - 
Yamaguchi 2001     Yes - F - n/a - - 
Yip 2005     Yes 
Neuro-
pathologist 
O Other - - - 
Zarow 1999     Yes 
Neuro-
pathologist 






Zubenko 1994     Yes 
Neuro-
pathologist 
- n/a n/a - - 
Berg 1998     Yes - 
Unknown for CAA 
but F; T; P; LM; 
Other - - - 
Jicha 2008     Yes - 
Unknown for CAA  
but F; T; P; O; C; 
Ot; LM; 
Other - - - 
Oyama 1995 
11    Yes - F; T; O; Other - - - 
Roher 2003     Yes - LM; P; Other - - - 
Stopa 2008     Yes - F Other - Yes - 
Thomas 2000     Yes 
Image 
analysis 
T Other - - - 






















IHC CR HE ThS        
Alafuzoff 2009     Yes - F; T; P; n/a n/a - - 
Attems 2008     Yes - F; Ot; O; LM; Olichney - - Yes 
Durany
 
2000     Yes - O; T; Ot; LM; Other - - - 
Etiene 1998     Yes - T; LM; Other - - - 
Greenberg
 
1998 some    Yes - 
Cerebral cortex and 
cerebellum 
Vonsattel - Yes - 
Honig
 
2005 - - - - - - - - 
Lashley 2008     Yes 
Neuro-
pathologist 
F; T; P; O; LM; Olichney - - - 
Lewis
 
2006     Yes 
Image 
analysis 
T; F; Other - - - 
Love
 
2003     Yes - F; T; Olichney - - - 
Nelson
 
2010     Yes - 
Not known for 
CAA 
- n/a - - 
Pahnke
 
2003     Yes - T; Ot; LM; Other - Yes - 
Petrovitch
 
2008     Yes 
Neuro-
pathologist 
F; T; P; O; Ot; LM; Other - - - 
Peuralinna
 
2011     Yes - F; P; T; O; Ot; C Other - - - 
Sonnen
 
2010 - - 
Neuro-
pathologist 
- - - - - 
Tiraboschi
 
2004     Yes - F; P; T; Ot; LM; Other - - - 
Zipser
 
2007     Yes - F - - - - 
 
Dark grey shading: studies providing data for the meta-analyses; light grey shading: studies providing a qualitative statement about the ε4 allele association with CAA; 
no shading: studies known to have APOE genotype and CAA data but providing no data about association between APOE genotype and CAA; “-“: data not available; 
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n/a: not applicable; IHC: immunohistochemistry; CR: congo red; HE: Hematoxylin and Eosin; ThS: thioflavin S; 
1 
Consistency: were the same pathological assessment 
methods used consistently? (i.e. was the same method used throughout the study or did it vary with time, recruiting centre etc.); 
2 
Rater qualification: qualification of 
the person assessing CAA; 
3
 Locations rated: F=frontal cortex; T=temporal cortex; P=parietal cortex; O=occipital cortex; Ot=other; C=cerebellar cortex;  
LM=leptomeninges (assumed leptomeninges were assessed when the scale used in the study included assessment of leptomeningeal vessels); 
4 
Grading system: scale 




nter- and intra-rater reliability of the grading system used; 
6 
Blinding to genotype: blinding of CAA raters to genotyping results; 
7 
Blinding to clinical information: blinding of CAA raters to relevant clinical information such as 
participants’ dementia and Alzheimer’s disease status, history of intracerebral haemorrhage, age; 
8 
Inter-rater reliability was looked at in a previous study and described 
as "good" but using methods that were unclear; 
9 
Leclercq 2005 – only IHC results assessed blind to genotype and clinical information; 
10
 Premkumar 1996 – some 
rated by neuropathologist, not known for some; 
11
 Oyama 1995 – assumed IHC was used based on a reference to a previous study on same participants; If an included 
study referenced another study regarding how pathology assessment was done, then I generally assumed the method and scale used were the same, however, other 
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Table 3.4 Quality scores of studies included in the meta-analyses of APOE genotype associations with CAA  





















>239 none any complete R P D C 
 0 1 2 0 1 2 0 1 0 1 0 1 2 0 1  (0-9) 
Alafuzoff 1999
 
               209 4 
Attems 2005
 
               53 2 
Caselli 2010
 
               179 4 
Chalmers 2003
 
               120 4 
Christoforidis 2005
 
               118 2 
Chui 2006
 
               73 4 
Cruz-Sanchez 2000
 
               73 2 
Davidson 2006
 
               146 4 
Greenberg 1995
 
               93 4 
Leclercq 2005
 
               88 3 
Mortimer 2009
 
               267 8 
Nicoll 2011
 
               310 7 
Olichney 2000
 
               247 5 
Pfeifer 2002
 
               201 6 
Premkumar 1996
 
               240 6 
Schneider 2005
 
               208 5 
Tanskanen 2005
 
               71 3 
Thal 2002
 
               56 2 
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>239 none any complete R P D C 
 0 1 2 0 1 2 0 1 0 1 0 1 2 0 1  (0-9) 
Walker 2000
 
               244 6 
Yamada 2002
 
               201 4 
Yamaguchi 2001
 
               101 1 
Yip 2005
 
               99 2 
Zarow 1999
 
               42 4 
Zubenko 1994
 
               91 2 
 
1 
Blinding: genotypers to pathology data, CAA raters to genotyping data, CAA raters to clinical information (0: no blinding, 1: blinding at least one way, 2: blinding all 
three ways); 
2 
Study design: prospective [P] or retrospective [R]; 
3 
Data format: dichotomous [D] or continuous [C]; 
4 
Pathology assessment: points assigned based on 
whether method for assessing CAA reported, neuropathologist-rated CAA, >1 brain location examined (0: no criteria fulfilled; 1: one to two criteria fulfilled; 2: all 
three criteria fulfilled); 
5 
Genotyping reporting: points assigned based on whether source of DNA and genotyping method reported (0: none or one criteria reported; 1: 
both criteria reported); 
6 
N: number of participants.  
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Table 3.5 Summary of meta-analyses of association between APOE genotype and presence 
versus absence of CAA 
 
n: number of participants with CAA present; N: total number of participants; Dark grey shading: 
statistically significant results; FE: results using the fixed-effects method; RE: results using the 











CAA present versus CAA 
absent 
Number of dichotomous 
studies: 
n/N (4+ /2+) versus n/N 
(4-/2-/33) 
4+ versus 4- 
genotypes 
FE 
OR 2.9 (95% CI 2.5 to 3.3); 
p<0.00001 14 studies: 382/594 versus 
388/1100 
RE 
OR 3.1 (95% CI 2.3 to 4.1); 
p<0.00001 
4+ versus 3/3 
genotypes 
FE 
OR 2.7 (95% CI 2.2 to 3.3); 
p<0.00001 9 studies: 262/405 versus 
209/672 
RE 
OR 3.3 (95% CI 2.0 to 5.5); 
p<0.00001 
2+ versus 2- 
genotypes 
FE 
OR 0.6 (95% CI 0.5 to 0.9); 
p=0.003 8 studies: 40/134 versus 
372/871 
RE 
OR 0.7 (95% CI 0.4 to 1.1); 
p=0.1 
2+ versus 3/3 
genotypes 
FE 
OR 0.9 (95% CI 0.7 to 1.3); 
p=0.55 8 studies: 40/134 versus 
147/512 
RE 
OR 1.0 (95% CI 0.6 to 1.6); 
p=0.95 
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Table 3.6 Subgroups for meta-analyses of APOE genotype associations with CAA based on 
participants’ clinical dementia and Alzheimer’s disease status 
First author and 
publication year 
Participants’ description by subgroup 
Alafuzoff 1999
 
D: 106 participants with clinical and pathological (CERAD) 
diagnosis of AD  
ND: 103 clinically not demented participants 
Attems 2005
 M: 20/53 participants had a clinical and pathological diagnosis 
of AD, 33/53 not diagnosed with AD 
Caselli 2010
 ND: 158 clinically not demented participants and 21 
participants with mild cognitive impairment 
Chalmers 2003
 
D: 86 participants clinical and pathological (CERAD) diagnosis 
of AD  





M: 8/125 participants had a clinical and pathological diagnosis 
of AD. Data provided for only 116 of the 125 participants 
Chui 2006
 
M: Severe dementia participants were excluded. 13/79 were not 
demented, 13/79 had cognitive impairment, 53/79 were 




D: 35 participants: 28/35 participants with clinical and 
pathological (Braak) diagnosis of AD; 7/35 participants with 
clinical and pathological diagnosis of small vessel disease 
dementia 
ND: 38 clinically not demented participants 
Davidson 2006
 D: 146 participants with clinical and pathological (CERAD) 
diagnosis of AD 
Greenberg 1995
 
M: 88 clinically demented and non-demented participants 
Leclercq 2005
 
M: 88 participants whose dementia status not known 
Mortimer 2009
 M: 135/267 participants were clinically demented at death, 
166/267 met the study´s neuropathologic criteria for AD 
Nicoll 2011
 
M: 151/308 participants had a clinical diagnosis of dementia; 
135/308 did not have clinical dementia; dementia status for 
22/308 not known 
Olichney 2000
 D: 246 participants with clinical and pathological (Khachaturian 
and CERAD) diagnosis of AD 




M: 138/211 participants were clinically not demented, 22/211 
participants had a clinical and pathological diagnosis of AD, 
27/211 participants diagnosed with vascular dementia, 24/211 




M: 34 participants with neurological conditions other than AD 
(i.e. ALS, CJD), questionable dementia  
D: 190 participants with clinical and pathological (Khachaturian 
and CERAD) diagnosis of AD  
ND: 16 clinically not demented participants 
Schneider 2005
 M: 102/214 participants clinically diagnosed with AD. Data 
provided for 208 participants.  
Tanskanen 2005
 
D: 47 participants clinically demented  
ND: 24 clinically not demented participants 
Thal 2002
 
D: 15 participants with clinical and pathological (Braak, NIA-
Reagan Institute criteria) diagnosis of AD  
ND: 41 clinically not demented participants 
Walker 2000
 M: 244 participants, cases with clinical evidence of overt 
dementia were excluded 
Yamada 2002
 M: 82/201 participants had a pathologically confirmed 
diagnosis of AD  
Yamaguchi 2001
 M: 101 participants who had not been formally assessed for 
dementia, but showed no signs of dementia in daily life  
Yip 2005
 D: 99 participants with clinical and pathological (CERAD, 
NIA-Reagan Institute criteria) diagnosis of AD 
Zarow 1999
 D: 42 participants with clinical and pathological (Khachaturian, 
CERAD) diagnosis of AD 
Zubenko 1994 
D: 91 participants with clinical and pathological (Khachaturian) 
diagnosis of AD 
 
D: clinically demented participants; ND: clinically not demented participants (though may have some 
AD-related changes on neuropathology); M: mixed demented and not demented participants (studies 
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Table 3.7 Summary of subgroup analyses results for meta-analyses of association of APOE ε4+ versus ε4- genotypes with CAA 
Subgroup 
Fixed-effects method Random-effects method 
OR (95% CI) 
Subgroup 
difference 




Clinically demented participants 2.37 (1.85-3.05) 
pdiff = 0.38 
2.74 (1.53-4.93) 
pdiff = 0.89 Clinically not demented participants 3.32 (2.16-5.11) 3.25 (1.88-5.63) 




Participants with pathologically confirmed AD 2.25 (1.75-2.90) 
pdiff = 0.25 
2.33 (1.29-4.24) 
pdiff = 0.64 Clinically not demented participants 3.32 (2.16-5.11) 3.25 (1.88-5.63) 
Mixed participants 2.74 (2.25-3.33) 3.23 (2.20-4.74) 
Ethnicity 
Asian participants 2.08 (1.33-3.25) 
pdiff = 0.13 
2.25 (1.18-4.28) 
pdiff = 0.33 
Caucasian participants 3.00 (2.58-3.48) 3.21 (2.36-4.38) 
Study quality 
score 
0-2 points 2.48 (1.69-3.63) 
pdiff = 0.18 
2.48 (1.69-3.63) 
pdiff = 0.43 3-4 points 2.61 (2.10-3.24) 2.74 (1.83-4.11) 
5-9 points 3.37 (2.71-4.18) 4.00 (2.15-7.45) 
Study size 
< 140 2.82 (2.20-3.62) 
pdiff = 0.45 
2.89 (2.12-3.95) 
pdiff = 0.8 140-239 2.58 (1.98-3.35) 2.74 (1.63-4.60) 
>239 3.21 (2.56-4.04) 3.72 (1.73-8.02) 
Blinding 
Any blinding 3.28 (2.64-4.06) 
pdiff = 0.13 
3.85 (2.13-6.96) 
pdiff = 0.3 
No blinding 2.62 (2.17-3.17) 2.71 (2.02-3.65) 
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Study design 
Prospective study design 3.66 (2.87-4.68) 
pdiff = 0.02 
3.97 (2.63-5.99) 
pdiff = 0.18 
Retrospective study design 2.56 (2.15-3.05) 2.72 (1.89-3.92) 
Data format 
Continuous data format 2.48 (2.06-2.98) 
pdiff = 0.009 
2.43 (1.59-3.72) 
pdiff = 0.11 




1 point 2.22 (1.84-2.67) 
pdiff <0.0001 
2.40 (1.79-3.22) 
pdiff = 0.05 
2 points 4.20 (3.37-5.24) 4.16 (2.62-6.62) 
Genotyping 
reporting quality 
0 points 2.29 (1.64-3.19) 
pdiff = 0.13 
2.29 (1.64-3.19) 
pdiff = 0.12 
1 point 3.04 (2.60-3.56) 3.33 (2.37-4.67) 
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APOE ε4 allele possession associated with increased severity of CAA in the 
neocortex but not in hippocampal or entorhinal regions 
Jicha 2008
 








D 24 Homozygosity for the APOE ε4 allele associated with increased severity of CAA 
Stopa 2008
 
M 75 No overall association with APOE genotype 
Thomas 2000
 




Homozygosity for the APOE ε4 allele associated with increased severity of CAA 
APOE ε2 allele possession associated with a trend towards less severe CAA 
Chalmers 2003
2 
M 120 No association with homozygosity for the APOE ε2 allele  
 
“-“: data not available; M: mixed clinically demented and non-demented participants; D: clinically demented participants; 
1
 Number of participants in the study for 
whom association between APOE genotype and CAA assessed; 
2 
Study also provided data for meta-analysis of the association between APOE ε4 allele and CAA.  
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Figure 3.1 Selection of studies included in the systematic review of APOE genotype associations with CAA 
 

























1,618 publications excluded 
on the basis of screening 
titles, abstracts ± full texts 
Publications screened 
(1,754 publications) 
APOE ɛ2/ɛ3/ɛ4 & 
 hereditary CAA  








Relevant studies  
(136 publications) 
702 duplicate publications 
excluded 









APOE ɛ2/ɛ3/ɛ4  
& sporadic CAA 
107 publications 









-49: overlapping participants 
-12: number of participants <35 
 
Excluded: 
-99: vasculopathic changes not assessed 
-2: number of participants <10 
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Figure 3.2 Meta-analysis of association of APOE ε4+ versus ε4- genotypes with CAA (fixed-
effects method) 





23df=80.68; p<0.00001;  
OR = odds ratio; CI = confidence interval; No. participants = total number of participants contributing 
to the analysis (10 participants excluded because of missing data: Christoforidis 2 participants, 
Greenberg 5 participants, Nicoll 2 participants, Olichney 1 participant); Squares represent study-
specific ORs, with their size proportional to the study weight based on the fixed-effects method; 







Total 2.89 (2.51, 3.33) 
Zubenko 2.90 (1.03, 8.14) 
Zarow 1.11 (0.37, 3.34) 
Yip 1.69 (0.80, 3.56) 
Yamaguchi 1.96 (0.60, 6.44) 
Yamada 1.57 (0.89, 2.79) 
Walker 1.31 (0.83, 2.07) 
Thal 2.60 (0.77, 8.73) 
Tanskanen 9.72 (2.49, 38.02) 
Schneider 5.92 (2.23, 15.72) 
Premkumar 12.67 (6.76, 23.74) 
Pfeifer 4.35 (1.75, 10.83) 
Olichney 2.39 (1.48, 3.86) 
Nicoll 2.67 (1.61, 4.42) 
Mortimer 7.36 (4.31, 12.56) 
Leclercq 9.97 (1.17, 84.91) 
Greenberg 2.92 (1.19, 7.12) 
Davidson 1.14 (0.62, 2.07) 
Cruz-Sánchez 2.06 (0.76, 5.60) 
Chui 2.30 (1.40, 3.77) 
Christoforidis 3.27 (1.39, 7.69) 
Chalmers 5.71 (2.89, 11.27) 
Caselli 2.97 (1.57, 5.60) 
Attems 8.50 (1.70, 42.61) 
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Figure 3.3 Meta-analysis of association of APOE ε4+ versus ε4- genotypes with CAA (random-
effects method) 
 





23df=80.68; p<0.00001;  
OR = odds ratio; CI = confidence interval; No. participants = total number of participants contributing 
to the analysis (10 participants excluded because of missing data: Christoforidis 2 participants, 
Greenberg 5 participants, Nicoll 2 participants, Olichney 1 participant); Squares represent study-
specific ORs, with their size proportional to the study weight based on the random-effects method; 










Total 3.08 (2.32, 4.09) 
Zubenko 2.90 (1.03, 8.14) 
Zarow 1.11 (0.37, 3.34) 
Yip 1.69 (0.80, 3.56) 
Yamaguchi 1.96 (0.60, 6.44) 
Yamada 1.57 (0.89, 2.79) 
Walker 1.31 (0.83, 2.07) 
Thal 2.60 (0.77, 8.73) 
Tanskanen 9.72 (2.49, 38.02) 
Schneider 5.92 (2.23, 15.72) 
Premkumar 12.67 (6.76, 23.74) 
Pfeifer 4.35 (1.75, 10.83) 
Olichney 2.39 (1.48, 3.86) 
Nicoll 2.67 (1.61, 4.42) 
Mortimer 7.36 (4.31, 12.56) 
Leclercq 9.97 (1.17, 84.91) 
Greenberg 2.92 (1.19, 7.12) 
Davidson 1.14 (0.62, 2.07) 
Cruz-Sánchez 2.06 (0.76, 5.60) 
Chui 2.30 (1.40, 3.77) 
Christoforidis 3.27 (1.39, 7.69) 
Chalmers 5.71 (2.89, 11.27) 
Caselli 2.97 (1.57, 5.60) 
Attems 8.50 (1.70, 42.61) 
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Figure 3.4 Meta-analysis of association of APOE ɛ4+ versus ɛ3/ɛ3 genotypes with CAA (fixed-
effects method) 
 





11df=48.94; p<0.00001; No. participants = total number of participants in the study (5 participants 
excluded because of missing data: Christoforidis 2 participants, Nicoll 2 participants, Olichney 1 
participant); OR = odds ratio; CI = confidence interval; Squares represent study-specific ORs, with 
their size proportional to the study weight based on the fixed-effects model; Horizontal lines represent 




















0.5 1 2 5 10 100 
Total 2.68 (2.15, 3.32) 
Walker 1.00 (0.59, 1.69) 
Thal 3.68 (1.04, 13.10) 
Tanskanen 10.00 (2.50, 39.98) 
Premkumar 11.30 (5.92, 21.57) 
Pfeifer 4.52 (1.80, 11.31) 
Olichney 2.39 (1.46, 3.90) 
Nicoll 2.91 (1.71, 4.94) 
Leclercq 8.06 (0.94, 68.96) 
Davidson 1.14 (0.60, 2.14) 
Cruz-Sánchez 1.95 (0.69, 5.54) 
Christoforidis 4.10 (1.66, 10.09) 
Attems 8.50 (1.66, 43.41) 
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Figure 3.5 Meta-analysis of association of APOE ɛ4+ versus ɛ4- genotypes with CAA by clinical 
dementia status  
 
 
Total 2.67 (2.31, 3.08) 
Subtotal 2.74 (2.25, 3.33) 
Yamaguchi 1.96 (0.60, 6.44) 
Yamada 1.57 (0.89, 2.79) 
Walker 1.31 (0.83, 2.07) 
Schneider 5.92 (2.23, 15.72) 
Premkumar (M) 12.75 (2.12, 76.57) 
Pfeifer 4.35 (1.75, 10.83) 
Nicoll 2.67 (1.61, 4.42) 
Mortimer 7.36 (4.31, 12.56) 
Leclercq 9.97 (1.17, 84.91) 
Greenberg 2.91 (1.19, 7.12) 
Chui 2.30 (1.40, 3.77) 
Christoforidis 3.27 (1.39, 7.69) 
Attems 8.50 (1.70, 42.61) 
Mixed 
Subtotal 3.32 (2.16, 5.11) 
Thal (ND) 1.58 (0.38, 6.65) 
Tanskanen (ND) 4.00 (0.42, 37.78) 
Premkumar (ND) 
Cruz-Sánchez (ND) 0.84 (0.14, 5.10) 
16.34 (1.71, 156.35) 
Caselli 2.97 (1.57, 5.60) 
Alafuzoff (ND) 5.03 (2.35, 10.77) 
Subtotal 2.37 (1.85, 3.05) 
Zubenko 2.90 (1.03, 8.14) 
Zarow 1.11 (0.37, 3.34) 
Yip 1.69 (0.80, 3.56) 
Thal (D) 
17.64 (2.06, 151.15) 
Premkumar (D) 17.15 (7.56, 38.90) 
Olichney 2.39 (1.48, 3.86) 
Davidson 1.14 (0.62, 2.07) 
Cruz-Sánchez (D) 2.86 (0.72, 11.31) 
Chalmers (D) 5.60 (2.39, 13.14) 
Alafuzoff (D) 1.02 (0.49, 2.12) 
Dementia 
No Dementia 
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2df=1.91; pdiff=0.38;  
OR = odds ratio; CI = confidence interval; Dementia (D) = participants with clinical dementia; No 
dementia (ND) = participants with no clinical dementia; Mixed (M) = participants with and without 
clinical dementia; No. participants = total number of participants contributing to the analysis (10 
participants excluded because of missing data: Christoforidis 2 participants, Greenberg 5 participants, 
Nicoll 2 participants, Olichney 1 participant); OR not estimable for 15 participants in Thal dementia 
group and for 16 participants in Premkumar no dementia group, because either all participants in both 
genotype groups had CAA, or no participant in either genotype group had CAA; Squares represent 
study-specific ORs, with their size proportional to the study weight based on the fixed-effects method; 
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Figure 3.6 Summary of meta-analyses of association of APOE ɛ4+ versus ɛ4- genotypes with 
CAA by subgroups  
 
 
AD = Alzheimer’s disease; OR = odds ratio; CI = confidence interval; Diamonds represent the pooled 
ORs; Horizontal lines represent 95% CIs; I
2
 = heterogeneity between subgroups; p = statistical 
significance of between subgroup difference. 
 
0.1 0.2 0.5 1 2 5 10 
Genotyping reporting: 1 point 3.04 (2.60, 3.56) 
Genotyping reporting: 0 points 2.29 (1.64, 3.19) 
Pathology assessment: 2 points 4.20 (3.37, 5.24) 
Pathology assessment: 1 point 2.22 (1.84, 2.67) 
Continuous data format 2.48 (2.06, 2.98) 
Dichotomous data format 3.64 (2.91, 4.55) 
Retrospective study design 2.56 (2.15, 3.05) 
Prospective study design 3.66 (2.87, 4.68) 
No blinding 2.62 (2.17, 3.17) 
Any blinding 3.28 (2.64, 4.06) 
Study size >239 3.21 (2.56, 4.04) 
Study size 140-239 2.58 (1.98, 3.35) 
Study size <140 2.82 (2.20, 3.62) 
Subgroups contributing to the quality score  
5-9 points 3.37 (2.71, 4.18) 
3-4 points 2.61 (2.10, 3.24) 
0-2 points 2.48 (1.69, 3.63) 
Subgroups by study quality score 
Caucasian participants 3.00 (2.58, 3.48) 
Asian participants 2.08 (1.33, 3.25) 
Subgroups by ethnicity  
Mixed (demented and non-demented) participants 2.74 (2.25, 3.33) 
Clinically not demented participants 3.32 (2.16, 5.11) 
Participants with pathologically confirmed AD 2.25 (1.75, 2.90) 
Subgroups by pathological confirmation of AD 
Mixed (demented and non-demented) participants 2.74 (2.25, 3.33) 
Clinically not demented participants 3.32 (2.16, 5.11) 
Clinically demented participants 2.37 (1.85, 3.05) 
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Figure 3.7 Meta-analysis of association of APOE ε4+ versus ε4- genotypes with CAA by 
pathologically confirmed AD diagnosis  
 
 
Total 2.62 (2.27, 3.03) 
Subtotal 2.74 (2.25, 3.33) 
Yamaguchi 1.96 (0.60, 6.44) 
Yamada 1.57 (0.89, 2.79) 
Walker 1.31 (0.83, 2.07) 
Schneider 5.92 (2.23, 15.72) 
Premkumar (M) 12.75 (2.12, 76.57) 
Pfeifer 4.35 (1.75, 10.83) 
Nicoll 2.67 (1.61, 4.42) 
Mortimer 7.36 (4.31, 12.56) 
Leclercq 9.97 (1.17, 84.91) 
Greenberg 2.91 (1.19, 7.12) 
Chui 2.30 (1.40, 3.77) 
Christoforidis 3.27 (1.39, 7.69) 
Attems 8.50 (1.70, 42.61) 
Mixed 
Subtotal 3.32 (2.16, 5.11) 
Thal (ND) 1.58 (0.38, 6.65) 
Tanskanen (ND) 4.00 (0.42, 37.78) 
Premkumar (ND) - 
Cruz-Sánchez (ND) 0.84 (0.14, 5.10) 
16.34 (1.71, 156.35) 
Caselli 2.97 (1.57, 5.60) 
Alafuzoff (ND) 5.03 (2.35, 10.77) 
Subtotal 2.25 (1.75, 2.90) 
Zubenko 2.90 (1.03, 8.14) 
Zarow 1.11 (0.37, 3.34) 
Yip 1.69 (0.80, 3.56) 
Thal (D) - 
Premkumar (D) 17.15 (7.56, 38.90) 
Olichney 2.39 (1.48, 3.86) 
Davidson 1.14 (0.62, 2.07) 
Cruz-Sánchez (D) 1.19 (0.26, 5.50) 
Chalmers (D) 5.60 (2.39, 13.14) 
Alafuzoff (D) 1.02 (0.49, 2.12) 
AD dementia 
No Dementia 
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2df=2.75; pdiff=0.25;  
OR = odds ratio; CI = confidence interval; AD = Alzheimer’s disease; D = neuropathologically 
confirmed AD participants; ND = clinically not demented participants; M = demented and not 
demented participants; No. participants = total number of participants contributing to the analysis (10 
participants excluded because of missing data: Christoforidis 2 participants, Greenberg 5 participants, 
Nicoll 2 participants, Olichney 1 participant); OR not estimable for 15 participants in Thal dementia 
group and for 16 participants in Premkumar no dementia group because either all participants in both 
genotype groups had CAA, or no participant in either genotype group had CAA; Squares represent 
study-specific ORs, with their size proportional to the study weight based on the fixed-effects method; 
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Figure 3.8 Meta-analysis of association of APOE ε4+ versus ε4- genotypes with CAA by ethnicity 
 














1df=2.33; pdiff=0.13;  
OR = odds ratio; CI = confidence interval; No. participants = total number of participants contributing 
to the analysis (10 participants excluded because of missing data: Christoforidis 2 participants, 
Greenberg 5 participants, Nicoll 2 participants, Olichney 1 participant); Squares represent study-
specific ORs, with their size proportional to the study weight based on the fixed-effects method; 





Total 2.89 (2.51, 3.33) 
Subtotal 3.00 (2.58, 3.48) 
Zubenko 2.90 (1.03, 8.14) 
Zarow 1.11 (0.37, 3.34) 
Yip 1.69 (0.80, 3.56) 
Walker 1.31 (0.83, 2.07) 
Thal 2.60 (0.77, 8.73) 
Tanskanen 9.72 (2.49, 38.02) 
Schneider 5.92 (2.23, 15.72) 
Premkumar 12.67 (6.76, 23.74) 
Olichney 2.39 (1.48, 3.86) 
Nicoll 2.67 (1.61, 4.42) 
Mortimer 7.36 (4.31, 12.56) 
Leclercq 9.97 (1.17, 84.91) 
Greenberg 2.92 (1.19, 7.12) 
Davidson 1.14 (0.62, 2.07) 
Cruz-Sánchez 2.06 (0.76, 5.60) 
Chui 2.30 (1.40, 3.77) 
Christoforidis 3.27 (1.39, 7.69) 
Chalmers 5.71 (2.89, 11.27) 
Caselli 2.97 (1.57, 5.60) 
Attems 8.50 (1.70, 42.61) 
Alafuzoff 4.27 (2.57, 7.09) 
Caucasian participants 
Subtotal 2.08 (1.33, 3.25) 
Yamaguchi 1.96 (0.60, 6.44) 
Yamada 1.57 (0.89, 2.79) 
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Figure 3.9 Meta-analysis of association of APOE ε4+ versus ε4- genotypes with CAA by study 
quality score 
 


















2df=3.44; pdiff=0.18;  
OR = odds ratio; CI = confidence interval; No. participants = total number of participants contributing 
to the analysis (10 participants excluded because of missing data: Christoforidis 2 participants, 
Greenberg 5 participants, Nicoll 2 participants, Olichney 1 participant); Squares represent study-
specific ORs, with their size proportional to the study weight based on the fixed-effects method; 
Horizontal lines represent 95% CIs; Diamonds represent the pooled ORs.  
 
Total 2.89 (2.51, 3.33) 
Subtotal 3.37 (2.71, 4.18) 
Walker 1.31 (0.83, 2.07) 
Schneider 5.92 (2.23, 15.72) 
Premkumar 12.67 (6.76, 23.74) 
Pfeifer 4.35 (1.75, 10.83) 
Olichney 2.39 (1.48, 3.86) 
Nicoll 2.67 (1.61, 4.42) 
Mortimer 7.36 (4.31, 12.56) 
5-9 points 
Subtotal 2.61 (2.10, 3.24) 
Zarow 1.11 (0.37, 3.34) 
Yamada 1.57 (0.89, 2.79) 
Tanskanen 9.72 (2.49, 38.02) 
Leclercq 9.97 (1.17, 84.91) 
Greenberg 2.92 (1.19, 7.12) 
Davidson 1.14 (0.62, 2.07) 
Chui 2.30 (1.40, 3.77) 
Chalmers 5.71 (2.89, 11.27) 
Caselli 2.97 (1.57, 5.60) 
Alafuzoff 4.27 (2.57, 7.09) 
3-4 points 
Subtotal 2.48 (1.69, 3.63) 
Zubenko 2.90 (1.03, 8.14) 
Yip 1.69 (0.80, 3.56) 
Yamaguchi 1.96 (0.60, 6.44) 
Thal 2.60 (0.77, 8.73) 
Cruz-Sánchez 2.06 (0.76, 5.60) 
Christoforidis 3.27 (1.39, 7.69) 
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Figure 3.10 Meta-analysis of association of APOE ε4+ versus ε4- genotypes with CAA by study 
size 
 


















2df=1.59; pdiff=0.45;  
OR = odds ratio; CI = confidence interval; No. participants = total number of participants contributing 
to the analysis (10 participants excluded because of missing data: Christoforidis 2 participants, 
Greenberg 5 participants, Nicoll 2 participants, Olichney 1 participant); Squares represent study-
 
Total 2.89 (2.51, 3.33) 
Subtotal 3.21 (2.56, 4.04) 
Walker 1.31 (0.83, 2.07) 
Premkumar 12.67 (6.76, 23.74) 
Olichney 2.39 (1.48, 3.86) 
Nicoll 2.67 (1.61, 4.42) 
Mortimer 7.36 (4.31, 12.56) 
Study size >239 
Subtotal 2.58 (1.98, 3.35) 
Yamada 1.57 (0.89, 2.79) 
Schneider 5.92 (2.23, 15.72) 
Pfeifer 4.35 (1.75, 10.83) 
Davidson 1.14 (0.62, 2.07) 
Caselli 2.97 (1.57, 5.60) 
Alafuzoff 4.27 (2.57, 7.09) 
Study size 140-239 
Subtotal 2.82 (2.20, 3.62) 
Zubenko 2.90 (1.03, 8.14) 
Zarow 1.11 (0.37, 3.34) 
Yip 1.69 (0.80, 3.56) 
Yamaguchi 1.96 (0.60, 6.44) 
Thal 2.60 (0.77, 8.73) 
Tanskanen 9.72 (2.49, 38.02) 
Leclercq 9.97 (1.17, 84.91) 
Greenberg 2.92 (1.19, 7.12) 
Cruz-Sánchez 2.06 (0.76, 5.60) 
Chui 2.30 (1.40, 3.77) 
Christoforidis 3.27 (1.39, 7.69) 
Chalmers 5.71 (2.89, 11.27) 
Attems 8.50 (1.70, 42.61) 
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specific ORs, with their size proportional to the study weight based on the fixed-effects method; 
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Figure 3.11 Meta-analysis of association of APOE ε4+ versus ε4- genotypes with CAA by 
blinding 














1df=2.29; pdiff=0.13;  
OR = odds ratio; CI = confidence interval; No. participants = total number of participants contributing 
to the analysis (10 participants excluded because of missing data: Christoforidis 2 participants, 
Greenberg 5 participants, Nicoll 2 participants, Olichney 1 participant); Squares represent study-
specific ORs, with their size proportional to the study weight based on the fixed-effects method; 
Horizontal lines represent 95% CIs; Diamonds represent the pooled ORs.  
 
 
Total 2.89 (2.51, 3.33) 
Subtotal 2.62 (2.17, 3.17) 
Zubenko 2.90 (1.03, 8.14) 
Zarow 1.11 (0.37, 3.34) 
Yip 1.69 (0.80, 3.56) 
Yamaguchi 1.96 (0.60, 6.44) 
Yamada 1.57 (0.89, 2.79) 
Thal 2.60 (0.77, 8.73) 
Tanskanen 9.72 (2.49, 38.02) 
Schneider 5.92 (2.23, 15.72) 
Olichney 2.39 (1.48, 3.86) 
Davidson 1.14 (0.62, 2.07) 
Cruz-Sánchez 2.06 (0.76, 5.60) 
Christoforidis 3.27 (1.39, 7.69) 
Chalmers 5.71 (2.89, 11.27) 
Caselli 2.97 (1.57, 5.60) 
Attems 8.50 (1.70, 42.61) 
Alafuzoff 4.27 (2.57, 7.09) 
No blinding 
Subtotal 3.28 (2.64, 4.06) 
Walker 1.31 (0.83, 2.07) 
Premkumar 
Pfeifer 4.35 (1.75, 10.83) 
Nicoll 2.67 (1.61, 4.42) 
Mortimer 7.36 (4.31, 12.56) 
Leclercq 9.97 (1.17, 84.91) 
Greenberg 2.92 (1.19, 7.12) 
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Figure 3.12 Meta-analysis of association of APOE ε4+ versus ε4- genotypes with CAA by 
genotyping reporting quality 
 














1df=2.30; pdiff=0.13; OR = odds ratio; CI = confidence interval; No. 
participants = total number of participants contributing to the analysis (10 participants excluded 
because of missing data: Christoforidis 2 participants, Greenberg 5 participants, Nicoll 2 participants, 
Olichney 1 participant); Squares represent study-specific ORs, with their size proportional to the study 
weight based on the fixed-effects method; Horizontal lines represent 95% CIs; Diamonds represent 
the pooled ORs.  
 
 
Total 2.89 (2.51, 3.33) 
Subtotal 3.04 (2.60, 3.56) 
Zubenko 2.90 (1.03, 8.14) 
Zarow 1.11 (0.37, 3.34) 
Yamada 1.57 (0.89, 2.79) 
Walker 1.31 (0.83, 2.07) 
Thal 2.60 (0.77, 8.73) 
Tanskanen 9.72 (2.49, 38.02) 
Schneider 5.92 (2.23, 15.72) 
Premkumar 12.67 (6.76, 23.74) 
Pfeifer 4.35 (1.75, 10.83) 
Olichney 2.39 (1.48, 3.86) 
Nicoll 2.67 (1.61, 4.42) 
Mortimer 7.36 (4.31, 12.56) 
Leclercq 9.97 (1.17, 84.91) 
Greenberg 2.92 (1.19, 7.12) 
Davidson 1.14 (0.62, 2.07) 
Cruz-Sánchez 2.06 (0.76, 5.60) 
Christoforidis 3.27 (1.39, 7.69) 
Chalmers 5.71 (2.89, 11.27) 
Attems 8.50 (1.70, 42.61) 
Alafuzoff 4.27 (2.57, 7.09) 
1 point 
Subtotal 2.29 (1.64, 3.19) 
Yip 1.69 (0.80, 3.56) 
Yamaguchi 1.96 (0.60, 6.44) 
Chui 2.30 (1.40, 3.77) 
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Figure 3.13 Meta-analysis of association of APOE ε4+ versus ε4- genotypes with CAA by study 
design 
 














1df=5.48; pdiff=0.02;  
OR = odds ratio; CI = confidence interval; No. participants = total number of participants contributing 
to the analysis (10 participants excluded because of missing data: Christoforidis 2 participants, 
Greenberg 5 participants, Nicoll 2 participants, Olichney 1 participant); Squares represent study-
specific ORs, with their size proportional to the study weight based on the fixed-effects method; 
Horizontal lines represent 95% CIs; Diamonds represent the pooled ORs. 
 
 
Total 2.89 (2.51, 3.33) 
Subtotal 2.56 (2.15, 3.05) 
Zubenko 2.90 (1.03, 8.14) 
Zarow 1.11 (0.37, 3.34) 
Yip 1.69 (0.80, 3.56) 
Yamaguchi 1.96 (0.60, 6.44) 
Yamada 1.57 (0.89, 2.79) 
Walker 1.31 (0.83, 2.07) 
Thal 2.60 (0.77, 8.73) 
Premkumar 12.67 (6.76, 23.74) 
Olichney 2.39 (1.48, 3.86) 
Leclercq 9.97 (1.17, 84.91) 
Greenberg 2.92 (1.19, 7.12) 
Davidson 1.14 (0.62, 2.07) 
Cruz-Sánchez 2.06 (0.76, 5.60) 
Christoforidis 3.27 (1.39, 7.69) 
Chalmers 5.71 (2.89, 11.27) 
Attems 8.50 (1.70, 42.61) 
Alafuzoff 4.27 (2.57, 7.09) 
Retrospective studies 
Subtotal 3.66 (2.87, 4.68) 
Tanskanen 9.72 (2.49, 38.02) 
Schneider 5.92 (2.23, 15.72) 
Pfeifer 4.35 (1.75, 10.83) 
Nicoll 2.67 (1.61, 4.42) 
Mortimer 7.36 (4.31, 12.56) 
Chui 2.30 (1.40, 3.77) 





































Chapter 3. APOE ɛ2/ɛ3/ɛ4 polymorphism associations with sporadic CAA  169 
 
Figure 3.14 Meta-analysis of association of APOE ε4+ versus ε4- genotypes with CAA by study 
data format 
 














1df=6.77; pdiff=0.009;  
OR = odds ratio; CI = confidence interval; No. participants = total number of participants contributing 
to the analysis (10 participants excluded because of missing data: Christoforidis 2 participants, 
Greenberg 5 participants, Nicoll 2 participants, Olichney 1 participant); Squares represent study-
specific ORs, with their size proportional to the study weight based on the fixed-effects method; 
Horizontal lines represent 95% CIs; Diamonds represent the pooled ORs.  
 
 
Total 2.89 (2.51, 3.33) 
Subtotal 3.64 (2.91, 4.55) 
Zubenko 2.90 (1.03, 8.14) 
Yamaguchi 1.96 (0.60, 6.44) 
Thal 2.60 (0.77, 8.73) 
Tanskanen 9.72 (2.49, 38.02) 
Schneider 5.92 (2.23, 15.72) 
Premkumar 12.67 (6.76, 23.74) 
Pfeifer 4.35 (1.75, 10.83) 
Nicoll 2.67 (1.61, 4.42) 
Leclercq 9.97 (1.17, 84.91) 
Greenberg 2.92 (1.19, 7.12) 
Cruz-Sánchez 2.06 (0.76, 5.60) 
Chui 2.30 (1.40, 3.77) 
Christoforidis 3.27 (1.39, 7.69) 
Attems 8.50 (1.70, 42.61) 
Dichotomous data 
Subtotal 2.48 (2.06, 2.98) 
Zarow 1.11 (0.37, 3.34) 
Yip 1.69 (0.80, 3.56) 
Yamada 1.57 (0.89, 2.79) 
Walker 1.31 (0.83, 2.07) 
Olichney 2.39 (1.48, 3.86) 
Mortimer 7.36 (4.31, 12.56) 
Davidson 1.14 (0.62, 2.07) 
Chalmers 5.71 (2.89, 11.27) 
Caselli 2.97 (1.57, 5.60) 
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Figure 3.15 Meta-analysis of association of APOE ε4+ versus ε4- genotypes with CAA by 
pathology assessment quality 
 














1df=18.91; pdiff<0.0001;  
OR = odds ratio; CI = confidence interval; No. participants = total number of participants contributing 
to the analysis (10 participants excluded because of missing data: Christoforidis 2 participants, 
Greenberg 5 participants, Nicoll 2 participants, Olichney 1 participant); Squares represent study-
specific ORs, with their size proportional to the study weight based on the fixed-effects method; 
Horizontal lines represent 95% CIs; Diamonds represent the pooled ORs.  
 
 
Total 2.89 (2.51, 3.33) 
Subtotal 4.20 (3.37, 5.24) 
Zarow 1.11 (0.37, 3.34) 
Schneider 5.92 (2.23, 15.72) 
Premkumar 12.67 (6.76, 23.74) 
Pfeifer 4.35 (1.75, 10.83) 
Nicoll 2.67 (1.61, 4.42) 
Mortimer 7.36 (4.31, 12.56) 
Greenberg 2.92 (1.19, 7.12) 
Chui 2.30 (1.40, 3.77) 
Chalmers 5.71 (2.89, 11.27) 
2 points 
Subtotal 2.22 (1.84, 2.67) 
Zubenko 2.90 (1.03, 8.14) 
Yip 1.69 (0.80, 3.56) 
Yamaguchi 1.96 (0.60, 6.44) 
Yamada 1.57 (0.89, 2.79) 
Walker 1.31 (0.83, 2.07) 
Thal 2.60 (0.77, 8.73) 
Tanskanen 9.72 (2.49, 38.02) 
Olichney 2.39 (1.48, 3.86) 
Leclercq 9.97 (1.17, 84.91) 
Davidson 1.14 (0.62, 2.07) 
Cruz-Sánchez 2.06 (0.76, 5.60) 
Christoforidis 3.27 (1.39, 7.69) 
Caselli 2.97 (1.57, 5.60) 
Attems 8.50 (1.70, 42.61) 
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Figure 3.16 Meta-analysis of effects of APOE ε4 dose on presence versus absence of CAA 
 
 
Total 7.04 (4.81, 10.29) 
Zubenko 3.52 (0.99, 12.46) 
Zarow 1.57 (0.30, 8.13) 
Walker 23.06 (6.78, 78.46) 
Thal 7.00 (0.34, 144.73) 
Premkumar 117.87 (6.97, 1992.1) 
Olichney 6.72 (3.19, 14.13) 
Nicoll 2.39 (0.67, 8.54) 
Leclercq 94.00 (6.92, 1276.4) 
Davidson 2.92 (1.25, 6.78) 
Cruz-Sánchez 13.40 (0.60, 298.97) 
Chalmers 49.41 (15.76, 154.93) 
Attems 4.00 (0.40, 39.58) 
ɛ4/ɛ4 vs ɛx/ɛx 
Total 3.38 (2.34, 4.88) 
Zubenko 1.34 (0.43, 4.17) 
Zarow 1.85 (0.32, 10.57) 
Walker 14.65 (4.31, 49.85) 
Thal 3.67 (0.16, 84.51) 
Premkumar 12.42 (0.73, 212.29) 
Olichney 3.56 (1.77, 7.16) 
Nicoll 0.88 (0.24, 3.29) 
Leclercq 20.67 (2.61, 163.79) 
Davidson 2.62 (1.14, 6.02) 
Cruz-Sánchez 7.86 (0.34, 180.34) 
Chalmers 6.36 (2.20, 18.38) 
Attems 0.31 (0.02, 6.12) 
ɛ4/ɛ4 vs ɛ4/ɛx 
Total 2.09 (1.69, 2.58) 
Zubenko 2.62 (0.86, 7.93) 
Zarow 0.98 (0.29, 3.31) 
Walker 1.06 (0.66, 1.69) 
Thal 2.00 (0.57, 6.97) 
Premkumar 9.75 (5.16, 18.42) 
Olichney 1.69 (1.03, 2.79) 
Nicoll 2.71 (1.60, 4.57) 
Leclercq 4.55 (0.45, 45.74) 
Davidson 0.93 (0.48, 1.80) 
Cruz-Sánchez 1.72 (0.61, 4.81) 
Chalmers 3.56 (1.71, 7.42) 
Attems 13.00 (1.53, 110.75) 
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11df=34.11; p=0.0003;  
OR = odds ratio; CI = confidence interval; No. participants = total number of participants contributing 
to the analysis (excluded due to missing data: Nicoll 2011: 2 participants; Davidson 2006 and 
Olichney 2000: 1 participant); Squares represent study-specific ORs, with their size proportional to 
the study weight based on the fixed-effects method; Horizontal lines represent 95% CIs; Diamonds 
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Figure 3.17 Meta-analysis of association of APOE ε2+ versus ε2- genotypes with CAA (fixed-
effects method) 





10df=18.57; p=0.05;  
OR = odds ratio; CI = confidence interval; No. participants = total number of participants contributing 
to the analysis (5 participants excluded because of missing data: Christoforidis 2 participants, Nicoll 2 
participants, Olichney 1 participant); Squares represent study-specific ORs, with their size 
proportional to the study weight based on the fixed-effects method; Horizontal lines represent 95% 








Total 0.64 (0.47, 0.86) 
Walker 0.52 (0.31, 0.87) 
Thal 3.08 (0.58, 16.40) 
Tanskanen 0.53 (0.12, 2.33) 
Premkumar 0.13 (0.04, 0.39) 
Olichney 1.29 (0.48, 3.43) 
Nicoll 0.68 (0.35, 1.29) 
Leclercq 0.29 (0.02, 5.41) 
Davidson 0.48 (0.15, 1.52) 
Cruz-Sánchez 0.55 (0.10, 2.85) 
Christoforidis 1.80 (0.60, 5.40) 
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Figure 3.18 Meta-analysis of association of APOE ε2+ versus ε2- genotypes with CAA (random-
effects method) 





10df=18.57; p=0.05;  
OR = odds ratio; CI = confidence interval; No. participants = total number of participants contributing 
to the analysis (5 participants excluded because of missing data: Christoforidis 2 participants, Nicoll 2 
participants, Olichney 1 participant); Squares represent study-specific ORs, with their size 
proportional to the study weight based on the random-effects method; Horizontal lines represent 95% 

















Total 0.68 (0.42, 1.08) 
Walker 0.52 (0.31, 0.87) 
Thal 3.08 (0.58, 16.40) 
Tanskanen 0.53 (0.12, 2.33) 
Premkumar 0.13 (0.04, 0.39) 
Olichney 1.29 (0.48, 3.43) 
Nicoll 0.68 (0.35, 1.29) 
Leclercq 0.29 (0.02, 5.41) 
Davidson 0.48 (0.15, 1.52) 
Cruz-Sánchez 0.55 (0.10, 2.85) 
Christoforidis 1.80 (0.60, 5.40) 
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Figure 3.19 Meta-analysis of association of APOE ɛ2+ versus ɛ3/ɛ3 genotypes with CAA (fixed-
effects method) 
 





10df=17.30; p=0.07; No. participants = total number of participants in the study (6 participants 
excluded because of missing data: Christoforidis 2 participants, Nicoll 2 participants, Olichney 1 
participant, Davidson 1 participant); OR = odds ratio; CI = confidence interval; Squares represent 
study-specific ORs, with their size proportional to the study weight based on the fixed-effects model; 






















0.01 0.1 0.2 0.5 1 2 5 10 100 
Total 0.90 (0.65, 1.26) 
Walker 0.48 (0.26, 0.89) 
Thal 4.96 (0.87, 28.15) 
Tanskanen 1.00 (0.22, 4.56) 
Premkumar 0.47 (0.15, 1.52) 
Olichney 2.35 (0.83, 6.60) 
Nicoll 1.00 (0.51, 1.98) 
Leclercq 0.95 (0.04, 24.77) 
Davidson 0.49 (0.14, 1.71) 
Cruz-Sánchez 0.74 (0.13, 4.20) 
Christoforidis 2.95 (0.93, 9.40) 
Attems 1.00 (0.12, 8.06) 
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Dots represent individual studies contributing data for the meta-analysis, the position of the study on 
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Dots represent individual studies contributing data for the meta-analysis, the position of the study on 
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Chapter 4: APOE ɛ2/ɛ3/ɛ4 polymorphism 
associations with severe CAA 
vasculopathy 
Chapter contents: 
4.1     Introduction 
4.2     Methods 
4.2.1     Search strategy 
4.2.2     Inclusion/exclusion criteria 
4.2.3     Data extraction 
4.2.4     Meta-analyses 
4.3     Results 
4.3.1     Included studies 
4.3.2     Study characteristics  
4.3.3     Meta-analyses results 
4.4     Discussion 
4.4.1     Main findings 
4.4.2     Strengths and limitations 
4.4.3     Outstanding issues 
4.4.4     Conclusions 
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 4. APOE ɛ2/ɛ3/ɛ4 polymorphism associations 
with severe CAA vasculopathy 
 Neuropathological studies suggest that CAA causes lobar ICH 
 While only the APOE ε4 allele is associated with presence of histopathological 
CAA (shown in Chapter 3), both APOE ε4 and ε2 are associated with lobar ICH 
 A popular explanation is that ε4 promotes amyloid deposition, while ε2 promotes 
progression to severe CAA vasculopathy that causes vessel rupture and ICH  
 In this chapter, I present my systematic review and series of meta-analyses, 
looking at the association between the APOE ɛ2/ɛ3/ɛ4 polymorphism and 
progression to severe CAA vasculopathy 
 I used a comprehensive search strategy, critically appraised study quality and 
obtained unpublished data by contacting authors  
 I conclude that while 4 may increase the risk of developing severe CAA  
vasculopathy, current evidence does not support the theory of ɛ2 role in this 
 Before reliable conclusions can be drawn about APOE 2 specific effects, larger 
numbers of individuals will need to be included in CAA histopathology studies 
4.1 Introduction 
Sporadic cerebral amyloid angiopathy (CAA) is characterised by deposition of 
amyloid- protein in leptomeningeal and cortical blood vessels, with a prevalence in 
population-based autopsy studies of 20-40% in non-demented and 50-60% in 
demented elderly people (Charidimou et al. 2012a). Neuropathological case-control 
and cross-sectional studies, as well as the increased incidence of intracerebral 
haemorrhage (ICH) in patients with Alzheimer’s disease, suggest that CAA causes 
lobar ICH (Chi et al. 2013, Samarasekera et al. 2012).
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CAA is thought to be responsible for up to a third of all ICH in elderly people 
(Pezzini and Padovani 2008). The prevalence of ICH in cases with CAA in a recent 
systematic review was about 11% (Samarasekera et al. 2012). It is unknown why 
only a few people with CAA pathology develop an ICH, but it seems likely to 
involve biological pathways additional to and distinct from those involved in 
vascular amyloid deposition. Cases of CAA with ICH not only have a greater 
proportion of amyloid-laden blood vessels (McCarron et al. 1999), but also more 
often demonstrate severe CAA with associated vasculopathy (Figure 4.1) (Mandybur 
1986, McCarron et al. 1999, Okazaki et al. 1979, Vonsattel et al. 1991).  
Apolipoprotein E genotype (APOE) is associated with both histopathologically-
confirmed CAA and CAA-related clinical phenotypes, including lobar ICH. My 
systematic review and meta-analyses in Chapter 3 demonstrated a dose-dependent 
association between histopathologically confirmed CAA and ε4 allele but there was 
no convincing association with ε2-containing genotypes (Rannikmäe et al. 2013). 
However, a recent large-scale genetic association study found that both 4- and 2-
containing genotypes were associated with lobar ICH, particularly when attributed to 
CAA (Biffi et al. 2010). Furthermore, APOE ε2 but not ε4 predicted initial 
hematoma volume, haematoma expansion, increased mortality and poor functional 
outcome of lobar ICH (Biffi et al. 2011, Brouwers et al. 2012). The generally 
accepted explanation for these findings is that while APOE 4 promotes vascular 
amyloid deposition, 2 promotes progression to severe CAA with associated 
vasculopathy leading to vessel rupture and ICH (Figure 4.1) (Greenberg et al. 1998, 
McCarron et al. 1999).  
In this chapter, I aim to study the evidence behind these proposed allele-specific 
effects, by performing a systematic review, incorporating a comprehensive search 
strategy, a thorough assessment of study quality, and a series of meta-analyses 
looking at the association between the APOE ɛ2/ɛ3/ɛ4 polymorphism and 
progression to severe CAA vasculopathy.  
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4.2 Methods  
4.2.1 Search strategy  
I sought all studies of adult humans published in any language, which had conducted 
both APOE genotyping and histopathological assessment for CAA, including 
assessment for severe CAA with associated vasculopathic changes. From now on 
when using the term ‘severe CAA’, I am referring to severe CAA with associated 
vasculopathic changes.   
I used the same search strategy as in Chapter 3, searching OVID Medline (1950 to 
March 2012) and Embase (1980 to March 2012), using a combination of search 
terms for APOE, genes and CAA (Appendix 3). I also checked the bibliographies of 
all relevant studies and reviews identified, and searched Google Scholar for other 
studies citing relevant studies.  
4.2.2 Inclusion/exclusion criteria  
For the analyses reported in this chapter, I included all studies of adult humans 
published in any language, which had conducted both APOE genotyping and 
histopathological assessment for CAA, including assessment for severe CAA with 
associated vasculopathic changes (blood vessel dilatation; microaneurysm formation; 
fibrinoid degeneration; cracking and double-barrelling of the vessel wall; and 
paravascular leakage of blood). The assessment for severe CAA could have occurred 
either as part of the Vonsattel grading scale, which includes such changes in its 
‘severe’ category (Appendix 5), or through specifically reporting on some or all of 
the relevant histopathological characteristics.  
To avoid the effects of possible reporting bias (whereby positive results are more 
likely to be included within publications than negative ones) and to increase the size 
of the relevant dataset, I considered studies to be eligible for inclusion whether or not 
they actually reported on any association of APOE with severe CAA. 
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My focus was on assessing the potential influence of APOE genotypes (in particular 
APOE 2) on severe CAA preceding rupture. Because APOE 2 is already known to 
be associated with CAA-related ICH (perhaps – but not definitely – causally), and 
severe CAA is more commonly found in such cases, I reasoned that including brains 
with ICH in my analyses would inevitably yield an association of APOE 2 with 
severe CAA, without necessarily meaning that APOE 2 influences risk through 
promoting the most severe stages of CAA pathology that precede rupture. Hence, to 
avoid selection bias, I excluded studies that had selected participants on the basis of 
having had a CAA-related ICH. For the same reason, I excluded participants selected 
on the basis of having had a CAA-related ICH from the included studies. However I 
included studies that had recruited participants with CAA-related ICH as an 
unselected part of the spectrum of CAA severity.  
I also excluded studies of hereditary CAA cases and those with less than ten eligible 
participants (thereby excluding <3% of overall eligible participants).  
One of my three colleagues (clinical research fellow Dr Neshika Samarasekera, 
Professor Rustam Al-Shahi Salman or Professor Cathie Sudlow) and I independently 
selected eligible studies, resolving disagreements by discussion and mutual 
consensus.  
4.2.3 Data Extraction   
For each study included, I extracted information on:  
 first author; 
 publication year;  
 country in which the study was conducted; 
 source, description, mean age, ethnicity and gender of participants; 
 study size.  
I assessed selected genotyping characteristics based on the STREGA (Strengthening 
the Reporting of Genetic Association Studies) and MOOSE (Meta-analysis of 
 
Chapter 4. APOE ɛ2/ɛ3/ɛ4 polymorphism associations with severe CAA 
vasculopathy  184 
 
Observational Studies in Epidemiology) recommendations (Little et al. 2009, Stroup 
et al. 2000). I extracted information on: 
 DNA source;  
 number of participants in whom genotyping was attempted and in whom it 
was successful; 
 genotyping method; 
 blinding of genotyping staff to pathology data. 
I assessed the quality and characteristics of CAA pathology assessment using my 
own previously developed criteria (Chapter 3). I extracted data on: 
 the method of CAA assessment;  
 qualification of CAA rater(s);  
 brain locations examined;  
 blinding of CAA raters to genotyping results and relevant clinical 
information.  
For the planned meta-analyses, I required summary data on the numbers of 
participants with each APOE genotype (ε3ε3, ε2ε3, ε3ε4, ε4ε4, ε2ε2, ε2ε4) and 
whether or not CAA was present or absent. For those with CAA, I required, for each 
genotype, their CAA severity on the Vonsattel scale and/or data on the presence or 
absence of specific vasculopathic changes associated with severe CAA. These data 
were not all provided in the publications I identified.  
To facilitate the sharing and analysis of the unpublished data required, I formed a 
collaborative group including the principal investigators of the relevant studies. I 
created a structured data extraction form and completed it as far as possible by 
entering data from the relevant publication(s) (Appendix 6). Principal investigators 
and/or their colleagues then checked the information entered, made any necessary 
corrections, and entered additional unpublished data if required and available. 
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4.2.4 Meta-analyses  
For the meta-analyses I used Cochrane Review Manager (version 5) software. I 
included only individuals with CAA present on histopathological assessment, 
calculating study-specific, fixed-effects and random-effects pooled, unadjusted odds 
ratios (ORs) with 95% confidence intervals (CIs) for: 
 severe versus mild or moderate CAA among ε4 carriers (4+) versus those 
with other genotypes (4-), and 
 severe versus mild or moderate CAA among ε2 carriers (2+) versus those 
with other genotypes (2-).  
I used the Mantel-Haenszel method which is the default method for fixed-effects 
meta-analysis in Review Manager and is considered to have better statistical 
properties than other methods when there are few events (The Cochrane 
Collaboration) and the DerSimonian and Laird method for the random-effects 
analyses.  
I then repeated the analyses comparing: 
 severe versus moderate CAA (excluding mild CAA and so focussing on the 
severe end of the CAA spectrum);  
 severe versus mild/moderate CAA among 4+  and among ε2+ versus ε3ε3  
 severe versus moderate CAA among 4+  and among ε2+ versus ε3ε3 
I used the wild-type ε3ε3 as a comparison group to avoid potential bias from mixed 
effects of ε2 and ε4 in the comparison group.  
I also repeated some of the analyses performed in Chapter 3 for the subset of studies 
included here: I included individuals both with and without CAA, comparing the 
presence versus absence of CAA among ε4+ versus 4-, and versus 33, and among 
ε2+ versus 2-, and versus 33 genotypes.  
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 statistics.  
4.3 Results  
4.3.1 Included studies 
From 1754 publications identified for screening, eight studies were relevant (Figure 
4.2). I excluded two with <10 eligible participants (Eng et al. 2004, van Horssen et 
al. 2005), leaving six eligible studies. These six studies included 645 unique 
participants, of whom 102 had been selected on the basis of having had an ICH, 
leaving 543 that were eligible for my study (Chui et al. 2006, Davis et al. 1999, 
Greenberg et al. 1995, Greenberg et al. 1998, Kalaria and Premkumar 1995, 
McCarron et al. 1999). Only one of the six studies had previously reported on the 
association between the APOE genotype and severe CAA (assessed using Vonsattel 
scale) (Appendix 5), finding a significantly greater frequency of APOE 2 in severe 
versus moderate CAA cases (Greenberg et al. 1998). This study and four others that 
had rated CAA on the Vonsattel scale, between them including 497 eligible 
participants (92% of all 543 potentially eligible participants) (Chui et al. 2006, Davis 
et al. 1999, Greenberg et al. 1995, Kalaria and Premkumar 1995), were able to share 
their unpublished data in collaborative meta-analyses. Data were unavailable from 
one additional study (46 eligible participants) that had assessed various different 
CAA-associated vasculopathic changes (double barrelling of the vessel wall, 
fibrinoid necrosis and microaneurysm formation), including those that are not part of 
the Vonsattel scale (McCarron et al. 1999).  
4.3.2 Study characteristics 
All of the five studies included in the meta-analyses used autopsy brains from brain 
tissue banks or a population-based prospective study with an autopsy component. 
There were between 57 and 227 eligible participants per study. Mean age at death 
was between 77 and 84 years and about half of all participants were male. Three 
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studies (357 participants) were conducted in predominantly white populations in the 
USA while information on ethnicity was unavailable for two studies (140 
participants). About 50% of participants had clinical dementia (mainly 
neuropathologically confirmed AD), about 20% were known not to be demented, and 
in the remaining 30% dementia status was unknown (Table 4.1).  
DNA source was brain tissue in three studies, blood in one study, and brain tissue or 
blood in one study. Number in whom genotyping was attempted and in whom it was 
successful was available in four studies. Genotyping method was PCR and 
genotypers were blinded to pathology data in all studies (Table 4.2). 
Methods for pathological assessment were variable, reflecting a lack of agreed 
standards for CAA pathology assessment at the time these studies were conducted. 
Raters were blinded to genotyping data in all studies, and to relevant clinical 
information in four studies. In one study pathologists had access to minimal clinical 
information. Raters in all studies were qualified neuropathologists. In all studies 
locations rated included the frontal-, temporal-, parietal- and occipital cortex. In one 
study the leptomeningeal vessels, and in two studies the cerebellar cortical vessels 
were also rated (Table 4.2).  
4.3.3 Meta-analyses results   
4.3.3.1 Association between APOE ɛ4 and CAA severity on the 
Vonsattel scale 
Fixed-effects meta-analysis of data from 353 participants with CAA included in five 
studies showed, for 4+ versus 4- genotypes, a significant association with severe 
versus mild/moderate CAA (OR 2.55, 95% CI 1.44 to 4.52; p=0.001) but no 
significant association with severe versus moderate CAA (OR 1.64, 95% CI 0.88 to 
3.07; p=0.12) (Figure 4.3, Figure 4.4) There was no significant heterogeneity 









3df=1.19; p=0.76 respectively).  
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Results were similar and conclusions unchanged when I used 33 genotypes as the 
comparison group (Figure 4.5, Figure 4.6). Comparing severe CAA with 
mild/moderate CAA showed an OR 2.88 (95% CI 1.55 to 5.35; p=0.0008) and 
comparing severe CAA with moderate CAA an OR of 1.95 (95% CI 0.98 to 3.87; 
p=0.06).  
Results were also similar and conclusions unchanged when I performed the analyses 
using the random-effects method (Table 4.3).  
Associations with the presence versus absence of CAA were consistent with results 
from my previous analysis in Chapter 3 showing a clearly significant association 
with 4+ (4+ versus 4-: OR 4.91, 95% CI 3.12 to 7.73; p<0.00001) (Figure 4.7).  
4.3.3.2 Association between APOE ɛ2 and CAA severity on the 
Vonsattel scale 
For 2+ versus 2- genotypes, the associations were non-significant. 2+ genotypes 
compared to 2- genotypes for association with severe versus mild/moderate CAA 
with the fixed-effects method showed an OR of 1.74 (95% CI 0.70 to 4.32; p=0.23) 
and for association with severe versus moderate CAA an OR of 2.78 (95% CI 0.86 to 
8.98; p=0.09) (Figure 4.8, Figure 4.9). The confidence intervals were wide due to 
small numbers of participants, particularly in the 2+ group, which included 22 and 
12 individuals respectively, only seven of whom had severe CAA. There was 





3df=6.24; p=0.1) and minimal heterogeneity for 




3df=3.38; p=0.34).  
Results were similar and conclusions unchanged when I used 33 genotypes as the 
comparison group (rather than 2-) or when I performed the analyses using the 
random-effects method (Table 4.3, Figure 4.10, Figure 4.11, Figure 4.12). 
Comparing ɛ2+ versus ɛ3/ɛ3 genotypes for association with severe CAA versus 
mild/moderate CAA using the fixed-effects method showed a marginally significant 
association (OR 3.18, 95% CI 1.14 to 8.89; p=0.03) but the association was no 
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longer significant when analysed with the random-effects method (OR 3.40, 95% CI 
0.89 to 12.96; p=0.07). Comparing severe CAA with moderate CAA using the fixed-
effects method showed a non-significant OR of 3.45 (95% CI 0.89 to 13.35; p=0.07) 
and the result was similar when using the random-effects method (Table 4.3).  
Associations with the presence versus absence of CAA were consistent with results 
from my previous analysis in Chapter 3 showing no robust association with 2 
(Figure 4.13, Figure 4.14, Figure 4.15). 
4.4 Discussion 
4.4.1 Main findings 
After collecting and analysing data from five out of six existing relevant studies 
identified through a systematic search (including >90% of all eligible participants), 
meta-analyses suggested a possible association of APOE 4 with progression to 
severe CAA as well as the expected association of 4 (and not of 2) with the 
presence of CAA (Rannikmäe et al. 2014, Rannikmäe et al. 2013). However, I was 
unable to confirm a statistically significant association between APOE 2+ genotypes 
and severe CAA. It should be emphasised that, although I included all available data 
from relevant publications, the relative rarity of 2+ genotypes (only 22 of 353 
individuals with CAA in the collaborative dataset) made the 2-based analyses very 
imprecise.  
Since my systematic review, at least two further relevant studies have been 
published, suggesting that the theory of the APOE ɛ2 allele driving CAA 
vasculopathy and in that way promoting ICH is not yet confirmed. One study in 65 
cases found no overall association between the ɛ2 or ɛ4 alleles and CAA 
vasculopathy (Love et al. 2014). Another study in 105 pathologically confirmed 
CAA cases found that vasculopathy was not more common in cases with ICH 
compared to cases without ICH. In addition they found a trend towards the ɛ2 allele 
being associated with ICH, which suggests that ɛ2 is associated with ICH through 
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mechanisms other than promoting vasculopathy (Charidimou et al. 2015a). 
Unfortunately these studies do not provide raw data to be included in the meta-
analyses performed in this chapter.   
I performed the analyses using the fixed-effects method and then repeated all 
analyses using the random-effects method to confirm the robustness of any 
significant results. As discussed in Chapter 3, it is generally recommended to use the 
fixed-effects method when the underlying assumption is that the true allele effect is 
the same in all studies included in the meta-analysis, and to use the random-effects 
method when the underlying assumption is that the true allele effect is different in 
the included studies (Borenstein et al. 2010). I chose to use both methods to confirm 
robustness of any significant results and also because there was heterogeneity 
between some studies. In addition, even when no apparent heterogeneity can be 
detected with the statistical tests, this does not exclude the presence of heterogeneity 
because the test for heterogeneity often has poor power, and therefore can be non-
significant even if the true level of heterogeneity is substantial (Borenstein et al. 
2010). This approach is supported by the Cochrane Collaboration, which 
recommends comparing the fixed- and random-effects estimates if one is concerned 
about the influence of small-study effects on the results of meta-analysis in which 
there is evidence of between-study heterogeneity (The Cochrane Collaboration 
2011). If the estimates are similar, then any small-study effects have little impact on 
the effect estimate.  
4.4.2 Strengths and limitations 
The strengths of this study are the thorough search methods along with critical 
appraisal of the quality of included studies (which was generally good), inclusion of 
unpublished data through establishing a collaborative group to share data, and 
inclusion of these data in meta-analyses. In addition, I was careful to avoid selection 
bias by excluding cases selected on the basis of having had an ICH, since this 
phenotype has known associations both with severe CAA and with APOE 2 and 4. 
 
Chapter 4. APOE ɛ2/ɛ3/ɛ4 polymorphism associations with severe CAA 
vasculopathy  191 
 
This study has a number of limitations. First, although the analysis includes data 
from >90% of eligible cases identified, I was unable to include cases from one small 
study (McCarron et al. 1999).
 
In that study, APOE 2 allele-carriers had a statistically 
significant excess of fibrinoid necrosis compared with non-2 carriers, but CAA-
related ICH cases were included in these analyses. Second, despite including data 
from almost all relevant cases from the published literature, total numbers were 
relatively small and confidence intervals wide, especially for analyses of the effects 
of APOE 2. Third, methods for histopathological assessment varied between 
studies, potentially introducing heterogeneity and reducing the likelihood of 
detecting a consistent effect across studies. Fourth, APOE allele-specific effects on 
severe CAA may differ according to the presence or absence of Alzheimer’s disease, 
particularly for APOE 2, which has been associated with a decreased risk of 
Alzheimer’s dementia (Verghese et al. 2011). I could not perform informative 
subgroup analysis, however, because of the small overall numbers of participants and 
because dementia status was unknown for a large number of participants. Fifth, while 
the studies included here assessed those severe CAA-associated vasculopathic 
changes that are specifically alluded to in the Vonsattel scale, other vasculopathic 
changes may also be relevant. Sixth, both APOE allele-specific and other genetic 
associations may differ by CAA subtype. For example, there is preliminary evidence 
that APOE ε4 may be associated with CAA type 1 (where CAA is found in cortical 
capillaries), and ε2 with CAA type 2 (where amyloid is deposited in leptomeningeal 
and cortical vessels with the exception of cortical capillaries) (Thal et al. 2002). If 
CAA types 1 and 2 represent different pathological entities, the mechanisms and 
genetic risk factors for severe CAA and ICH could also differ. I did not have the 
necessary data to explore this in my study. Finally, the validity of including 
unpublished data that have not passed peer-review can be questioned, however the 
peer-review filter may be imperfect and there is some evidence from other fields to 
suggest that inclusion of unpublished data may lead associations to lose their 
statistical significance, suggesting that the published literature is shaped by selective 
reporting biases (Kyzas et al. 2005).  
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This study provides an example of the importance of systematic review and meta-
analysis methods in studying genetic associations, and how narrative reviews not 
informed by systematic reviews can be affected by citation bias (Greenberg 2009). 
Although studies in the area of CAA have continued to reference particular studies 
selectively, it is to be hoped that increasing recognition of the importance of 
systematic and unbiased assessments of the body of evidence on a particular topic 
will increasingly inform and direct future and ongoing research efforts.  
4.4.3 Outstanding issues 
Further large methodologically robust studies adhering to current reporting standards 
are needed to definitively answer the question about the effects of the APOE 
genotype on progression to severe CAA vasculopathy. Also, the allele-specific 
effects on severe CAA may differ by CAA subtype and according to the presence or 
absence of Alzheimer’s disease. Finally, there may be other genetic influences that 
interact with the APOE genotype to increase risk of or protect against severe CAA 
and ICH. 
4.4.4 Conclusions 
This study confirms existing strong evidence that APOE 4 promotes cerebral 
amyloid angiopathy, and further suggests that 4 may increase the risk of developing 
severe CAA among those with CAA. However, while these findings do not exclude a 
biologically meaningful association between the APOE 2 allele and progression to 
severe CAA, I did not find convincing evidence to support this. Much larger numbers 
of individuals will need to be included in CAA histopathology studies before reliable 
conclusions can be drawn about the specific effects of APOE 2 on CAA. In 
particular, the hypothesis that APOE 2 influences risk of ICH through promoting 
progression of CAA to its severe form is not supported by the existing, relevant, 
unbiased data. Future research efforts in this area will also be helped substantially by 
the use of standardised histopathological grading system for CAA (including 
assessment of CAA types 1 and 2) (Love et al. 2014), and by the consistent reporting 
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of dementia – and specifically Alzheimer’s disease – status among individuals 
included in histopathology studies (Dubois et al. 2013). 
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Brief description of participants  Study size









Prospective study of > 60 year old 
cognitively normal volunteers from 
community 
57 0/0 83.9 (7.4) Caucasian 46% 
Greenberg  
1995 and 1998 
USA
 
Brains selected from a brain tissue 
resource centre 






People from a longitudinal study of 
ischaemic vascular dementia, AD and 
















77-79 Caucasian 45% 
1
Number of eligible participants genotyped & assessed for CAA; 
3
Mean age for 138 participants; 
4
42 out of a larger sample of 79 participants were clinically demented 
and 34/79 had clinically diagnosed and neuropathologically confirmed Alzheimer’s disease; 
5
Authors provided unpublished data for additional 34 controls not included 
in the original publication; 
6
211 participants clinically demented, 177 participants with clinically diagnosed and neuropathologically confirmed Alzheimer’s disease; “-
“: data not available. 
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Number of participants in whom genotyping attempted and in whom it was successful; 
2
Method for assessing CAA from the pathology samples: IHC = 
immunohistochemistry; CR = Congo Red; HE = Hematoxylin and Eosin; PL = polarised light; ThS = Thioflavin S; 
3
Blinding: G to P = genotypers to pathology data; 
P to G = pathologists to genotyping data; P to C = pathologists to relevant clinical information such as participants’ dementia and Alzheimer’s disease status, history of 
intracerebral haemorrhage, age; “” done; “-“ not done; 
4
Qualification of the person rating CAA; NP = neuropathologist; 
5
Locations examined for CAA vasculopathic 
changes: F= frontal cortex; T= temporal cortex; P= parietal cortex; O= occipital cortex; C= cerebellar cortex; LM= leptomeninges; 
6
Data applies to both Greenberg 
1995 and 1998 publications;  
7
Minimal clinical information available to pathologists; “-“: data not available. 
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Table 4.3 Summary of meta-analyses of APOE genotype associations with severe CAA vasculopathy  
Comparison  
Severe CAA versus mild/moderate 
CAA 




FE OR 2.6 (95% CI 1.4 to 4.5); p=0.001 
74/224 versus 19/129 
OR 1.6 (95% CI 0.9 to 3.1); p=0.12 
74/169 versus 19/69 




FE OR 2.9 (95% CI 1.6 to 5.4); p=0.0008 
74/224 versus 15/114 
OR 2.0 (95% CI 0.98 to 3.9); p=0.06 
74/169 versus 15/61 




FE OR 1.7 (95% CI 0.7 to 4.3); p=0.23 
7/22 versus 86/331 
OR 2.8 (95% CI 0.9 to 9.0); p=0.09 
7/12 versus 86/226 




FE  OR 3.2 (95% CI 1.1 to 8.9); p=0.03 
7/22 versus 15/114 
OR 3.5 (95% CI 0.9 to 13.4); p=0.07 
7/12 versus 15/61 
RE OR 3.4 (95% CI 0.9 to 13); p=0.07 OR 3.2 (95% CI 0.5 to 20.5); p=0.22 
 
n: number of participants with severe CAA; N: total number of participants; Dark grey shading: statistically significant results; FE: results using the fixed-effects 
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Figure 4.1 Proposed theory and current state of evidence about associations between APOE and CAA phenotype 
 
Adapted from Figure 1 in Acta Neuropathologica 2005;110: 345–359 “Sporadic cerebral amyloid angiopathy: pathology, clinical implications, and possible 
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Figure 4.2 Selection of studies included in the systematic review of APOE genotype associations with severe CAA vasculopathy  
 



























1,618 publications excluded 
on the basis of screening 
titles, abstracts ± full texts 
Publications screened 
(1,754 publications) 
APOE ɛ2/ɛ3/ɛ4 & 
 hereditary CAA  








Relevant studies  
(136 publications) 
702 duplicate publications 
excluded 









APOE ɛ2/ɛ3/ɛ4  
& sporadic CAA 
107 publications 









-49: overlapping participants 
-12: number of participants <35 
 
Excluded: 
-99: vasculopathic changes not assessed 
-2: number of participants <10 
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Figure 4.3 Meta‐analysis of association of APOE ɛ4+ versus APOE ɛ4- genotypes with severe CAA versus mild/moderate CAA 
 




3df=1.22; p=0.75; OR = odds ratio; CI = confidence interval; ɛ4+ = participants with ɛ4 containing 
genotypes; ɛ4- = participants without ɛ4 containing genotypes; n = number of participants with severe CAA; N = total number of participants with CAA of any severity 
(mild, moderate or severe); Squares represent study-specific ORs, with their size proportional to the study weight based on the fixed-effects method; Horizontal lines 
represent 95% CIs; Diamond represents the pooled OR; 
1
Results of two studies conducted in one centre were combined for the analyses (Greenberg et al. 1995, 






0.01 0.1 0.2 0.5 1 2 5 10 100 
Total 2.55 (1.44, 4.52) 
Kalaria 3.32 (1.57, 7.02) 
Greenberg
1 
1.76 (0.63, 4.93) 
Davis 1.60 (0.09, 27.55) 
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Figure 4.4 Meta‐analysis of association of APOE ɛ4+ versus APOE ɛ4- genotypes with severe CAA versus moderate CAA 
 




3df=1.19; p=0.76; OR = odds ratio; CI = confidence interval; ɛ4+ = participants with ɛ4 containing 
genotypes; ɛ4- = participants without ɛ4 containing genotypes; n = number of participants with severe CAA; N = total number of participants with moderate and severe 
CAA; Squares represent study-specific ORs, with their size proportional to the study weight based on the fixed-effects method; Horizontal lines represent 95% CIs; 
Diamond represents the pooled OR; 
1






0.01 0.1 0.2 0.5 1 2 5 10 100 
Total 1.64 (0.88, 3.07) 
Kalaria 1.80 (0.79, 4.11) 
Greenberg
1 
1.50 (0.50, 4.47) 
Davis 4.00 (0.19, 84.20) 












ɛ4-: n/N OR (95%CI) 
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Figure 4.5 Meta‐analysis of association of APOE ɛ4+ versus APOE ɛ3/ɛ3 genotypes with severe CAA versus mild/moderate CAA 
 




3df=0.49; p=0.92; OR = odds ratio; CI = confidence interval; ɛ4+ = participants with ɛ4 containing 
genotypes; ɛ3/ɛ3 = participants with an ɛ3/ɛ3 genotype; n = number of participants with severe CAA; N = total number of participants with CAA of any severity (mild, 
moderate or severe); Squares represent study-specific ORs, with their size proportional to the study weight based on the fixed-effects method; Horizontal lines 
represent 95% CIs; Diamond represents the pooled OR; 
1
Results of two studies conducted in one centre were combined for the analyses (Greenberg et al. 1995, 





0.01 0.1 0.2 0.5 1 2 5 10 100 
Total 2.88 (1.55, 5.35) 
Kalaria 3.26 (1.50, 7.10) 
Greenberg
1 
2.29 (0.70, 7.48) 
Davis 1.47 (0.08, 25.32) 
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Figure 4.6 Meta‐analysis of association of APOE ɛ4+ versus APOE ɛ3/ɛ3 genotypes with severe CAA versus moderate CAA 
  





OR = odds ratio; CI = confidence interval; ɛ4+ = participants with ɛ4 containing genotypes; ɛ3/ɛ3 = participants with an ɛ3/ɛ3 genotype; n = number of participants 
with severe CAA; N = total number of participants with moderate and severe CAA; Squares represent study-specific ORs, with their size proportional to the study 
weight based on the fixed-effects method; Horizontal lines represent 95% CIs; Diamond represents the pooled OR; 
1
Results of two studies conducted in one centre 





0.1 0.2 0.5 1 2 5 10 100 
Total 1.95 (0.98, 3.87) 
Kalaria 1.80 (0.76, 4.22) 
Greenberg
1 
2.12 (0.62, 7.29) 













ɛ3/ɛ3: n/N OR (95%CI) 
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Figure 4.7 Meta‐analysis of association of APOE ɛ4+ versus APOE ɛ4- genotypes with presence versus absence of CAA 
  





OR = odds ratio; CI = confidence interval; ɛ4+ = participants with ɛ4 containing genotypes; ɛ4- = participants without ɛ4 containing genotypes; n = number of 
participants with CAA present; N = total number of study participants; Squares represent study-specific ORs, with their size proportional to the study weight based on 
the fixed-effects method; Horizontal lines represent 95% CIs; Diamond represents the pooled OR; 
1
Results of two studies conducted in one centre were combined for 





0.5 1 2 5 10 100 
Total 4.91 (3.12, 7.73) 
Kalaria 5.84 (2.88, 11.83) 
Greenberg
1 
3.24 (1.46, 7.18) 
Davis 9.60 (1.15, 79.92) 
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Figure 4.8 Meta‐analysis of association of APOE ɛ2+ versus APOE ɛ2- genotypes with severe CAA versus mild/moderate CAA 
  





OR = odds ratio; CI = confidence interval; ɛ2+ = participants with ɛ2 containing genotypes; ɛ2- = participants without ɛ2 containing genotypes; n = number of 
participants with severe CAA; N = total number of participants with CAA of any severity (mild, moderate or severe); Squares represent study-specific ORs, with their 
size proportional to the study weight based on the fixed-effects method; Horizontal lines represent 95% CIs; Diamond represents the pooled OR; 
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Figure 4.9 Meta‐analysis of association of APOE ɛ2+ versus APOE ɛ2- genotypes with severe CAA versus moderate CAA 
 





OR = odds ratio; CI = confidence interval; ɛ2+ = participants with ɛ2 containing genotypes; ɛ2- = participants without ɛ2 containing genotypes; n = number of 
participants with severe CAA; N = total number of participants with moderate and severe CAA; Squares represent study-specific ORs, with their size proportional to 
the study weight based on the fixed-effects method; Horizontal lines represent 95% CIs; Diamond represents the pooled OR; 
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Figure 4.10  Meta‐analysis of association of APOE ɛ2+ versus APOE ɛ3/ɛ3 genotypes with severe CAA versus mild/moderate CAA (fixed-effects method) 
 





OR = odds ratio; CI = confidence interval; ɛ2+ = participants with ɛ2 containing genotypes; ɛ3/ɛ3 = participants with an ɛ3/ɛ3 genotype; n = number of participants 
with severe CAA; N = total number of participants with CAA of any severity (mild, moderate or severe); Squares represent study-specific ORs, with their size 
proportional to the study weight based on the fixed-effects method; Horizontal lines represent 95% CIs; Diamond represents the pooled OR; 
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Figure 4.11 Meta‐analysis of association of APOE ɛ2+ versus APOE ɛ3/ɛ3 genotypes with severe CAA versus mild/moderate CAA (random-effects method) 
 





OR = odds ratio; CI = confidence interval; ɛ2+ = participants with ɛ2 containing genotypes; ɛ3/ɛ3 = participants with an ɛ3/ɛ3 genotype; n = number of participants 
with severe CAA; N = total number of participants with CAA of any severity (mild, moderate or severe); Squares represent study-specific ORs, with their size 
proportional to the study weight based on the random-effects method; Horizontal lines represent 95% CIs; Diamond represents the pooled OR; 
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Figure 4.12 Meta‐analysis of association of APOE ɛ2+ versus APOE ɛ3/ɛ3 genotypes with severe CAA versus moderate CAA 
 





OR = odds ratio; CI = confidence interval; ɛ2+ = participants with ɛ2 containing genotypes; ɛ3/ɛ3 = participants with an ɛ3/ɛ3 genotype; n = number of participants 
with severe CAA; N = total number of participants with moderate and severe CAA; Squares represent study-specific ORs, with their size proportional to the study 
weight based on the fixed-effects method; Horizontal lines represent 95% CIs; Diamond represents the pooled OR; 
1
Results of two studies conducted in one centre 
were combined for the analyses (Greenberg et al. 1995, Greenberg et al. 1998). 
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Figure 4.13 Meta‐analysis of association of APOE ɛ2+ versus APOE ɛ2- genotypes with presence versus absence of CAA (fixed-effects method) 
 





OR = odds ratio; CI = confidence interval; ɛ2+ = participants with ɛ2 containing genotypes; ɛ2- = participants without ɛ2 containing genotype; n = number of 
participants with CAA present; N = total number of study participants; Squares represent study-specific ORs, with their size proportional to the study weight based on 
the fixed-effects method; Horizontal lines represent 95% CIs; Diamond represents the pooled OR; 
1
Results of two studies conducted in one centre were combined for 
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Figure 4.14 Meta‐analysis of association of APOE ɛ2+ versus APOE ɛ2- genotypes with presence versus absence of CAA (random-effects method) 
 





OR = odds ratio; CI = confidence interval; ɛ2+ = participants with ɛ2 containing genotypes; ɛ2- = participants without ɛ2 containing genotypes; n = number of 
participants with CAA present; N = total number of study participants; Squares represent study-specific ORs, with their size proportional to the study weight based on 
the random-effects method; Horizontal lines represent 95% CIs; Diamond represents the pooled OR; 
1
Results of two studies conducted in one centre were combined 
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Figure 4.15 Meta‐analysis of association of APOE ɛ2+ versus APOE ɛ3/ɛ3 genotypes with presence versus absence of CAA 
 





OR = odds ratio; CI = confidence interval; ɛ2+ = participants with ɛ2 containing genotypes; ɛ3/ɛ3 = participants with an ɛ3/ɛ3 genotype; n = number of participants 
with CAA present; N = total number of study participants; Squares represent study-specific ORs, with their size proportional to the study weight based on the random-
effects method; Horizontal lines represent 95% CIs; Diamond represents the pooled OR; 
1
Results of two studies conducted in one centre were combined for the 
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5. APOE ɛ2/ɛ3/ɛ4 polymorphism associations 
with severity of hereditary CAA 
 Many types of hereditary CAA exist, distinguished by their genetic cause  
 Phenotypic variability between cases suggests modulation by additional factors 
 Understanding hereditary CAA mechanisms may contribute towards 
understanding those of sporadic CAA 
 APOE ε4 allele is associated with presence, and possibly severity of sporadic 
CAA (shown in Chapters 3 and 4) 
 In this chapter, I aimed to study whether APOE also affects histopathological 
severity of hereditary CAA 
 I performed a systematic review of published studies assessing the association of 
APOE ɛ2/ɛ3/ɛ4 polymorphism with histopathological CAA severity in hereditary 
CAA cases  
 I conclude that there is no evidence for an association of APOE ɛ4 with CAA 
severity in hereditary CAA cases. However there were too few studies and 
participants, and limited data about study quality to draw firm conclusions  
 There are no published data about the association between APOE ɛ2 and CAA 
severity in hereditary CAA 
5.1 Introduction 
Amyloid-β peptide is by far the most common amyloid subunit implicated in 
sporadic forms of CAA and Alzheimer’s disease (AD). Amyloid-β CAA is also 
prominent in variants of familial AD (FAD) due to mutations of the amyloid 
precursor protein (APP), presenilin-1 (PSEN1) or presenilin-2 (PSEN2) genes, and in 
several forms of hereditary CAA (HCAA) due to mutations in the APP gene. 
Missense mutations of the APP can be within or just outside the coding region of the 
amyloid-β peptide. Mutations localised close to the β-secretase or γ-secretase 
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cleavage sites with amino acid substitutions flanking the amyloid-β sequence result 
in clinico-pathological phenotypes of early-onset FAD, while those resulting in 
amino acid substitution within the amyloid-β sequence are more often associated 
with a neuropathological phenotype that includes prominent CAA (HCAAs) (Revesz 
et al. 2009). Eight types of HCAAs (some also known as hereditary cerebral 
haemorrhage with amyloidosis or HCHWA) caused by mutations in six sites on the 
APP gene have been described (Kamp et al. 2014, Zhang-Nunes et al. 2006): 
 HCAA due to mutation in codon 678; 
 HCAA Flemish-type (mutation in codon 692); 
 HCAA Dutch-type (mutation in codon 693); 
 HCAA Italian-type (mutation in codon 693); 
 HCAA Arctic-type (mutation in codon 693); 
 HCAA Iowa-type (mutation in codon 694); 
 HCAA Piedmont-type or Italian-type II (mutation in codon 705); 
 HCAA Italian-type III (mutation in codon 713). 
HCAAs of Italian-, Piedmont- and Dutch-types are associated primarily with lobar 
cerebral haemorrhages, white matter lesions, and cognitive impairment, and only 
variable extents of the plaque and neurofibrillary pathologies characteristic of AD 
(Zhang-Nunes et al. 2006). HCAAs of Italian III-, Iowa-, Arctic-, Flemish- types and 
HCAA associated with codon 678 mutation are associated both with CAA (and 
sometimes ICH) and with dementia, often of the AD type (Kamp et al. 2014). 
Compared to sporadic CAA, the HCAAs generally have a more severe clinical 
course, with an earlier age of onset and earlier age of death (Zhang-Nunes et al. 
2006). Overall the similarities between HCAAs and sporadic forms of CAA are more 
striking than the differences. 
Over-expression of the wild-type APP without amino acid substitution in the protein 
sequence also results in severe parenchymal and vascular amyloid-β deposition. This 
can be seen in FAD caused by duplication of the APP gene, and in Down’s syndrome 
(Revesz et al. 2009). 
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A number of other proteins are also involved in rare familial diseases in which CAA 
is a characteristic morphological feature. These proteins include: the ABri and ADan 
subunits in BRI2 gene-related familial British and familial Danish dementia; variant 
cystatin C in cystatin C gene-related HCHWA-Icelandic type; variant transthyretins 
in TTR gene-related meningo-vascular amyloidosis; disease-associated prion protein 
(PsP
Sc
) in PRPN gene-related hereditary prion disease with premature stop codon 
mutations; and mutated gelsolin (AGel) in gelsolin gene-related familial amyloidosis 
of Finnish type (Revesz et al. 2009). In the case of these rare familial diseases, 
mainly vascular deposits of the pathological protein can be found not only in the 
central nervous system, but also in a variety of peripheral tissues and systemic organs 
(Revesz et al. 2009). 
There is phenotypic variability between HCAAs caused by different mutations, 
which is at least partly explained by altered APP processing and the varying 
properties of the respective mutant peptides compared to the wild-type amyloid-β 
(Zhang-Nunes et al. 2006). However, the phenotypic expression is also very variable 
between cases affected by the same mutation, suggesting modulation by additional 
factors. For example, in cases with HCAA-Dutch type, the first and best described 
HCAA, affecting three large families originating from the coastal villages of Katwijk 
and Scheveningen in the Netherlands, clinical features such as age at onset, age at 
death, occurrence of dementia and the number of strokes vary considerably between 
the cases (Bornebroek et al. 1997b, Kamp et al. 2014, Zhang-Nunes et al. 2006). In 
addition, extent and severity of radiological and pathological features of HCAA can 
vary (Bornebroek et al. 1997a, Natté et al. 2001). Another example of phenotypic 
heterogeneity between carriers of the same mutation is HCAA-Iowa type. Affected 
members of the Iowa family carrying the mutation reported no episodes of clinically 
manifest ICH, while a second family from Spain carrying the same mutation 
demonstrated ICH in three of the four affected members (Zhang-Nunes et al. 2006) 
and a recently reported Polish family also presented with ICH (Iwanowski et al. 
2015) 
Various factors, hypothesised to modulate the disease phenotype in cases with 
HCAA Dutch-type, have been studied (Zhang-Nunes et al. 2006). The mortality rate 
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is shown to be higher in females, and when the disease has been paternally 
transmitted (Bornebroek et al. 1997b). Genetic polymorphisms in the APOE and PS1 
genes have also been investigated, and shown not to influence the clinical phenotype 
of the disease (Bornebroek et al. 1997a, Haan et al. 1994, Zhang-Nunes et al. 2006).   
Understanding the mechanisms of hereditary forms of a disease may contribute 
towards better understanding the mechanisms of sporadic forms of the same disease. 
My systematic review and meta-analyses in Chapter 3 demonstrated a dose-
dependent association between histopathologically confirmed sporadic CAA and 
APOE ε4 containing genotypes. I therefore aimed to study how the APOE genotype 
affects the variation in phenotypic presentation (in this case the severity of cerebral 
amyloid angiopathy) of hereditary diseases where CAA is a prominent feature.  
In this chapter, I aim to assess the evidence for an association between the APOE 
ɛ2/ɛ3/ɛ4 polymorphism and severity of CAA in brain pathology samples of cases 
with genetically proven HCAA and FAD by performing a systematic review of 
relevant published data.  
5.2 Methods 
5.2.1 Search strategy 
I sought all studies of adult humans published in any language, in which cases with a 
confirmed genetic mutation causing HCAA and/or FAD had been genotyped for the 
APOE ɛ2/ɛ3/ɛ4 polymorphism and had CAA assessed pathologically (using autopsy 
or biopsy).  
I used the same search strategy as in Chapter 3, searching OVID Medline (1950 to 
March 2012) and Embase (1980 to March 2012), using a combination of search 
terms for APOE, genes and CAA (Appendix 3). I also checked the bibliographies of 
all relevant studies and reviews identified, and searched Google Scholar for studies 
citing relevant studies.  
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5.2.2 Inclusion/exclusion criteria 
For the analyses reported in this chapter, I included all studies in which >1 case with 
a genetic mutation causing HCAA and/or FAD had been genotyped for the APOE 
ɛ2/ɛ3/ɛ4 polymorphism and had CAA assessed pathologically (using autopsy or 
biopsy), regardless of whether any association between the polymorphism and CAA 
was reported on. A clinical research fellow colleague (Dr Neshika Samarasekera) 
and I independently selected eligible studies, resolving disagreements by discussion. 
5.2.3 Data extraction 
For each study included, I extracted information on:  
 first author;  
 publication year;  
 participant source and description;  
 genetic mutation causing HCAA and/or FAD;  
 number of cases in whom the APOE ɛ2/ɛ3/ɛ4 polymorphism was genotyped 
and CAA was assessed pathologically;  
 if available, any data about studying the association between the APOE 
ɛ2/ɛ3/ɛ4 polymorphism and severity of CAA on pathological assessment, 
and information about the scale used to assess CAA severity.  
5.3 Results 
5.3.1 Included studies 
Of 1754 publications identified for screening I included 24 relevant studies (Figure 
5.1) (Bornebroek et al. 1997a, Bornebroek et al. 1997b, Bugiani et al. 2010, Cabrejo 
et al. 2006, Dorfman et al. 2010, Fukutani et al. 1997, Gustafson et al. 1998, Halliday 
et al. 1997, Kumar-Singh et al. 2002, Lemere et al. 1996, Mann et al. 1996a, Mann et 
al. 1996b, Mann et al. 1996c, Mann et al. 2001, Natté et al. 2001, Nochlin et al. 1998, 
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Roks et al. 2000, Rosenberg et al. 2000, Rovelet-Lecrux et al. 2006, Singleton et al. 
2000, Tomidokoro et al. 2010, Vinters et al. 1998, Yasuda et al. 2000, Yokota et al. 
2002). 
5.3.2 Study characteristics 
Most studies were either clinico-pathologic descriptions of affected families, or 
pathologic studies of archival autopsy specimens of individuals carrying a mutation 
causing HCAA/FAD.  
The total number of eligible non-overlapping cases (genetically confirmed mutation 
causing HCAA or FAD, genotyped for the APOE ɛ2/ɛ3/ɛ4 polymorphism and CAA 
assessed pathologically) across studies was between 92 and 197 (Table 5.1). There 
was uncertainty about the exact number of cases because the total number of cases in 
two studies was unclear, and the number of non-overlapping eligible cases across 
studies could not be confidently calculated due to limited information available from 
the publications. The number of eligible cases per study ranged from two to 52. The 
median number of eligible cases per study was four (Table 5.1).  
Eight studies included cases of HCAA due to a mutation in codons 692-694 of the 
APP gene on chromosome 21: four studies included cases of HCAA-Dutch type; two 
studies cases of HCAA-Flemish type; and two studies cases of HCAA-Italian and 
HCAA-Iowa type. 16 studies included cases of FAD due to a mutation in the APP 
(codons 670, 671, 717 or duplications), PS1 or PS2 genes on chromosomes 21, 14 or 
1 respectively: six studies included cases of FAD due to a mutation in APP; nine 
studies due to a mutation in PS1; and one study due to a mutation in PS2.   
5.3.3 Association between APOE ɛ2/ɛ3/ɛ4 polymorphism and 
severity of hereditary CAA 
Only three of the 24 eligible studies reported that they had studied the association 
between APOE ɛ2/ɛ3/ɛ4 polymorphism and severity of CAA on pathology 
(Bornebroek et al. 1997a, Natté et al. 2001, Mann et al. 2001).  
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The first study included eight eligible cases of HCAA-Dutch type (Bornebroek et al. 
1997a), the second study included 14 to 16 eligible cases of HCAA-Dutch type 
(Natté et al. 2001), and the third study included 52 cases with FAD due to a mutation 
in the PS1 gene (Mann et al. 2001). Two of these three studies included partly 
overlapping cases of HCAA-Dutch type (Bornebroek et al. 1997a, Natté et al. 2001). 
The total number of non-overlapping cases in these three studies was between 66 and 
75, but the exact number of non-overlapping cases could not be identified based on 
information available from the publications.  
In the Bornebroek et al. (1997a) study, CAA severity was rated semi-quantitatively 
on a previously published scale (Ellis et al. 1996) as follows:  
 0 = no CAA; 
 1 = sparse or mild CAA; 
 2 = moderate CAA; 
 3 = frequent or severe CAA.  
In the Natté et al. (2001) study, CAA amount was measured semi-quantitatively with 
computerised morphometry following immunohistochemistry by calculating: 
 the percent of cortical area occupied by amyloid-β positive vessel walls; 
 the lumen/vessel diameter ratio of amyloid-β positive cortical vessels.   
In the Mann et al. (2001) study, CAA severity was measured on a scale as follows:  
 1 = few leptomeningeal vessels weakly or patchily stained; 
 2 = few leptomeningeal vessels strongly or evenly stained, with mild 
      intracortical vascular involvement; 
 3 = many leptomeningeal and intracortical vessels patchily or strongly 
      stained; 
 4 = many leptomeningeal and intracortical vessels strongly or evenly stained, 
      with dysphoric angiopathy.  
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The Bornebroek et al. study found that all included cases had severe CAA in all 
cortical areas and concluded that modulation by APOE genotype was impossible to 
detect, but unlikely (Bornebroek et al. 1997a). The Natté et al. and Mann et al. 
studies made a general statement about the association between the APOE genotype 
and CAA severity, but did not show raw data or describe exact statistical methods 
used to test the association, probably because this was not the primary aim of the 
studies (Natté et al. 2001, Mann et al. 2001). Natté et al. (2001) reported that cases 
with an APOE ɛ4 allele did not have a higher amount of CAA compared to cases 
without an APOE ɛ4 allele. Mann et al. (2001) reported that there was no correlation 
between possession of the ɛ4 allele and CAA severity across all cases. It was unclear 
from the publications if the analyses looking at the association between CAA 
severity and APOE genotype had taken into account the possible effect of age of the 
cases, the duration of illness, and in the case of Mann et al. study, the location of the 
mutation along the PS1 gene. All three studies may have included cases with CAA-
related ICH as an unselected part of the spectrum of CAA severity, but the exact 
numbers of CAA-related ICH cases were not available. 
No study commented about the association between the APOE ɛ2 allele and CAA 
severity.  
5.4 Discussion 
5.4.1 Main findings 
With my thorough systematic search I identified 24 studies in >90 individuals with 
HCAA or FAD, with data on both APOE genotype and CAA histopathology 
assessment. Only three studies including >65 cases had investigated and reported on 
the association between APOE ɛ2/ɛ3/ɛ4 polymorphism and CAA severity in cases 
with HCAA and FAD. These three studies did not find an association between 
possession of the APOE ɛ4 allele and CAA severity in cases with HCAA Dutch-type 
and PS1-related FAD. There were too few studies and cases, and insufficient data 
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about the methods used to test for an association, to draw firm conclusions. There 
was no data about the association between APOE ɛ2 and CAA severity.  
To my knowledge, this is the first systematic review looking at the association 
between APOE ɛ2/ɛ3/ɛ4 genetic polymorphism and pathological CAA severity in 
cases with HCAA and FAD. Previous studies in cases with HCAA Dutch-type have 
shown that age of onset, age at death, occurrence of dementia, number of strokes, 
WMH lesion volume, focal lesions on MRI scan, and number of amyloid-β plaques 
in brain tissue are not influenced by the APOE ɛ2/ɛ3/ɛ4 genotype (Bornebroek et al. 
1997a, Haan et al. 1995, Haan et al. 1994). Furthermore, no association between the 
APOE ɛ4 allele and amyloid-β plasma levels was found in 22 HCAA Dutch-type 
patients (Bornebroek et al. 2003). Also for HCAA Flemish-type, there is no evidence 
that APOE genotype influences the age at onset of dementia or ICH, though the 
statistical power of analyses in these studies has been low (Haan et al. 1994, Roks et 
al. 2000). In contrast with these findings however, is a study showing that cultures of 
human brain pericytes with an ɛ4/ɛ4 genotype exhibited more Dutch-type amyloid β 
induced cell death than cultures with other APOE genotypes (Verbeek et al. 2000).  
Since my systematic review, I am aware of one further published study where 
association between CAA severity and presence of an APOE ɛ4 allele was 
investigated in ten FAD cases carrying a PS1 mutation. It reported a significantly 
greater proportion of cortical vessels (but not leptomeningeal vessels) affected by 
CAA in ɛ4 carriers. However the study included only three APOE ɛ4 carriers and 
correction for multiple testing was not undertaken, so these results should be 
interpreted with caution (Ryan et al. 2015).  
One possible explanation for the lack of apparent influence of the APOE genotype on 
CAA severity is that apoE may have a lower binding affinity for the mutant amyloid-
β and therefore won’t influence amyloid-β deposition (Bornebroek et al. 1997a). 
Alternatively, the studies that investigated this were not large enough to detect the 
association.  
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Interestingly, a recent study on genetic modifiers in CADASIL, a non-amyloidogenic 
hereditary SVD, found the APOE ε2 allele (but not the ε4 allele) to be an 
independent risk factor for higher WMH volumes in NOTCH3 mutation carriers. 
This further supports the need to investigate the associations of HCAA and FAD 
severity with not only ɛ4, but also ɛ2 allele, and include larger numbers of affected 
cases (Gesierich et al. 2015).  
5.4.2 Strengths and limitations 
The strengths of my study include a thorough search strategy and strict case inclusion 
criteria requiring confirmation of the mutation on genetic testing. My systematic 
review is also strengthened by the identification and characterisation of the 21 
studies that did not report investigating the association between the APOE genotype 
and CAA severity, but had the necessary data to do so. By contrast, many meta-
analyses do not account for otherwise relevant studies without the necessary data 
within their publications and so risk undetected reporting bias, since many studies 
report only significant findings and fail to mention non-significant ones. It was not 
possible to calculate the exact proportion of eligible cases for whom there was data 
about the association, out of all eligible cases in the 24 studies, but it was in the range 
of 30% to 80%. Identifying these studies also opens up the possibility to contact the 
authors of the studies directly, to enquire about any unpublished relevant data. In the 
case of my study, I decided contacting the authors of the 21 studies was extremely 
unlikely to change my conclusions, considering the number of included cases in 
these 21 studies was very small, ranging from two to eight (median 3.5).  
My study has some limitations. First, despite including data from all relevant studies 
from the published literature, because HCAA and FAD are relatively rare conditions, 
the number of included cases was small. Second, there were no data about the 
association between APOE and CAA severity in cases with HCAA and FAD due to 
mutations other than PS1 and APP Dutch-type. Third, the three studies that had 
looked at the association probably included cases with CAA-related ICH as a 
spectrum of CAA severity. The exact proportion of these cases was not available 
from the publications, but it is likely to be high (especially in the case of HCAA 
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Dutch-type) considering that CAA-related ICH is one of the reasons leading to death 
and autopsy in these cases. Depending on the proportion of ICH cases, these studies 
may not be able to distinguish a genetic association with CAA severity from an 
association with CAA-related ICH. Fourth, the scales of assessing CAA severity in 
pathology samples were variable, and as demonstrated by the Bornebroek et al study, 
cases of HCAA often have severe CAA anyway (Bornebroek et al. 1997a) so 
modulation by APOE genotype may be difficult to detect. It may therefore be more 
appropriate to use a scale that also takes into account vasculopathic changes 
associated with severe CAA as a way of quantifying severe CAA, as suggested by 
Vinters et al (1998). Fifth, it was unclear from the publications if the analyses 
looking at the association between CAA severity and APOE genotype had taken into 
account the possible effect of age of the cases and the duration of illness. Sixth, the 
study that looked at the association in cases with a PS1 mutation included 52 cases 
with mutations at different locations along the PS1 gene, which may mean slightly 
different phenotypes were being compared. Mann et al (2001) even report an 
association between CAA severity and mutation location in the PS1 gene (mutations 
between codons one to 200 were associated with less severe CAA, compared to 
mutations after codon 200). It was unclear from the publication if this was taken into 
account when the association of CAA severity with APOE was studied. 
5.4.3 Outstanding issues 
Since cases of HCAA and FAD often have severe CAA anyway, it may be more 
appropriate for future studies to use a scale that quantifies severe CAA further by 
taking into account vasculopathic changes. This may help detecting modulation by 
APOE genotype and other factors.  
Studies did not report looking at the association between APOE ɛ2 and CAA 
severity. This would be an interesting question to look at, considering the generally 
accepted but not proven theory addressed in Chapter 4, suggesting that while APOE 
4 promotes vascular amyloid deposition, 2 promotes progression to severe CAA 
with associated vasculopathy leading to vessel rupture and ICH.  One intriguing 
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observation is the different phenotype of the same HCAA Iowa-type mutation in 
families in Iowa and Spain – three out of four affected Spanish family members 
presented with haemorrhagic stroke while none of the 12 Iowa family members had a 
haemorrhagic stroke. It has been speculated that this is possibly explained by the 
presence of APOE ɛ2 in the Spanish proband with haemorrhagic stroke and APOE ɛ4 
in the Spanish brother and the Iowa family members without ICH. However, in the 
absence of APOE data from other affected members in both pedigrees, the 
involvement of APOE in determining the phenotype of the Iowa mutation remains 
speculative (Greenberg et al. 2003). More recently, a Polish family with the Iowa 
mutation presenting with ICH has been reported, but the APOE genotype is not 
available from the publication (Iwanowski et al. 2015).  
Future studies could also investigate the association between APOE and CAA 
severity in cases with HCAA and FAD due to mutations other than PS1 and APP 
Dutch-type. 
5.4.4 Conclusions 
Unlike in the case of sporadic CAA, there is no evidence for an association between 
APOE ɛ4 and CAA severity in cases with HCAA and FAD. However, the data are 
sparse, largely due to the relative rarity of these conditions, and the studies that have 
investigated this have provided limited data in their publications, which limits 
interpreting the robustness of the results. There are no data about the association 
between APOE ɛ2 and CAA severity.  
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Figure 5.1 Selection of studies included in the systematic review of APOE genotype associations with hereditary CAA severity  
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6. Other genetic polymorphisms (non-APOE 
ɛ2/ɛ3/ɛ4) associated with sporadic CAA 
 Identifying genetic polymorphisms associated with histopathologically confirmed 
CAA should increase understanding of the underlying mechanisms   
 Several candidate genes have been investigated, often selected based on their 
known involvement with AD and the amyloid processing pathway  
 I performed a systematic review to study the associations between any (non-
APOE ɛ2/ɛ3/ɛ4) genetic polymorphism and histopathological CAA  
 I conclude that there are too few studies and participants to draw firm 
conclusions about the effect of non-APOE ε2/ε3/ε4 genetic polymorphisms on 
CAA, but some positive associations (with TGF-β1, TOMM40 and CR1 genes) 
merit replication in further larger studies  
6.1 Introduction 
Sporadic cerebral amyloid angiopathy (CAA) is characterised by deposition of 
amyloid- protein in leptomeningeal and cortical blood vessels, with a prevalence in 
population-based autopsy studies of 20-40% in non-demented and 50-60% in 
demented elderly people (Charidimou et al. 2012a). CAA is associated with 
increasing age, dementia, lobar intracerebral haemorrhage (ICH), lobar brain 
microbleeds, white matter hyperintensities, small cortical infarcts and superficial 
siderosis (Linn et al. 2010, Masuda et al. 1988, Neuropathology Group MRC CFAS 
2001, Samarasekera et al. 2012). Identifying genetic polymorphisms associated with 
histopathologically confirmed CAA should increase understanding of the 
mechanisms leading to CAA and associated diseases. 
While APOE is the most widely studied candidate gene, several other candidate 
genes have also been investigated for an association with pathologically confirmed 
CAA. These candidate genes have mainly been selected based on their known 
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association with Alzheimer’s disease, or in some cases, based on their involvement 
in the amyloid processing pathway.  
In this chapter, I aim to assess the evidence for associations between any non-
APOE ɛ2/ɛ3/ɛ4 genetic polymorphisms and histopathologically confirmed CAA by 
carrying out a systematic review. 
6.2 Methods 
6.2.1 Search strategy 
I sought all studies of adult humans published in any language, in which participants 
had been genotyped for any genetic polymorphism and had CAA pathology assessed 
(using autopsy or biopsy), regardless of whether any association between the 
polymorphism and CAA was reported on.  
I used the same search strategy as in Chapter 3, searching OVID Medline (1950 to 
March 2012) and Embase (1980 to March 2012), using a combination of search 
terms for APOE, genes and CAA (Appendix 3). I also checked the bibliographies of 
all relevant studies and reviews identified, and searched Google Scholar for studies 
citing relevant studies.  
6.2.2 Inclusion/exclusion criteria 
For the analyses reported in this chapter, I included studies where participants had 
been genotyped for any non-APOE ɛ2/ɛ3/ɛ4 genetic polymorphism and had CAA 
assessed pathologically. I excluded studies that assessed genetic associations with 
CAA-related ICH versus CAA-free controls, because these would not be able to 
distinguish a genetic association with CAA from an association with ICH. However, 
I included studies that had recruited participants with CAA-related ICH as an 
unselected part of the spectrum of CAA severity. A clinical research fellow colleague 
(Dr Neshika Samarasekera) and I independently selected eligible studies, resolving 
disagreements by discussion and mutual consensus. 
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6.2.3 Data extraction 
For each study included I extracted information on:  
 first author; 
 publication year; 
 participant source and description; 
 study size; 
 gene(s) and polymorphism(s) studied; 
 association between the polymorphism studied and pathological CAA.  
6.3 Results 
6.3.1 Included studies 
Of 1754 publications identified for screening, 26 studies were relevant (Figure 6.1). I 
excluded two studies because they compared genetic associations with CAA-related 
ICH versus CAA-related ICH free controls (McCarron et al. 2003, Zunarelli et al. 
1997). I included the remaining 24 studies in 4617 participants (Figure 6.1) (Biffi et 
al. 2012, Chalmers et al. 2004, Chapuis et al. 2009, Chapuis et al. 2006, 
Christoforidis et al. 2005, Cuenco et al. 2008, Davidson et al. 2006, Durany et al. 
2000, Hamaguchi et al. 2005, Kölsch et al. 2007, Lendon et al. 2002, Pahnke et al. 
2003, Peila et al. 2007, Peuralinna et al. 2011, Shi et al. 2006, Zubenko et al. 1999, 
Thal et al. 2010, Valant et al. 2012, Yamada et al. 2002, Yamada et al. 1997, 
Yamada et al. 1998a, Yamada et al. 1998b, Yamada et al. 1999, Yamada et al. 2003).  
6.3.2 Study characteristics 
All studies used autopsy brains from a brain bank, clinical autopsies or brain 
pathological material (mainly autopsy, some biopsy) arising during the course of a 
population-based prospective study. The median number of eligible participants per 
study who were both genotyped and assessed pathologically was 150. Across the 24 
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studies polymorphisms in 25 different genes were studied. A polymorphism in the 
LRP1 gene was investigated in three studies including 597 participants in total. 
Polymorphisms in five genes (TGF-β1, ACT, CYP46, ACE1, APOE promoter) were 
investigated in two studies each, including 187 to 524 participants per gene in total. 
All other polymorphisms were investigated in only one study and the number of 
participants per study ranged from 50 to 723 per study (Table 6.1).  
6.3.3 Association between non-APOE ε2/ε3/ε4 polymorphisms 
and CAA  
There were insufficient data for formal meta-analyses, but there were some positive 
associations with CAA. There was a consistent trend towards an association with the 
T allele of rs1800470 in the transforming growth factor β1 gene (TGF-β1) in two 
studies including 449 participants. One study in 723 participants demonstrated an 
association between 14 SNPs in the translocase of outer mitochondrial membrane 40 
gene (TOMM40) and CAA severity. One study found that the A allele of rs6656401 
in the complement component receptor 1 gene (CR1) was associated with more 
severe CAA. Other studies found no overall significant associations although some 
reported associations in particular subgroups (Table 6.1, Table 6.2).  
6.4 Discussion 
6.4.1 Main findings 
There were too few studies and participants to draw firm conclusions about the 
effects of non-APOE ɛ2/ɛ3/ɛ4 genetic polymorphisms on histopathological CAA. 
There were some positive associations – with TGF-β1, TOMM40 and CR1 genes – 
which merit replication in further larger studies or pooled datasets (Rannikmäe et al. 
2013) (Appendix 7). 
The transforming growth factor β1 is multifunctional cytokine, which is expressed in 
the periphery, and by glia and neurons in the brain. It is a potent regulator of injury 
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and inflammatory responses in the central nervous system. In experimental studies, 
TGF-β1 mRNA levels and protein production increase after a cerebral ischaemic 
event. It appears to protect the area surrounding the ischaemic region by maintaining 
neuronal viability and function through an interaction with microglia and astrocyte 
metabolism. In contrast to its neuroprotective properties after ischaemic events, 
TGF-β1 on chromosome 19 has been implicated in the neurotoxic events associated 
with the Alzheimer’s disease amyloid cascade. However, its exact role in the process 
is still under investigation. The C allele of rs1800470 causes an amino acid 
substitution at codon 10, and has been associated with a higher level of TGF-β1 
mRNA and protein compared to the wild-type T allele. The C allele has been 
associated with a reduced risk of myocardial infarction, rheumatoid arthritis and 
osteoporosis. The possible reported association between the T allele of the TGF-β1 
gene and CAA may be mediated by the lack of protective action on the endothelium, 
by influence on Aβ clearance and deposition through activation of astrocytes and 
microglia, or by some other as yet unknown mechanism (Hamaguchi et al. 2005, 
Peila et al. 2007). 
The TOMM40 gene on chromosome 19 encodes a subunit of the translocase of the 
outer membrane complex Tom40. It lies in the mitochondria, and is involved in 
regulating protein traffic across the outer mitochondrial membrane. Some studies 
have suggested that genetic variation in TOMM40 is associated with AD risk. Valant 
et al. showed that genetic variants in TOMM40 were also associated with CAA 
severity, but not with CAA-related ICH. This is interesting, and supports the theory 
that the biological processes involved in vessel rupture differ from those implicated 
in the initial vascular amyloid deposition. The effect of TOMM40 on CAA may be 
mediated by its effects on mitochondrial metabolism (Valant et al. 2012).  
The complement component receptor 1 gene (CR1) is a member of the receptors of 
complement activation (RCA) family and is located in the 'cluster RCA' region of 
chromosome 1. It is associated with AD in GWAS studies. The association of a CR1 
gene polymorphism with CAA may be via clearance of Aβ peptide (Chibnik et al. 
2011). 
 
Chapter 6. Other genetic polymorphisms (non-APOE ɛ2/ɛ3/ɛ4) associated with 
sporadic CAA  239 
 
Since this systematic review, a genome-wide association meta-analysis of 
neuropathologic features of AD, including of cerebral amyloid angiopathy, has been 
undertaken, including just over 2800 individuals (Beecham et al. 2014). It does not 
confirm the association of CR1 with neuropathological CAA. This may be due to a 
relatively modest sample size for a GWAS study, or suggest a spurious association in 
the previous study (which likely includes overlapping subjects) (Biffi et al. 2012). A 
genome-wide significant association with CAA is identified for rs6857 in the APOE 
region. This SNP is also significantly associated with AD and other 
neuropathological features of AD, so the association with CAA may be explained by 
ascertainment bias.  No other significant genome-wide associations are observed for 
CAA. 
6.4.2 Strengths and limitations 
To my knowledge, this is the first systematic review of associations between non-
APOE ɛ2/ɛ3/ɛ4 genetic polymorphisms and pathologically proven CAA. My study 
benefits from thorough ascertainment of pertinent studies, which overcomes potential 
citation bias (the citation or non-citation of research findings, depending on the 
nature and direction of the results) that is very likely to affect the conclusions in non-
systematic reviews (Greenberg 2009).  
The main limitation was that there were insufficient data for formal meta-analyses 
and for drawing firm conclusions about associations. There were also not enough 
data to draw conclusions about potential biases associated with these candidate-gene 
studies, but reporting biases (when the dissemination of research findings is 
influenced by the nature and direction of results) are likely to occur (The Cochrane 
Collaboration 2011). More specifically, the results of this systematic review may be 
affected by: 
 publication bias: the publication or non-publication of findings depending on 
the nature and direction of the results  
and 
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 outcome reporting bias: selective reporting of some outcomes but not others, 
depending on the nature and direction of the results.  
Finally, the included studies were all candidate-gene studies, where small relative 
risks may not be detected as confounding and misclassification are more likely to 
obscure small to moderate relative risks than larger relative risks. Another possible 
limitation of these studies relates to the selection of candidate genes, which is often 
done on the basis of imperfect understanding of biological pathways (Manolio et al. 
2009, Tabor et al. 2002) and is prone to be affected by citation bias.  
6.4.3 Conclusions 
There were too few studies and participants to draw firm conclusions about the effect 
of non-APOE ε2/ε3/ε4 genetic polymorphisms on CAA, but there were some 
positive associations which merit replication in further larger studies or pooled 
datasets.  
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Study size: number of eligible participants genotyped and assessed for pathologically-confirmed CAA; 
2
 If an association is reported, then the authors reported this as 
a statistically significant association; 
3
 rs4935774, rs578506, rs582446, rs668387, rs689021, rs641120, rs1699102, rs2276412, rs3824968, rs2282649, rs1010159, 
rs1784933; 
4
 Signal region of the gene → A/T alleles that determine the amino acid alanine or threonine; 
5 
rs1571660, rs2829929, rs1394839, rs2829946, rs2829949, 
rs7282634, rs2040273, rs8126493, rs4175, rs2829961, rs3787620, rs373521, rs1145, rs2829973, rs1783025, rs380417, rs1787438, rs1783016, rs214488, rs383700, 
rs2829984, rs2234983, rs216779, rs400603, rs440666, rs2014146, rs216762, rs2070657, rs2830000, rs7278838, rs2830008, rs2830012, rs768039, rs2830028, rs3991, 
rs2830033, rs2830036, rs2830038, rs7283136, rs2830040, rs2830044, rs2830051, rs2830052, rs11702267, rs2830054, rs3827166, rs2830058, rs2830068, rs466609, 
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6
capillary CAA (or CAA-type 1): 
capillary Aβ-deposition present; non-capillary CAA (or CAA-type 2): no capillary Aβ-deposition present; 
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rs2075650, rs34404554, rs11556505, rs769449, 
rs12972156, rs12972970, rs157582, rs184017, rs157581, rs283815, rs157580, rs439401, rs34095326, rs10119; Unclear what the p-value for association with rs157580 
was (contradictory information in the original publication); 
8
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Table 6.2 Summary of reported associations between non-APOE ɛ2/ɛ3/ɛ4 genetic polymorphisms and CAA  
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TGF-β1: transforming growth factor β1; TOMM40: translocase of outer mitochondrial membrane 40; CR1: complement component receptor 1; LRP1: low-density 
lipoprotein receptor 1; ACT: α1 antichymotrypsin; CYP46: cholesterol 24-hydroxylase gene; ACE1: angiotensin 1 converting enzyme; APOE: apolipoprotein E;  
1
If an association is reported, then the authors have reported this as a statistically significant association 
2
rs2075650, rs34404554, rs11556505, rs769449, rs12972156, rs12972970, rs157582, rs184017, rs157581, rs283815, rs157580, rs439401, rs34095326, rs10119; 
Unclear what the p-value for association with rs157580 is (contradictory information in the original publication);  
3
Signal region of the gene → A/T alleles that determine the amino acid alanine or threonine 
4
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Figure 6.1 Selection of studies included in the systematic review of non-APOE ɛ2/ɛ3/ɛ4 genetic polymorphisms and CAA 
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7. Contribution of variants in COL4A1 and 
COL4A2 genes to sporadic SVD 
 Understanding genetic associations with SVD would provide insight into 
underlying mechanisms 
 Genes causing rare Mendelian forms of a disease may also contain variants 
conferring risk for sporadic forms of a disease with a similar phenotype 
 Mutations in COL4A1 and COL4A2 genes cause Mendelian subcortical SVD and 
hence I hypothesised that common variants in COL4A1 and COL4A2 are 
associated with sporadic subcortical SVD 
 I conducted meta-analyses of GWAS data to determine associations of common 
SNPs in COL4A1/COL4A2 with clinical and radiological manifestations of SVD  
 I conclude that there is an association between common variation in COL4A2 and 
sporadic cerebral SVD, particularly deep intracerebral haemorrhage 
 These findings merit replication studies 
7.1 Introduction  
Genes causing rare familial forms of a disease may also contain variants conferring 
risk for sporadic forms of a disease with a similar phenotype. There are several 
examples of this. Polymorphisms in the APP gene associated with autosomal 
dominant familial Alzheimer’s disease (AD) confer risk to sporadic forms of AD and 
age-related cognitive decline (Jonsson et al. 2012). Variants in the TREX1 gene are 
associated with both familial chilblain lupus and sporadic forms of systemic lupus 
erythematosus (Lee-Kirsch et al. 2007). Common variants near ABCG8 and LCAT 
genes reached genome-wide significance for an association with lipid levels, while 
rare variants in these genes are known to cause Mendelian forms of dyslipidaemia 
(Kathiresan et al. 2009). Whether genes involved in familial forms of cerebral SVD 
also confer risk to sporadic SVD remains uncertain. It has been suggested that rare 
variants in the NOTCH3 gene, mutations in which cause cerebral autosomal 
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dominant arteriopathy with subcortical infarcts and leukoencephalopathy 
(CADASIL), are associated with white matter hyperintensities (WMH) in the general 
population (Schmidt et al. 2011). However, a more recent study does not support a 
role for common NOTCH3 variation in the risk of sporadic SVD (Rutten-Jacobs et 
al. 2015).   
Collagen IV is a major component of the basement membrane, a specialised 
extracellular matrix structure that compartmentalises tissues, provides structural 
support and influences cell behaviour. In blood vessel walls, the basement membrane 
separates smooth muscle cells from the endothelial cells lining the vessel lumen. 
Vertebrates express six collagen type IV chains (1-6(IV)), encoded by the genes 
COL4A1-6. In the endoplasmic reticulum, three distinct obligatory heterotrimeric 
molecules (protomers) are formed, each containing three alpha chains, 
1.1.2(IV), 3.4.5(IV) and 5.5.6(IV), but only 1.1.2(IV) is present in 
the vasculature. The alpha chains contain a N-terminal 7S domain, a collagen domain 
consisting of G-X-Y repeats in which every third amino acid is a highly conserved 
glycine residue, and a C-terminal NC1 domain that initiates protomer formation. 
After secretion, protomers interact to form a collagen IV network within the 
basement membrane (Khoshnoodi et al. 2008).  
The COL4A1 and COL4A2 genes are located in tandem on chromosome 13q34 and 
have a shared communal bi-directional promoter (Khoshnoodi et al. 2008). Dominant 
missense COL4A1/COL4A2 mutations lead to a spectrum of Mendelian disorders, 
characterised by eye, kidney and cerebrovascular defects, including intracranial 
aneurysms and SVD. These disorders manifest clinically as porencephaly 
(cerebrospinal fluid filled cavities due to ICH), deep ICH, and lacunar ischaemic 
strokes, and radiologically as WMH and mainly subcortical brain microbleeds 
(Vahedi and Alamowitch 2011). The clinical phenotype appears to be influenced by 
the type and position of the mutation, as well as genetic and environmental modifiers 
(Van Agtmael and Bruckner-Tuderman 2010).  
The mutations are associated with basement membrane defects, but can also lead to 
intracellular retention of mutant protein, swollen endoplasmic reticulum vesicles and 
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increased expression of chaperones and apoptosis. This suggests that endoplasmic 
reticulum stress, which is pathogenic when chronic, may also play a role in disease 
pathogenesis (Jeanne et al. 2012, Murray et al. 2014, Van Agtmael et al. 2010, Van 
Agtmael et al. 2005). However, the exact contributions of endoplasmic reticulum 
stress and basement membrane defects to disease development remain unknown. 
Recent data suggest that manipulation of chaperone levels, intracellular collagen 
accumulation, and endoplasmic reticulum stress (e.g. with 4-phenyl butyric acid), are 
potential therapeutic options for collagen IV diseases including haemorrhagic stroke 
(Murray et al. 2014). 
There are some data to suggest that variants in COL4A1 and COL4A2 may also be 
associated with sporadic cardiovascular diseases. Common SNPs in COL4A1 may be 
associated with the presence of intracranial aneurysms (Ruigrok et al. 2006), vascular 
stiffness, coronary artery calcification and coronary artery disease (Adi et al. 2013, 
O'Donnell et al. 2011, Schunkert et al. 2011, Tarasov et al. 2009, Yamada et al. 
2008). Furthermore, rare mutations in COL4A1 and COL4A2 have recently been 
shown to be associated with sporadic ICH (Jeanne et al. 2012, Schmidt et al. 2011, 
Weng et al. 2012). 
I therefore hypothesized that variants in the COL4A1 and COL4A2 genes may confer 
risk for sporadic cerebral SVD. 
In this chapter, I aim to investigate whether there is an association between 
common SNPs in collagen genes and sporadic SVD. I do this by conducting meta-
analyses of GWAS data among individuals of European ancestry, to determine 
associations of common SNPs in the COL4A1/COL4A2 genomic region with clinical 
and radiological manifestations of SVD (deep ICH, lacunar ischaemic stroke and 
white matter hyperintensities).  
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7.2 Methods 
7.2.1 Identifying participating studies 
Through the International Stroke Genetics Consortium (ISGC) 
(http://www.strokegenetics.org/)
1
, a non-systematic literature review, and personal 
contact with researchers in the field of stroke genetics, I identified the large consortia 
that hold GWAS data for the phenotypes that were of interest to me: intracerebral 
haemorrhage (ICH) and ischaemic stroke (IS) including their subtypes, and WMH. I 
approached these consortia with formal collaboration proposals and/or by emailing 
the principal investigator(s) directly, describing my proposed project and inviting 
them to collaborate by sharing data. I participated in the relevant teleconference calls 
to introduce my project and answer any questions.  
The consortia and investigators approached were all very positive and agreed to 
participate in this project. As a result I established an international collaborative 
group that included four large consortia (partly united under the ISGC umbrella): the 
ISGC ICH GWAS consortium (Woo et al. 2014), the Metastroke consortium 
(Traylor et al. 2012), the WMH in Ischaemic Stroke GWAS Collaboration (Adib-
Samii et al. 2013)  and the CHARGE consortium WMH Group (Fornage et al. 2011)  
[http://web.chargeconsortium.com/]). These consortia included data from the 
majority of large GWAS studies of relevant cerebrovascular phenotypes in 
individuals of European ancestry, available at the time of starting this project in 
2012: ICH and its subtypes (deep and lobar), ischaemic stroke and its TOAST 
subtypes (large vessel disease [LVD], cardio-embolic [CE] and small vessel 
disease/lacunar IS), WMH volume in ischaemic stroke cases and WMH volume in 
population-based studies (Table 7.1).  
 
                                                 
1
 Professor Cathie Sudlow is on the ISGC steering committee and I am an ISGC member.  
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7.2.2    Data collection  
I collected study characteristics data and genotype-phenotype association data from 
relevant publications, by direct communication with study and/or consortium leads, 
and other study team members. I also undertook a visit to a collaborator’s (Professor 
Jonathan Rosand) laboratory in the Center for Human Genetic Research at the 
Massachusetts General Hospital in Boston, USA, to access some of the data and 
perform some of the relevant analyses. 
7.2.2.1 Study characteristics  
I extracted information for each study contributing data to the analysis about:  
 overall study characteristics: study design, inclusion and exclusion criteria, 
phenotype definition and diagnostic criteria, and, where relevant, methods of 
phenotype measurement; 
 study participants’ characteristics: ancestry, numbers of cases ± controls for 
each phenotype, mean age and standard deviation of cases ± controls; 
 genotyping and association analysis methods: GWAS panel used, quality 
control steps, imputation (software, reference panel, quality parameters), 
software and statistical model used for association analyses, handling of 
population stratification, Hardy-Weinberg equilibrium, adjusting for cryptic 
or overt relatedness, strand and build of the human genome on which results 
provided. 
7.2.2.2 Genotype data 
I collected existing GWAS data from participating studies for the COL4A1 and 
COL4A2 genomic region of ~464 kbp, which includes >1000 single nucleotide 
polymorphisms (SNPs) covering the bi-directional communal promoter, introns, 
exons and a 50kbp upstream and downstream flanking region (Human Genome 
reference build 19 [hg19] coordinates 110.751.310 – 111.215.373). For each 
phenotype (deep ICH, lobar ICH, all ICH, LVD IS, CE IS, lacunar IS, all IS, WMH 
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volume in IS and WMH volume in population-based studies) I collected the 
following study-level summary genotype-phenotype association data for all directly 
genotyped and imputed SNPs in the region:  
 SNP reference (rs) number and position; 
 effect allele/non-effect allele and their frequencies; 
 association effect size estimate (ß-coefficient); 
 standard error of the ß-coefficient; 
 p-value for the association; 
 for imputed SNPs, the imputation quality measure used and its value.   
7.2.3 Data analysis  
7.2.3.1 Calculating the significance threshold 
To allow for multiple testing, I used a modified version of the Nyholt method (Li and 
Ji 2005). This method takes into account the linkage disequilibrium (LD) between 
SNPs: based on the spectral decomposition of matrices of pairwise LD between 
SNPs, it calculates the ‘effective number’ (N) of SNPs tested. It uses this number to 
calculate the statistical significance threshold by applying the Bonferroni correction 
for N independent tests (p<0.05/N). I used the publicly available HapMap II CEU 
(release 23) dataset (Utah residents of northern and western European ancestry) 
genotype information to calculate N using the web interface 
http://gump.qimr.edu.au/general/daleN/SNPSpD/.  
The modified Nyholt method controls accurately for the error rate in evaluations of 
real and simulated data. I decided it was more appropriate for my data than the 
standard Bonferroni correction (which would be overly conservative due to the 
assumption that all SNPs are independent), or the conventional GWAS significance 
p-value (which would be overly conservative because it assumes the study is 
hypothesis-free) (Li and Ji 2005, Nyholt 2004, Nyholt 2005, Salyakina et al. 2005).  
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7.2.3.2 Meta-analyses of COL4A1/COL4A2 SNPs for each phenotype  
I performed meta-analyses of the genotype summary data from each contributing 
study, assessing associations of COL4A1 and COL4A2 SNPs with each of the 
cerebrovascular phenotypes available – both those assumed to represent cerebral 
SVD specifically (deep ICH, lacunar IS, WMH volume in IS and in population-based 
studies), and others (lobar ICH, all ICH, CE IS, LVD IS, all IS). I hypothesised that 
associations would be specific to – or at least strongest with – cerebral SVD 
phenotypes. I used a fixed-effects inverse-variance-based model in METAL genetic 
meta-analysis software, which weights the ß-coefficients by their estimated standard 
errors (Willer et al. 2010). I used a case-control approach for ICH, ischaemic stroke 
and their subtypes, generating, for each SNP, odds ratios (ORs) per additional minor 
allele for being a case versus control. I used a quantitative trait approach for WMH 
analysis, assessing, for each SNP, the effect per additional minor allele on the natural 
log-transformed WMH volume.  
Quality control measures had been applied to all individual studies prior to provision 
of data (Table 7.2, Table 7.3, Table 7.4, Table 7.5). Data from the included studies 
had been imputed to different reference datasets and their releases (HapMap II, 
HapMap III or 1000 Genomes) using a range of imputation software (IMPUTE, 
MACH and BimBam) (Marchini and Howie 2010) and were provided with reference 
to one of two different Human Genome reference builds (hg18 or hg19) (Abecasis et 
al. 2010, Altshuler et al. 2010, Frazer et al. 2007) (Table 7.2, Table 7.3, Table 7.4, 
Table 7.5). To permit consistent analyses and interpretation of the data across all 
included phenotypes and studies, I converted all the data to the same reference build 
(hg19) and limited the analyses to SNPs present in the HapMap II release 23 CEU 
population (Utah residents of northern and western European ancestry) only. This 
strategy provided the maximum set of 1070 SNPs represented in all studies and 
phenotypes.  
I filtered these data based on imputation quality scores (r
2
 ≥ 0.3 [MACH, BimBam, 
IMPUTE]; info score ≥ 0.7 [PLINK]) and minor allele frequency (MAF) ≥ 1%. The 
imputation quality score cut-offs were chosen based on what is traditionally used and 
 
Chapter 7. Contribution of variants in COL4A1 and COL4A2 genes to sporadic SVD 257 
 
recommended by the respective websites. The MACH and Impute r
2
 scores are 
highly correlated with each other (Marchini and Howie 2010).  
7.2.3.3 Further exploration of significant SNPs across all phenotypes  
For any SNPs significantly associated with any of the nine phenotypes assessed, I 
examined associations with all other phenotypes. I focussed on comparisons of 
findings for cerebral SVD phenotypes (deep ICH, lacunar IS, WMH) versus non-
SVD phenotypes (lobar ICH, all ICH, CE IS, LVD IS, all IS). To display the data 
across all phenotypes in a uniform way, I performed data manipulations to display 
ORs together with their 95% confidence intervals (CIs) and p-values using forest 
plots, to indicate the size and direction of associations across phenotypes.  
To calculate ORs per additional minor allele for each SNP for being a case versus 
control for the ICH and ischaemic stroke phenotypes, I did the following: I 
calculated the ORs from the β-coefficients by using the EXP function in Excel 
(inverse of the natural logarithm). I calculated the 95% CIs of the ORs by first 
calculating the error factor (Excel formula: EF=EXP[1.96*SE]) and then dividing 
and multiplying the OR with the EF to calculate the lower and upper 95% CIs 
respectively (Table 7.6). 
I calculated the OR per 1 unit standard deviation (SD) change in WMH volume in 
ischaemic stroke cohorts from the β-coefficient by using the EXP function in Excel, 
as the WMH values had a SD of 1. For WMH in population cohorts, I divided the ß-
coefficients and SEs by their respective pooled SD across cohorts (0.684) first and 
then used the transformed β-coefficient and SE to calculate the respective ORs and 
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tests for heterogeneity of results across individual studies 
(Higgins et al. 2003). METAL calculated the 
2 
and the p-value, from which I 
derived the I
2
 value using the formula:  
 
7.2.3.4 Functional annotation of SNPs 
For SNPs with significant associations, I extracted a list of all other SNPs in 
moderate LD (defined as r
2 
≥ 0.3 with a maximum allowed distance limit of 500 bp) 
from the web-based SNP Annotation and Proxy Search tool (SNAP) 
(http://www.broadinstitute.org/mpg/snap/). This was based on CEU population data 
from the 1000 Genomes pilot 1 (Johnson et al. 2008). I then obtained the functional 
annotation data for these SNPs from the Ensembl genome browser 
(http://www.ensembl.org/index.html), Seattle Seq 
(http://snp.gs.washington.edu/SeattleSeqAnnotation138/) and Haploreg v2 
(http://www.broadinstitute.org/mammals/haploreg/haploreg.php) databases (Flicek et 
al. 2014, Ng et al. 2009, Ward and Kellis 2012), using all three databases with partly 
overlapping sources of information to ensure consistency of results.  
I further explored the functional significance of SNPs that were in high LD (r
2 
≥ 0.9 
with a maximum allowed distance limit of 500 bp) with the significant SNPs from 
my analyses using the online Genotype-Tissue Expression Portal (GTEx) eQTL 
(expression quantitative trait locus) browser (http://www.broadinstitute.org/gtex/) 
and the Regulome db database (http://regulome.stanford.edu/) (Boyle et al. 2012, 
GTEx Consortium 2013). An eQTL represents a locus in the genome in which 
variation between individuals is associated with a quantitative gene expression trait, 
often measured as mRNA abundance. The Regulome db database identifies whether 
the SNPs are located within known or predicted regulatory elements in the intergenic 
regions of the human genome. I focused particularly on data obtained from 
experiments using tissues relevant to cerebrovascular phenotypes, specifically central 
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nervous system (brain and spinal cord) and vasculature. The r
2
 cut-offs were chosen 
based on discussions with statistical genetics colleagues about what would be a 
generally accepted reasonable cut-off to use, and based on the manageability of data.   
I also explored whether SNPs with significant associations were in LD with the rare 
SNPs previously reported from sequencing studies to be associated with sporadic 
ICH (Jeanne et al. 2012, Weng et al. 2012). In addition, I looked up the LD between 
the significant SNPs from my analysis and the SNPs known to be associated with 
intracranial aneurysms, coronary artery calcification, myocardial infarction and 
vascular stiffness in cases of European origin (O'Donnell et al. 2011, Ruigrok et al. 
2006, Tarasov et al. 2009). I used the web-based tool SNAP (Johnson et al. 2008). If 
the SNP was not included in SNAP, I used the Haploview programme to check 
whether the SNP (based on its position) was in the same haplotype block as the 
previously reported rare SNPs (Barrett et al. 2005).   
7.3 Results 
7.3.1 Included data  
The entire dataset consisted of the following (Table 7.1):  
 three cohorts of 1545 patients with ICH and 1485 controls, including 
information on the main ICH subtypes (874 deep and 671 lobar);  
 15 cohorts of 12 389 patients with ischaemic stroke, including information 
on the main determined TOAST subtypes (2167 LVD, 2405 CE and 1854 
lacunar IS) (Adams et al. 1993),  and 62 004 controls; 
 nine cohorts of 2733 ischaemic stroke patients; 
 seven cohorts of 9361 individuals from population-based studies with brain 
MRI-based measures of WMH volume. 
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7.3.2 Study characteristics 
Table 7.2, Table 7.3, Table 7.4 and Table 7.5 include detailed descriptions of the 
design and characteristics of the participating studies (Adib-Samii et al. 2013, 
Falcone et al. 2013, Fornage et al. 2011, Rost et al. 2010, Traylor et al. 2012, Woo et 
al. 2002, Woo et al. 2014).  
Two ICH cohorts were from prospective hospital-based case-control studies, and one 
was from a prospective population-based case-control study. All studies included 
primary spontaneous ICH cases of European descent only, excluding trauma-, 
tumour- and vascular malformation-related ICH cases. Lobar ICH was defined as 
involving predominantly the cortex and underlying white matter, and deep ICH as 
involving predominantly the basal ganglia, periventricular white matter, internal 
capsule or infratentorial area. The mean age range was 67 to 74 years for all ICH 
cases, 65 to 71 years for deep ICH cases and 71 to 76 years for lobar ICH cases. The 
mean age range for controls was 66 to 73 years (Table 7.2).   
The ischaemic stroke sample consisted of 15 cohorts of patients of European 
ancestry. All studies used a case-control methodology. 11 studies were cross-
sectional and four were in large prospective population-based cohorts. Stroke was 
defined as a typical clinical syndrome with radiological confirmation and the 
subtyping was done with the TOAST classification system (Adams et al. 1993). The 
mean age range for patients was 41 to 82 years, and for controls 40 to 86 years 
(Table 7.3).  
The studies contributing data for WMH in ischaemic stroke phenotype were all 
hospital-based. They included cases of ischaemic stroke (European ancestry) of any 
subtype and excluded cases of CADASIL, vasculitis, demyelinating and 
mitochondrial diseases. WMH was assessed in the hemisphere contralateral to acute 
ischaemic stroke. All supratentorial white matter lesions were included in WMH 
volume measurement with the exception of WMH corresponding to lacunar infarcts. 
WMH volume was analysed using semi-automated software. In the majority of 
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studies measurements were done from 1.5 T MRI FLAIR sequences. Mean age range 
was 58 to 71 years (Table 7.4).  
The seven studies providing data for the WMH in the population phenotype were all 
prospective population-based cohort studies. They excluded cases who had suffered 
from a stroke or TIA prior to the MRI. In five studies, WMH volume was estimated 
on a quantitative scale using custom-written computer programs based on automatic 
or semi-automatic analysis. In two studies WMH volume was estimated on a semi-
quantitative 10-point scale by visual comparison with templates. Majority of the 
studies had used a 1.5T MRI scanner and T1, T2 and FLAIR sequences. Mean age 
range was 63 to 76 years (Table 7.5).  
7.3.3 Significance threshold 
Based on the genotype data from the HapMap II CEU release 23 dataset, the 
‘effective number’ (N) of SNPs tested was 598, giving a final Nyholt significance 
threshold of p = 0.000084. This compares to the Bonferroni corrected p-value of 
p=0.00005 and a genome-wide significance p-value of p=5x10
-8
.   
7.3.4 Meta-analyses of COL4A1/COL4A2 SNPs for each 
phenotype  
Based on the significance threshold of p=0.000084, three common SNPs in COL4A2 
were significantly associated with the deep ICH phenotype (rs9521732: OR per 
additional A allele = 1.28, 95% CI 1.13 to 1.44, p=0.00007; rs9521733: OR per 
additional C allele = 1.29, 95% CI 1.14 to 1.46, p=0.00003; rs9515199: OR per 
additional C allele = 1.28, 95% CI 1.14 to 1.44, p=0.00006) (Figure 7.1, Table 7.7). 
These three SNPs were all intronic and in high LD with each other. One SNP 
(rs9521733) was directly genotyped in the majority of the cohorts, while two were 
imputed in all (rs951599) or in the majority (rs9521732) of the cohorts (Table 7.8). 
The associations across individual cohorts included in the deep ICH meta-analysis 
were highly consistent, with no significant heterogeneity (I
2
=0%, p>0.9) (Figure 
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7.2). There were no statistically significant associations of common SNPs in 
COL4A1/COL4A2 with any of the other phenotypes (Figure 7.3, Figure 7.4, Figure 
7.5, Figure 7.6, Figure 7.7, Figure 7.8, Figure 7.9, Figure 7.10).   
7.3.5 Associations with other cerebrovascular phenotypes of 
the three COL4A2 SNPs associated with deep ICH  
Figure 7.11 shows association results for the three SNPs significantly associated with 
deep ICH across all nine phenotypes assessed. Although these three SNPs were 
significantly associated only with deep ICH, there were suggestive associations with 
two other cerebral SVD phenotypes: lacunar ischaemic stroke (rs9521732: OR 1.09, 
95% CI 1.02 to 1.17, p=0.01639; rs9521733: OR 1.10, 95% CI 1.03 to 1.18, 
p=0.00734; rs9515199: OR 1.09, 95% CI 1.02 to 1.17, p=0.0145); and WMH 
volume in symptomatic ischaemic stroke cases (rs9521732: OR 1.07, 95% CI 1.01 to 
1.14, p=0.01442; rs9521733: OR 1.07, 95% CI 1.01 to 1.13, p=0.01642; rs9515199: 
OR 1.07, 95% CI 1.01 to 1.14, per 1 SD change in WMH volume; p=0.0145). There 
was no evidence for association of these SNPs with other non-SVD stroke subtypes 
(lobar ICH, CE and LVD IS), or with WMH volume in population-based studies 
(Figure 7.11) As expected, ORs for these SNPs with the all ICH and all ischaemic 
stroke phenotypes were intermediate between those for deep and lobar ICH, and for 
lacunar and non-SVD ischaemic stroke subtypes respectively, suggesting 
associations with these combined phenotypes were driven by results for deep ICH 
and lacunar ischaemic stroke (Figure 7.11). 
There was no or minimal heterogeneity between the individual cohorts’ results for 
lacunar ischaemic stroke (I
2
=0%; p>0.8) and for WMH in ischaemic stroke (I
2
=17%-
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7.3.6 Functional annotation of SNPs 
I identified 92 unique SNPs in moderate LD (r
2
≥0.3) with the three significant SNPs 
from my analyses. All of these SNPs (including the three significant SNPs) were 
intronic (Table 7.9).  
From these, I then selected all five SNPs that were in high LD (r
2
>0.9) with the three 
significant SNPs, giving a total of eight SNPs for analysis of functional annotation. 
The GTEx eQTL browser search revealed no significant eQTLs for any of these 
eight SNPs. However, the Regulome db database search revealed minimal binding 
evidence for four of the eight SNPs, suggesting that these SNPs are located in areas 
of the genome that may have some regulatory functions (Table 7.10). When I 
considered only results based on experiments carried out on tissues most relevant to 
cerebrovascular phenotypes (brain, spinal cord and blood vessels), there was still 
some evidence for these four SNPs being located in genomic areas of potential 
functional significance (Table 7.11). 
The three rare exonic COL4A2 SNPs reported in a previous sequencing study to be 
associated with sporadic ICH are rs117412802 (hg19 position: 111143601), 
rs62621875 (hg19 position: 111143681) and A1690T (hg19 position: 111164467) 
(Jeanne et al. 2012). Based on SNAP, rs117412802 was not in LD with the three 
SNPs significantly associated with deep ICH in my analyses (r
2
=0). rs62621875 and 
A1690T were not represented in SNAP but, there is unlikely to be LD between the 
SNPs associated with deep ICH in my analysis and these as they are not in the same 
haplotype block and distance from the three ICH SNPs is >100000 bases (Figure 
7.14). LD between the three significant SNPs and the three SNPs known to be 
associated with intracranial aneurysms, coronary artery calcification, myocardial 
infarction and vascular stiffness in cases with European origin was very low (r
2
=0 to 
0.01) (Table 7.12).  
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7.4 Discussion 
7.4.1 Main findings 
Here I present the first evidence for a significant association between an intronic 
locus in COL4A2 and deep ICH, a symptomatic cerebral SVD phenotype. I also 
found suggestive associations in the same direction for this locus with other cerebral 
SVD phenotypes: lacunar ischaemic stroke and WMH in ischaemic stroke cases. 
These results indicate that the COL4A2 gene is a locus conferring risk for sporadic 
forms of symptomatic cerebral SVD, particularly deep ICH (Rannikmäe et al. 2015) 
I did not find evidence for an association between these three SNPs (or any others in 
the COL4A1/COL4A2 region) and WMH assessed in largely asymptomatic 
individuals in population-based studies. The difference in results between WMH 
assessed among symptomatic people with ischaemic stroke and among those in 
population-based studies (both of which are often regarded as cerebral SVD 
phenotypes) could be due to genuine differences in the nature of the phenotype 
represented by WMH in these different groups and its genetic influences, differences 
in scanning and measurement techniques used in the contributing cohorts, or the play 
of chance. Interestingly, a recent GWAS study demonstrated shared genetic 
associations with white matter hyperintensity volumes in healthy individuals and 
patients with stroke, indicating common genetic susceptibility (Traylor et al. 2016). 
The SNPs identified in my study, and all SNPs in moderate LD with them, are 
intronic, and may be located in regulatory areas of the gene. The three SNPs from my 
analysis are not in close LD with the variants reported from previous sequence 
analyses in sporadic ICH. This demonstrates that they do not represent the same 
signal as that observed from the previously described exonic rare variants, but 
instead identify a novel intronic region of COL4A2 associated with deep ICH (and – 
possibly – with other cerebral SVD phenotypes). Interestingly, a recently published 
GWAS of WMH identified a COL4A2 SNP (rs9515201) significantly associated 
with WMH. This SNP is in close LD (r
2
>0.8) with the three SNPs identified in my 
study (Traylor et al. 2016).  
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7.4.2 Strengths and limitations 
This study has several strengths. I investigated a specific, pre-specified hypothesis, 
clearly defining the clinical phenotypes and candidate genes of interest, based on pre-
existing supporting data. I used a novel approach, investigating genetic associations 
across a range of cerebrovascular phenotypes, but focusing on a specific 
cerebrovascular sub-phenotype – cerebral SVD – thought to have distinct 
pathophysiological mechanisms and risk factors. Furthermore, through a network of 
collaborative groups, largely under the umbrella of the International Stroke Genetics 
Consortium, I was able to include in my in silico analyses the majority of the 
currently available data representing the phenotypes of interest in individuals of 
European ancestry.  
This study has some limitations. I have shown that SNPs in COL4A2 are associated 
with deep ICH by analysing data for the specific candidate COL4A1/2 region and by 
correcting appropriately for multiple testing within that region using the generally 
accepted modified Nyholt method (Li and Ji 2005, Nyholt 2004, Nyholt 2005, 
Salyakina et al. 2005, Traylor et al. 2012). However this association did not reach a 
genome-wide level of significance (possible reasons include study size) (Woo et al. 
2014), while associations with other cerebral SVD phenotypes (lacunar ischaemic 
stroke and WMH in ischaemic stroke cases) were suggestive, but not independently 
robust to multiple testing. In addition, although I corrected appropriately for the 
number of SNPs in the region, I did not adjust the statistical threshold for the number 
of phenotypes investigated. I considered that this would be overly conservative since 
these phenotypes are not completely independent of each other. As in any meta-
analysis, this study is dependent on accurate allocation of cases and controls, and 
accurate phenotype measurements in the original studies.  
7.4.3 Conclusions  
These results indicate an association between common variation in the COL4A2 gene 
and symptomatic small vessel disease, particularly deep intracerebral haemorrhage. 
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These findings merit replication studies, including in ethnic groups of non-European 
ancestry. 
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ICH 3 cohorts from the ISGC ICH GWAS consortium 
1,545 all ICH 
    • 874 deep 




15 cohorts from the ISGC / Metastroke consortium of ischaemic stroke 
case-control studies 
12,389 all IS 
    • 2,405 CE 
    • 2,167 LVD 





9 ischaemic stroke cohorts, that included individuals with MRI data on 




7 population-based cohorts, that included  individuals with MRI data on 




Numbers in bold indicate small vessel disease phenotypes. ISGC: International Stroke Genetics Consortium; CHARGE: Cohorts for Heart and Aging Research in 
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Table 7.2 Cohorts contributing data for the meta-analyses of association between COL4A1/COL4A2 SNPs and ICH: characteristics and summary statistics 
Cohort name GOCHA ISGC GERFHS 




3 separate prospective hospital-
based case-control cohorts 
Prospective population-based  
case-control 
Study inclusion and exclusion criteria 
Included: primary acute ICH cases presenting to participating centres, 
aged >55 years, confirmation of primary ICH on CT. Excluded: warfarin-, 
trauma-, brain tumour-, vascular malformation-related ICH, haemorrhagic 
transformation of ischaemic stroke, other secondary causes. 
 
Included: spontaneous ICH in the 
Greater Cincinnati/ Northern 
Kentucky region; age ≥18 years. 
Excluded: trauma-, brain tumour-, 
vascular malformation-related 
ICH. 
ICH diagnosis criteria 
Non-traumatic abrupt onset of severe headache, altered level of consciousness, and/or focal neurological deficit 
that is associated with a focal collection of blood within the brain parenchyma as observed on CT or at autopsy 
and is not due to haemorrhagic transformation of an infarction. 
Deep ICH diagnosis criteria 
Involving predominantly the basal ganglia, periventricular white matter, or internal capsule, and infratentorial 
ICH 
Lobar ICH diagnosis criteria Involving predominantly the cortex and underlying white matter 
Key study references Falcone et al. Stroke 2013 Woo et al. Am J Hum Genet 2014 Woo et al. Stroke 2002 
 SUBJECTS’ CHARACTERISTICS 
Ancestry of study sample European descent 
Total number of ICH cases 298 450 797 
Age of all cases with ICH (meanSD) 7410 7212 6715 
Number of deep ICH cases 125 279 470 
Age of cases with deep ICH (mean  
SD) 
7113 6914 6516 
Number of lobar ICH cases 173 171 327 
Age of cases with lobar ICH 
(meanSD) 
7611 7413 7112 
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Cohort name GOCHA ISGC GERFHS 
Number of controls 457 489 539 
Age of controls (meanSD) 728 7312 6615 
 GENOTYPING INFORMATION 
GWAS panel used Illumina HumanHap 610 Quad Affymetrix 6.0 
QC steps done before imputation 
QC steps before imputation done in every centre, including removal of population outliers, missing data and 
HWE departures 
Imputation software IMPUTE2 (https://mathgen.stats.ox.ac.uk/impute/impute_v2.html)  
Which reference imputation done to 1000-genomes (June 2011) 
Imputation quality metric reported IMPUTE info score & PLINK info score (http://pngu.mgh.harvard.edu/~purcell/plink/)  
QC filtering applied to imputed 
variants 
Removed SNPs with PLINK info score of <0.7 and minimum allele frequency (MAF) <1% 
Software and statistical model used 
for association analysed 
PLINK 
ICH = bo + b1*SNP + b2*age + b3*sex + b4*PC1 ... PC4 
Handling of population stratification 
Principal component (PC) analysis. Remotion of population outliers by visual inspection of PC1*PC2 plot, 
followed by inclusion of PC1-PC4 in regression models 
Hardy-Weinberg Equilibrium (HWE) Excluded if HWE p<1x10-6 
Adjusting for cryptic or overt 
relatedness 
Excluded individuals with an inferred first- or second-degree relative in the sample identified on the basis of 
pairwise allele sharing estimates (estimated genome proportion shared identical by descent) π>0.1875 
Strand and build of the human 
genome on which results are provided  
+ strand, build 37/hg19 
 
GOCHA: Genetics of Cerebral Hemorrhage with Anticoagulation; ISGC: International Stroke Genetics Consortium; GERFHS: Genetic and Environmental Risk 
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Table 7.3 Cohorts contributing data for the meta-analyses of association between COL4A1/COL4A2 SNPs and ischaemic stroke: characteristics and summary 
statistics 
Cohort name WTCCC2_UK WTCCC2_D ISGS & SWISS Rotterdam Milano ARIC ASGC Brains 
 STUDY INFORMATION 
Study design
1 




Included: Patients with ischaemic stroke who were of European ancestry from Europe, North America, and Australia, together with 
controls of matched ancestry. All studies used a case-control methodology. 
IS definition 
Stroke was defined as a typical clinical syndrome with radiological confirmation. Stroke subtyping was done with the TOAST 
classification system. 
Reference Traylor et al, 2012 
 SUBJECTS’ CHARACTERISTICS 
Ancestry of 
study sample 
European ancestry (from Europe, North-America, Australia) 


















No. CE cases 460 330 247 - 65 93 240 29 
No. LVD cases 498 346 229 - 74 31 421 120 
No. SVD cases 474 106 201 - 25 63 310 97 





































QC steps before imputation done in every centre, including removal of ancestry outliers defined by principal component analysis 
and poorly typed individuals. 
Imputation MaCH MaCH v1.0.16 MaCH MaCH v1.0.16 
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HapMap#22 HapMap2 CEU 
HapMap2 
CEU 














Logistic regression for all cohorts with a cross-sectional study design to model the multiplicative SNP effects on risk of the 
dichotomous outcome of stroke against ancestry-matched controls. Cox proportional-hazards models for prospective studies to 




Three cohorts used ancestry-informative principal components as covariates to correct for population stratification (ISGS/SWISS, 
ASGC, Brains). Age and sex were included as covariates in two centres (ISGS/SWISS and Brains). In all other centres no covariates 
were included. 
HWE All centres screened SNPs for HWE errors prior to imputation or analysis. 
Adjusting for 
cryptic or overt 
relatedness 
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Continued 
Cohort name CHS deCODE FHS GASROS GEOS HPS HVH 
 STUDY INFORMATION 
Study design
1 
PB CS PB CS CS CS CS 
Inclusion and 
exclusion criteria 
Included: Patients with ischaemic stroke who were of European ancestry from Europe, North America, and Australia, together 
with controls of matched ancestry. All studies used a case-control methodology. 
IS definition 
Stroke was defined as a typical clinical syndrome with radiological confirmation. Stroke subtyping was done with the TOAST 
classification system. 
Reference Traylor et al, 2012 
 SUBJECTS’ CHARACTERISTICS 
Ancestry of study 
sample 

















No. CE cases 147 399 48 169 90 - 88 
No. LVD cases - 255 - 95 37 - 61 
No. SVD cases 73 240 - 38 54 - 173 

















 GENOTYPING INFORMATION 








Illumina 610 Illumina 370 
QC filters applied 
before imputation 
QC steps before imputation done in every centre, including removal of ancestry outliers defined by principal component 
analysis and poorly typed individuals. 
Imputation software BIM-BAM IMPUTE 
MaCH 
v1.0.15 
MaCH v1.0.16 Not imputed MaCH BIM-BAM 
Reference imputed 
to 
NCBI b35 HapMap2 CEU HapMap#22 
HapMap3 CEU+TSI 
training set 
Not imputed HapMap2 #22 
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Cohort name CHS deCODE FHS GASROS GEOS HPS HVH 
Imputation quality 
metric reported 
O/E ratio IMPUTE info MaCH oevar n/a MaCH oevar O/E ratio 
QC filtering applied 
to imputed variants 
Included SNPs with imputation quality ≥0.3 (O/E variance or IMPUTE info score) and MAF ≥1%. 
Software and 
statistical model 
used for association 
analysed 
Logistic regression for all cohorts with a cross-sectional study design to model the multiplicative SNP effects on risk of the 
dichotomous outcome of stroke against ancestry-matched controls. Cox proportional-hazards models for prospective studies to 




One cohort used ancestry-informative principal components as covariates to correct for population stratification (GEOS). Sex 
was used as a covariate in one centre (GASROS) and one centre used recruitment phase (1 or 2) as a covariate (GEOS). In all 
other centres no covariates were included. 
HWE All centres screened SNPs for HWE errors prior to imputation or analysis. 
Adjusting for cryptic 
or overt relatedness 
All centres screened individuals for relatedness prior to imputation or analysis. 
 
CS: cross-sectional study; PB: prospective population-based study. 
1 
The approximate age of genotyping of the 2738 controls from the 1958 Birth Cohort. Age was not 
available for the remaining controls. MaCH oevar: the measure is the ratio of the empirically observed variance of the allele dosage to the expected binomial variance 
at Hardy-Weinberg equilibrium. WTCCC2: Wellcome Trust Case Control Consortium 2; UK: The United Kingdom of Great Britain and Northern Ireland; D: 
Germany; ISGS: Ischaemic stroke Genetics Study; SWISS: Sibling with Ischaemic Stroke Study; ARIC: Atherosclerosis Risk in Communities study; ASGC: 
Australian Stroke Genetics Collaborative; BRAINS: Bio-Repository of DNA in stroke; CHS: Cardiovascular Health Study; FHS: Framingham Heart Study; GASROS:  
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Table 7.4 Cohorts contributing data for the meta-analyses of association between COL4A1/COL4A2 SNPs and WMH in ischaemic stroke: characteristics and 
summary statistics 
Cohort name ASGC GASROS 
SWIS
S 









 STUDY INFORMATION 




Included: age >18 years; diagnosis of ischaemic stroke of any subtype 




WMH assessed in hemisphere contralateral 
to acute ischaemic stroke. All supratentorial 
WM lesions were included in WMH 
volume (WMHV) with the exception of 
WMH corresponding to lacunar infarcts; 
sequential axial FLAIR  images analysed 
using a validated, semi-automated protocol 
(MRIcro, Un. of Nottingham). 
WMH assessed in the hemisphere contralateral to acute ischaemic stroke. All 
supratentorial white matter lesions were included in WMH volume (WMHV) with the 
exception of WMH corresponding to lacunar infarcts; Analysed using DISPunc semi-






















1.5T GE Medical 
Signa, 1.5T Philips 



































Adib-Samii et al, 2013; Rost et al, 2010 
 
Chapter 7. Contribution of variants in COL4A1 and COL4A2 genes to sporadic SVD 276 
 
Cohort name ASGC GASROS 
SWIS
S 















No. assessed  104 975 115 209 65 152 323 65 75 447 203 
Age  
 (meanSD) 































Individuals removed if inferred sex 
discordant with recorded sex; if >5% 
missing genotype data. 
Individuals removed if inferred sex discordant with recorded sex; if >5% missing 
genotype data; 

















1000 G (June 
2010) 
 
1000G Phase 1 integrated variant set (March 2012) 
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Cohort name ASGC GASROS 
SWIS
S 
























WMHV from the hemisphere contralateral to acute ischaemic stroke was doubled to obtain whole brain values and adjusted for 
normal inter-individual variation in head size. Values were natural log transformed to a normal distribution. Within each group, rank- 
transformed residuals were derived from a linear regression model predicting WMHV with age, sex, and the first 2 ancestry principle 
components as covariates in GenABEL. Thus, the phenotype was adjusted for age because WMHV is highly age dependent. 
Principal components, derived using EIGENSTRAT, were included to correct for potential population stratification. Association 
analysis was undertaken in PLINK using pseudodosages, a fractional count of 0 to 1 alleles for each genotype weighted by 




Principal component analysis. Remotion of 
population outliers by visual inspection of 
PC1*PC2 plot, followed by inclusion of 
PC1-PC4 into regression models. 
2 ancestry informative principal components covariates were included in the model 
used to derive the WMH phenotype. 
HWE Excluded if HWE p<1x10-6 
Adjusting for 
cryptic or overt 
relatedness 
Excluded individuals with an inferred first- 
or second-degree relative in the sample 
identified on the basis of pairwise allele 
sharing estimates (genome proportion 
shared identical by descent) π>0.2. 
To obtain a set of putatively unrelated individuals, a hidden Markov model (HMM) 
was used to infer identity by descent and then individuals were removed iteratively to 
obtain a set with pairwise identity by descent of <5%. 
Strand and 
build of the 
human genome  
+ strand, build 37/hg19 
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Table 7.5 Cohorts contributing data for the meta-analyses of association between COL4A1/COL4A2 SNPs and WMH in the population: characteristics and 
summary statistics 






 STUDY INFORMATION 
Study design Prospective population-based cohort studies 
Study inclusion and 
exclusion criteria 
In all cohorts, participants were excluded if they lacked information on MRI, genotypes, or both, or if they suffered a stroke or 
transient ischaemic attack prior to MRI. In addition, CHS did not genotype participants with clinical cardiovascular disease at 
baseline. ASPS and RS did not perform MRI scans in participants with dementia, and FHS analyses excluded participants who 




In AGES-Reykjavik, ASPS, FHS, and Rotterdam, WMH volume was estimated on a quantitative scale using custom-written 
computer programs based on an automatic segmentation algorithm or a semiautomatic segmentation analysis involving operator-
guided removal of non-brain elements. In ARIC and CHS, WMH volume was estimated on a semi-quantitative 10-point scale by 
visual comparison with 8 templates that successively increased from barely detectable white matter lesions to extensive, confluent 
abnormalities. Study participants’ brain images were compared with the reference standards after aligning them to approximately 
the same apparent size. Hence, visual grades are inherently normalized for brain size. 








Picker or 0.35 
T Toshiba 
1 or 1.5 T Siemens 
Magnetom scanner 
1.5 T Siemens 
Vision scanner   
1.5 T GE 
Healthcare 
scanner 






MRI sequence used 
for assessing WMH 
T1- and T2-weighted scans in the axial plane were obtained for all participants. These were complemented by either scans 
obtained with fluid attenuation inversion recovery or proton density sequences to allow better separation of white matter 
hyperintensities and cerebrospinal fluid. 
Key study 
references 
Fornage M et al, 2011 
 SUBJECTS’ CHARACTERISTICS 
Ancestry of study 
sample 
European ancestry 
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Age of cases  
(meanSD) 
634 725 64 11 738 675 765 658 
 GENOTYPING INFORMATION 

























QC filters applied 
to genotype data 
before imputation 
Participant-specific quality control filters were applied based on missing call rate, cryptic relatedness, and number of Mendelian 
errors per individual. SNP-specific quality controls included filters for call rate, minor allele frequency, Hardy-Weinberg 






BIM-BAM 15 MaCH (v1.0.15 or 1.0.16) 
Which reference 




NCBI build 36 
+strand of 
NCBI build 35 




O/E ratio and oevar 
QC filtering 
applied to imputed 
variants 
Excluded SNPs with O/E ratio & oevar <0.3 and MAF<1% 
Software and 
statistical model 
used for association 
Within each study, a linear regression model was used to evaluate the association of the natural log-transformed volume of WMH 
(log[WMH + 1]) with the number of minor alleles (0 to 2) at each SNP. Analyses were adjusted only for age, sex, and total 
intracranial volume (except in ASPS, ARIC, and CHS). ARIC and CHS also adjusted for study site, and FHS adjusted for familial 
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HWE Excluded if Hardy-Weinberg p<1x10-5 in CHS and p<1x10-6 in AGES-Reykjavik, ARIC, ASPS, FHS, and Rotterdam 
Adjusting for 




Studies were screened for latent population substructure, including cryptic relatedness, using suitable programs: EIGENSTRAT 
in ARIC, FHS and AGES-Reykjavik, an IBD matrix in ASPS and Rotterdam, and using principal component analysis in CHS. 
Strand and build of 
the human genome  
+ strand; hg18 
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Table 7.6 Original measures of association (β) from the meta-analyses of association between 
COL4A1/COL4A2 SNPs and SVD, and the derived odds ratios (ORs) 
 Phenotype β (minor allele) SE of β 
OR  
(minor allele) 




















All ICH 0.1548 0.0519 1.17 1.05 to 1.29 
Deep ICH 0.2451 0.0614 1.28 1.13 to 1.44 
Lobar ICH 0.0489 0.068 1.05 0.92 to 1.20 
All IS 0.0261 0.0161 1.03 0.99 to 1.06 
CE IS 0.022 0.0321 1.02 0.96 to 1.09 
LVD IS -0.0465 0.0354 0.95 0.89 to 1.02 
Lacunar IS 0.0858 0.0357 1.09 1.02 to 1.17 
WMH in IS 0.0707 0.0289 1.07 1.01 to 1.14 
WMH in 
population  



















All ICH 0.1706 0.0521 1.19 1.07 to 1.31 
Deep ICH 0.2547 0.0614 1.29 1.14 to 1.46 
Lobar ICH 0.0674 0.068 1.07 0.94 to 1.22 
All IS 0.0294 0.0164 1.03 1.00 to 1.06 
CE IS 0.0151 0.0326 1.02 0.95 to 1.08 
LVD IS -0.0466 0.0353 0.95 0.89 to 1.02 
Lacunar IS 0.0979 0.0365 1.10 1.03 to 1.18 



















All ICH 0.1554 0.0519 1.17 1.06 to 1.29 
Deep ICH 0.2465 0.0614 1.28 1.14 to 1.44 
Lobar ICH 0.0487 0.068 1.05 0.92 to 1.20 
All IS 0.0308 0.0165 1.03 1.00 to 1.07 
CE IS 0.02 0.0332 1.02 0.96 to 1.09 
LVD IS -0.0406 0.036 0.96 0.89 to 1.03 
Lacunar IS 0.0891 0.0365 1.09 1.02 to 1.17 
WMH in IS 0.0707 0.0289 1.07 1.01 to 1.14 
WMH in 
population  
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rs9521732 COL4A2 A/C Intronic  0.0000652 A=0.413 
rs9521733 = 0.896 
rs9515199 = 1 
rs9521733 COL4A2 C/T Intronic  0.0000339 C=0.404 
rs9515199 = 0.896 
rs9521732 = 0.896 
rs9515199 COL4A2 C/T Intronic  0.0000599 C=0.414 
rs9521733 = 0.896 
rs9521732 = 1 
1 
Risk allele is marked in bold; MAF: minor allele frequency; r
2
: measure of linkage disequilibrium; Intronic: located in a non-coding region of the gene 
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Table 7.8 Imputed and directly genotyped COL4A2 SNPs  
Phenotype Study 
Imputation quality measures 









































































































































































































G: directly genotyped; n/a: SNP not available for the study. 
Imputation quality numbers provided reflect the minimum quality measure across sub-phenotypes, 




 MaCH oevar 
c 
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Table 7.9 Functional annotation of SNPs in moderate LD (r2>0.3) with rs9521732, rs9521733 
and rs9515199* 









 -  - intronic 
COL4A2 rs11594556
9 
- - intronic 
COL4A2 rs11619425 intron_variant intron-variant intronic 
COL4A2 rs11619427 intron_variant intron-variant intronic 
COL4A2 rs11619430 intron_variant intron-variant intronic 
COL4A2 rs11838637 intron_variant intron-variant intronic 
COL4A2 rs11838776 intron_variant intron-variant intronic 
COL4A2 rs12853693 intron_variant intron-variant intronic 
COL4A2 rs1888004 intron_variant intron-variant intronic 
COL4A2 rs1888005 intron_variant intron-variant intronic 
COL4A2 rs1927342 intron_variant intron-variant intronic 
COL4A2 rs1927343 - intron-variant intronic 
COL4A2 rs1927344 intron_variant intron-variant intronic 
COL4A2 rs1927345 intron_variant intron-variant intronic 
COL4A2 rs1927346 intron_variant intron-variant intronic 
COL4A2 rs1927347 intron_variant intron-variant intronic 
COL4A2 rs1927349 intron_variant intron-variant intronic 






COL4A2 rs1999013 intron_variant intron-variant intronic 
COL4A2 rs2149067 intron_variant intron-variant intronic 
COL4A2 rs2391825 intron_variant intron-variant intronic 
COL4A2 rs34402154 intron_variant intron-variant intronic 




COL4A2 rs4283091 intron_variant intron-variant intronic 
COL4A2 rs4492912 intron_variant intron-variant intronic 
COL4A2 rs4547215 intron_variant intron-variant intronic 
COL4A2 rs4586292 intron_variant intron-variant intronic 
COL4A2 rs4771674 intron_variant intron-variant intronic 
COL4A2 rs4771675 intron_variant intron-variant intronic 
COL4A2 rs4771676 intron_variant intron-variant intronic 
COL4A2 rs4773157 intron_variant intron-variant intronic 
COL4A2 rs4773169 intron_variant intron-variant intronic 
COL4A2 rs4773170 intron_variant intron-variant intronic 
COL4A2 rs4773171 - intron-variant intronic 
COL4A2 rs4773173 intron_variant intron-variant intronic 
COL4A2 rs4773174 intron_variant intron-variant intronic 
COL4A2 rs4773177 intron_variant intron-variant intronic 
COL4A2 rs55940034 intron_variant intron-variant intronic 
COL4A2 rs61963197 intron_variant intron-variant intronic 
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COL4A2 rs7318424 - intron-variant intronic 
COL4A2 rs7318742 intron_variant intron-variant intronic 
COL4A2 rs7321362 intron_variant intron-variant intronic 
COL4A2 rs7323228 intron_variant intron-variant intronic 
COL4A2 rs7326145 - intron-variant intronic 
COL4A2 rs7328731 intron_variant intron-variant intronic 
COL4A2 rs7333596 intron_variant intron-variant intronic 
COL4A2 rs7333748 - intron-variant intronic 
COL4A2 rs7334022 intron_variant intron-variant intronic 
COL4A2 rs750598 intron_variant intron-variant intronic 
COL4A2 rs7982993 - intron-variant intronic 
COL4A2 rs7983374 intron_variant intron-variant intronic 
COL4A2 rs7990844 intron_variant intron-variant intronic 
COL4A2 rs7991842 intron_variant intron-variant intronic 
COL4A2 rs7999034 intron_variant intron-variant intronic 
COL4A2 rs872587 - intron-variant intronic 
COL4A2 rs872588 intron_variant intron-variant intronic 
COL4A2 rs872589 intron_variant intron-variant intronic 
COL4A2 rs913746 - intron-variant intronic 
COL4A2 rs9284253 intron_variant intron-variant intronic 
COL4A2 rs9301454 intron_variant intron-variant intronic 
COL4A2 rs9515195 - intron-variant intronic 
COL4A2 rs9515196 - intron-variant intronic 
COL4A2 rs9515197 intron_variant intron-variant intronic 
COL4A2 rs9515199 intron_variant intron-variant intronic 
COL4A2 rs9515201 - intron-variant intronic 
COL4A2 rs9515204 intron_variant intron-variant intronic 
COL4A2 rs9521717 - intron-variant intronic 
COL4A2 rs9521718 - intron-variant intronic 
COL4A2 rs9521719 intron_variant intron-variant intronic 
COL4A2 rs9521720 intron_variant intron-variant intronic 
COL4A2 rs9521721 - intron-variant intronic 
COL4A2 rs9521729 intron_variant intron-variant intronic 
COL4A2 rs9521730 - intron-variant intronic 
COL4A2 rs9521732 intron_variant intron-variant intronic 
COL4A2 rs9521733 intron_variant intron-variant intronic 
COL4A2 rs9521734 intron_variant intron-variant intronic 
COL4A2 rs9521735 intron_variant intron-variant intronic 
COL4A2 rs9521739 intron_variant intron-variant intronic 
COL4A2 rs9521740 intron_variant intron-variant intronic 
COL4A2 rs9521742 - intron-variant intronic 
COL4A2 rs9521743 intron_variant intron-variant intronic 
COL4A2 rs9521744 intron_variant intron-variant intronic 
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COL4A2 rs9521746 intron_variant intron-variant intronic 
COL4A2 rs9521747 intron_variant intron-variant intronic 
COL4A2 rs9521748 intron_variant intron-variant intronic 
COL4A2 rs952359 intron_variant intron-variant intronic 
COL4A2 rs9555692 - intron-variant intronic 
COL4A2 rs9555694 - intron-variant intronic 
COL4A2 rs9555695 intron_variant intron-variant intronic 
COL4A2 rs9559780 - intron-variant intronic 
COL4A2 rs9559781 - intron-variant intronic 
COL4A2 rs9559788 - intron-variant intronic 
COL4A2 rs9583489 intron_variant intron-variant intronic 
COL4A2 rs9588151 intron_variant intron-variant Intronic 
 
-:SNP not included in database 
* the three SNPs significantly associated with deep ICH are shown in bold.  
1
 A sequence variant located 3' of a gene
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Table 7.10 Functional annotation of SNPs in high LD (r2>0.9) with rs9521732, rs9521733 and 
















rs9521732 no data n/a n/a n/a n/a 
rs9515199 no data n/a n/a n/a n/a 
rs9521735 no data n/a n/a n/a n/a 
rs4771674 no data n/a n/a n/a n/a 
rs9521733 5 -  -  
rs9521734 6   - - 
rs1999013 5   -  
rs9555695 4 -    
 
n/a: not applicable; - : no evidence; : evidence 
Grey boxes indicate that there is some evidence for this functional annotation based on experiments 
done on more relevant tissues: brain, spinal cord or blood vessel tissue.  
Regulome db score: The scoring system represents with increasing confidence that a variant lies in a 
functional location and is likely to result in a functional consequence (lower scores indicate increasing 
evidence for a variant to be located in a functional region). 
1: Likely to affect binding and linked to expression of a gene target 
2: Likely to affect binding 
3: Less likely to affect binding 
4-6: Minimal binding evidence (lack evidence of the variant actually disrupting the site of binding)
  
1
Motifs: the SNP is located in an area of short recurring patterns in DNA (motif) thought to have a 
regulatory function and hence may predict transcription factor binding sites.  
2
Histone modification: the SNP is located in an area of histone modification. Histones are proteins that 
associate with DNA in the nucleus and help condense it into chromatin. Histone modifications are a 
range of post-translational modifications to the N-terminal tails of the histones in chromatin, which 
include a series of methylations and acetylations at defined lysine and arginine residues. Histone 
modification profiles are associated with differences in gene transcription and hence can be used as a 
generic tool to identify functional elements in the genome.  
3
Protein binding: the SNP is located in an area binding a transcription factor.  
4
Chromatin structure: the SNP is located in an area of possible chromatin accessibility, suggesting the 
area has a regulatory function. Chromatin is a complex of DNA and proteins that forms chromosomes 
within the nucleus of eukaryotic cells.  
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blood vessel: adult blood 
microvascular endothelial cells, 
dermal-derived T3 
- -  - - - - - - 
Huvec 
blood vessel: umbilical vein 
endothelial cells T2 
 - -     - - 
Nha astrocytes from normal brain T3  - -  -   - - 
Astrocytes Astrocytes - - - -  - - - - 
HASP astrocytes normal spinal cord T3 - - - -  - - - - 
Sknshra 
neuroblastoma cell line - cancer 
brain T3 
 - - - - - - - - 
A549 
epithelial cell line derived from a lung 
carcinoma tissue T2 
 - -  -   - - 
Cd20ro01778 blood B cells T2 - - - - - -  - - 
Chorion chorion cells fetal membrane T3 - -  - - - -   
Cll 
chronic lymphocytic leukemia cell, T-
cell lymphocyte T3 
- - - - - - -  - 
Dnd41 leukemia T cell T3  - -  -   - - 
Gm12878 B lymphocyte T1  - -  -    - 
Gm12891 B-lymphocyte T3 - - - - - - -   
Gm12892 B-lymphocyte T3 - - - - - - -   
Gm18507 lymphoblastoid T3 - - - - - - -  - 
 























Gm19238 B lymphocyte T3 - - - - - - -  - 
Gm19239 B-lymphocyte T3 - - - - - - -  - 
H1hesc embryonic stem cells T1  - -  -    - 
H7es 
undifferentiated embryonic stem 
cells 
 - - - - - -  - 
H9es embryonic stem cell T3 - - - - - - -  - 
Helas3 cervical carcinoma cells T2  - -  -   - - 
Hepg2 hepatocellular carcinoma T2  - -  -   - - 
Hmec normal breast tissue T3  - -  -    - 
Hpde6e6e7 pancreatic duct T3 - -  - - - -  - 
Hsmm muscle T3  - -  -    - 
Hsmmt muscle T3  - -  -   - - 
Ips 
induced pluripotent stem cell derived 
from skin fibroblast T3 
- - - - - - -  - 
K562 leukemia T1  - -  -   - - 
K562b Leukemia - - - - - -  - - 
Monocd14ro
1746 
monocytes T2  - -  -   - 
 
NB4 
blood: acute promyelocytic leukemia 
cell line T3 
-  - - - - - - - 
Nhdfad adult dermal fibroblasts T3  - -  -   - - 
 























Nhek skin epidermal keratinocytes T3  - -  -     
Nhlf lung fibroblast T3  - -  -   - - 
Osteo 
 
 - -  -   - - 
Osteobl bone osteoblasts T3  - -  -   - - 
Panislets normal pancreas T3 - - - - - - -  - 
Phte primary tracheal epithelial cells T3 - - - - - - -  - 
Saec small airway epithelial cells - - - - - -  - - 
Stellate liver T3 - - - - - - -  - 
Urotsa 
 
- - - - - - -  - 
UrotsaUt189 
 
- - - - - - -  - 
 
1
cell line where experiment performed; 
2
tissue where cell line from;  
Dark grey cells: evidence from brain, spinal cord or blood vessel tissue.  
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Table 7.12 LD between three significant COL4A2 SNPs and SNPs associated with other cardiovascular phenotypes 
First author 
Year 
Ethnicity of cases Phenotype SNP 
LD with three ICH 
SNPs 
Tarasov et al, 2009 
Sardinian & Old-Order Amish 
 (distant founder population of 
European ancestry) 
Vascular stiffness rs3742207 r
2
: 0.004 to 0.01 
O’Donnel et al, 2011  European ancestry 






: 0 to 0.002 
Schunkert et al, 2011 Majority European ancestry Coronary artery disease rs4773144 r
2
: 0 
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Figure 7.1 Regional association plot for meta-analysis of association between COL4A1/COL4A2 
SNPs and deep ICH 
 
Dots mark individual SNPs; y-axis: p-value for association between each SNP and deep ICH; x-axis: 
position of SNPs. Most significantly associated SNP shown in purple (rs number on top) – colours for 
other SNPs depend on LD with this lead SNP (see r
2
 colour coding on figure). Recombination: 
exchange of a segment of DNA between two homologous chromosomes during meiosis leading to a 
novel combination of genetic material in the offspring. Recombination rate: measured as frequency of 
exchange per unit physical distance (centiMorgan [cM] / Mega base pair [Mb]). cM: unit of linkage 
that refers to the distance between two gene loci determined by the frequency with which 
recombination occurs between them. Two loci are said to be one cM apart if recombination is 
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Figure 7.2 Associations of significant COL4A2 SNPs across cohorts included in the meta-analysis 















2df = 0.08; p=0.9607 I
2
= 0% 
Reproduced from Rannikmäe et al, Neurology 2015; 84(9):918-26. Wolters Kluwer Health Lippincott 
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Figure 7.3 Regional association plot for meta-analysis of association between COL4A1/COL4A2 
SNPs and all ICH  
 
Legend as for Figure 7.1 
Dots mark individual SNPs; y-axis: p-value for association between each SNP and phenotype; x-axis: 
position of SNPs. 
 
Figure 7.4 Regional association plot for meta-analysis of association between COL4A1/COL4A2 
SNPs and lobar ICH  
 
Legend as for Figure 7.1 
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Figure 7.5 Regional association plot for meta-analysis of association between COL4A1/COL4A2 
SNPs and all IS  
 
Legend as for Figure 7.1 
 
Figure 7.6 Regional association plot for meta-analysis of association between COL4A1/COL4A2 
SNPs and CE IS 
 
Legend as for Figure 7.1 
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Figure 7.7 Regional association plot for meta-analysis of association between COL4A1/COL4A2 
SNPs and LVD IS  
 
Legend as for Figure 7.1 
 
Figure 7.8 Regional association plot for meta-analysis of association between COL4A1/COL4A2 
SNPs and lacunar IS  
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Figure 7.9 Regional association plot for meta-analysis of association between COL4A1/COL4A2 
SNPs and WMH in ischaemic stroke  
 
Legend as for Figure 7.1 
 
Figure 7.10 Regional association plot for meta-analysis of association between COL4A1/COL4A2 
SNPs and WMH in the population  
 
Legend as for Figure 7.1 
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Figure 7.11 Associations between the three COL4A2 SNPs significantly associated with deep 
ICH and all included phenotypes 
Figure represents pooled ORs across all cohorts. Significant or suggested associations in cerebral 
SVD phenotypes are shown in red; ICH=intracerebral haemorrhage; IS=ischaemic stroke; CE=cardio-
embolic; LVD=large vessel disease; Data for rs9521733 was unavailable in the WMH in population 
cohorts. Reproduced from Rannikmäe et al, Neurology 2015; 84(9):918-26. Wolters Kluwer Health 
Lippincott Williams & Wilkins©. 
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Figure 7.12 Associations between the three COL4A2 SNPs significantly associated with deep 
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Figure 7.13 Associations between the three COL4A2 SNPs significantly associated with deep 
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Figure 7.14 COL4A2 LD structure in the CEU population 
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The default algorithm: 95% confidence bounds on D prime are generated and each comparison is called "strong LD", "inconclusive" or "strong recombination". A 
block is created if 95% of informative (i.e. non-inconclusive) comparisons are "strong LD" (Gabriel et al. 2002). Numbers inside the “diamonds” represent the r
2
/100. 
Colour scheme: white if r
2
=0; grey if r
2 
>0 and <1; black if r
2
=1. The red circle marks the three SNPs significantly associated with a deep ICH phenotype in my 
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8. Summary and implications for future   
    research 
8.1 Main findings of thesis 
8.1.1 Reliability of ICH classification systems 
My objective in Chapter 2 was to perform a systematic review looking at the inter- 
and intra-rater reliability of existing ICH classification systems, to inform ICH 
subtyping in future large-scale prospective studies of ICH, including of ICH genetics. 
Among eight relevant studies, the inter- and intra-rater reliabilities of existing 
anatomical and mechanistic classification systems appeared to be substantial to 
almost perfect. However, there were insufficient data to assess factors potentially 
influencing reliability, reliability reporting quality was variable, and because no 
study had used all possible measures to reduce potential bias, reliability may have 
been overestimated. Furthermore, since all raters in these studies were experts, 
uncertainty remains about the generalisability of the results to less expert raters, who 
might usefully contribute to large-scale research studies. 
8.1.2 Genetic associations with CAA  
My objective in Chapter 3 was to perform a systematic review and series of meta-
analyses to assess the evidence for an association between the APOE ɛ2/ɛ3/ɛ4 
polymorphism and histopathologically confirmed CAA.  
Among 46 relevant studies in 6645 participants, overall study quality and 
pathological assessment methods varied widely, while genotyping reporting quality 
was generally limited. Meta-analyses showed a highly significant, dose-dependent 
association between APOE ε4 and pathologically proven CAA, robust to publication- 
and other small-study biases, and consistent across subgroups determined by 
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dementia status, ethnicity, and study quality. Meta-analyses showed no overall robust 
association between APOE ε2 and presence of pathological CAA. I concluded that 
despite study quality issues, a large body of evidence supports an association of 
APOE ε4 with the presence and severity of histopathologically confirmed CAA, at 
least in white populations, but there is no convincing robust association of 
histopathologically confirmed CAA with APOE ɛ2. 
My objective in Chapter 4 was to perform a systematic review and series of meta-
analyses to assess the evidence for an association between the APOE ɛ2/ɛ3/ɛ4 
polymorphism and progression to severe CAA vasculopathy. 
Among five included relevant studies in 497 participants study quality was very 
good. Meta-analyses suggested a possible association of APOE 4, but not of APOE 
2, with progression to severe CAA. Despite inclusion of all available relevant data, 
small numbers of individuals with 2+ genotypes made the 2-based analyses very 
imprecise. While I could not exclude a biologically meaningful association between 
the APOE 2 allele and progression to severe CAA, there was no convincing 
evidence to support the popular hypothesis that APOE 2 influences risk of ICH 
through promoting progression of CAA to its severe form. Much larger numbers of 
individuals will need to be included in CAA histopathology studies before reliable 
conclusions can be drawn about APOE allele-specific effects on progression to 
severe CAA.  
My objective in Chapter 5 was to perform a systematic review to assess the evidence 
for an association between the APOE ɛ2/ɛ3/ɛ4 polymorphism and CAA severity in 
brain pathology samples of cases with genetically proven hereditary CAA.  
There were very few relevant studies, data were sparse and incomplete reporting 
limited interpretation of study quality. There was no reported association between 
possession of the APOE ɛ4 allele and CAA severity in cases with hereditary CAA 
Dutch-type and presenilin-1 gene-related familial AD in the three relevant studies. 
No study reported looking at the association between APOE ɛ2 and CAA severity.  
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My objective in Chapter 6 was to perform a systematic review to assess the evidence 
for an association between any (non-APOE ɛ2/ɛ3/ɛ4) genetic polymorphism and 
histopathologically confirmed CAA. 
Among 24 relevant studies (4617 participants) where 25 different candidate genes 
were studied, there were some positive associations with CAA, but insufficient data 
for formal meta-analyses. Three reasonably convincing findings merit replication in 
further larger studies: there was a consistent trend towards an association with a SNP 
in the transforming growth factor β1 gene (TGF-β1) in two studies including 449 
participants; one study in 723 participants demonstrated an association between 14 
SNPs in the translocase of outer mitochondrial membrane 40 gene (TOMM40) and 
CAA severity; and one study in 544 participants found that a SNP in the complement 
component receptor 1 gene (CR1) was associated with more severe CAA. Otherwise 
there were no overall significant associations, although some studies reported 
associations in particular subgroups.  
8.1.3 Contribution of COL4A1 and COL4A2 to sporadic SVD 
My objective in Chapter 7 was to conduct meta-analyses of existing GWAS data to 
determine if there is an association between common SNPs in the COL4A1/COL4A2 
genomic region and clinical / radiological manifestations of SVD. 
I conducted a large collaborative individual cohort summary data meta-analysis 
involving: 1545 ICH cases and 1485 controls; 12 389 ischaemic stroke cases and 
62 004 controls; and 12 094 individuals with WMH assessed on MRI scans. I found 
a significant association between three SNPs in an intronic locus in COL4A2 and 
deep ICH, and suggestive associations in the same direction for these SNPs with 
other cerebral SVD phenotypes: lacunar ischaemic stroke and WMHs in ischaemic 
stroke cases. These results indicate that the COL4A2 gene is a locus conferring risk 
for sporadic forms of symptomatic cerebral SVD, particularly deep ICH. These 
findings merit replication studies, including in ethnic groups of non-European 
ancestry. 
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8.2 Implications for future research 
8.2.1 Intracerebral haemorrhage classification  
As shown in Chapter 2, reliability of existing ICH classification systems appears 
very good, but future studies should investigate their performance outside highly 
specialised centres with less experienced readers. Future comparisons of reliability 
studies should also be facilitated by studies following published reporting guidelines.  
In Chapter 2, I identified and highlighted several limitations of existing ICH 
classification systems, which, if addressed in future studies, should ensure their 
further refinement where needed and their appropriate use in diverse clinical and 
research settings.  
Overall, for large population-based prospective studies, including studies of ICH 
genetics, anatomical classification systems are likely to be more feasible, scalable, 
and appropriate, since they are free of assumptions about causal pathways. The 
development of such methods for use at scale will require clear definitions, 
classification protocols, and the availability of categories for multiple or uncertain 
locations. Mechanistic systems such as the SMASH-U and its modifications are 
likely to be appropriate for stratifying patients for clinical trials, some case-control 
studies, and in clinical practice to encourage a more systematic mechanistic work-up. 
Mechanistic systems have the advantage of already having a very clear set of rules 
and excellent reliability, but they could be further improved by including categories 
for cases with an uncertain and multiple overlapping mechanisms. The feasibility of 
collecting additional, more detailed information in large, prospective, population-
based studies also needs further assessment, since it would complement the more 
basic information required for anatomical sub-classification and – potentially – allow 
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8.2.2 Genetic associations with SVD 
There may be ethnic variation in genetic associations with CAA, but these have not 
been widely studied in non-white populations (Tzourio et al. 2008). Genetic 
associations may also differ by CAA location and subtype. For example, there is 
preliminary evidence that APOE ε4 may be associated with CAA type 1 and ε2 with 
CAA type 2 (Thal et al. 2002). The suggestion of different genetic influences on 
amyloid deposition in the vessel wall and progression to advanced vasculopathic 
changes leading to ICH requires further investigation, in particular the proposed 
differential effects of ε4 and ε2 alleles. It is also unclear what additional modulating 
factors – genetic and non-genetic – affect the variable phenotypic expression 
between cases affected by the same mutation causing hereditary CAA. Future studies 
should try and replicate associations between TGF-β1, TOMM40 and CR1 and CAA. 
Findings of an association between the COL4A1/COL4A2 locus and sporadic SVD 
also merit replication, including in ethnic groups of non-European ancestry.  
The estimated heritability of common cerebral small vessel disease clinical and 
radiological phenotypes (lacunar ischaemic stroke, ICH and white matter 
hyperintensities) ranges from 15% to 80%, but we are only scratching the surface in 
terms of identifying their genetic architecture. Many explanations for the missing 
heritability of complex diseases, such as SVD, have been suggested (Manolio et al. 
2009). These include: 
 small size of existing GWASs meaning much larger number of common 
variants of smaller effect are yet to be found; 
 role of rarer variants with possibly larger effects poorly detected by GWASs; 
 role of structural variants poorly captured by existing arrays; 
 low power to detect gene-gene and gene-environment interactions.  
While larger hypothesis-free GWAS studies are ongoing, alongside preparing for and 
running the whole exome and genome sequencing studies in large numbers of cases 
and controls, these could be complemented by hypothesis-driven candidate-gene 
studies.  
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Candidate-gene studies have been criticized firstly, for their failure to replicate 
significant findings in follow-up studies, and secondly, for their dependence on the 
ability to predict functional candidate genes and polymorphisms.  
Regarding the first criticism, there are many potential reasons for their lack of 
reproducibility, such as differences in the study design, population, and definition of 
the phenotype. There may also be real biological differences. In addition, sometimes 
the selected polymorphisms are not likely to be causal having been selected for 
various other reasons (e.g., ease of genotyping), and hence may not be in linkage 
disequilibrium with the causal variant across different populations. Future studies 
could address these criticisms by following proposed methodological criteria to try 
and reduce potential reasons for lack of reproducibility (Dichgans and Markus 2005). 
The second criticism relates to the selection of candidate genes on the basis of 
imperfect understanding of biological pathways (Manolio et al. 2009, Tabor et al. 
2002). I and others (Jeanne et al. 2012, Weng et al. 2012) have demonstrated a 
potential association between loci in the COL4A1/COL4A2 region with a cerebral 
SVD phenotype, although it awaits confirmation in replication studies. This 
successful approach – selecting candidate genes for a common disease based on their 
association with a Mendelian form of the same disease – could be one approach used 
in future studies of SVD genetics.  
Where appropriate, identified genetic associations should be followed up by 
functional studies to prove causation and better understand disease mechanisms.  
Future studies should also further investigate the correlation between various 
pathological, radiological and clinical markers of small vessel diseases. The 
classification of SVDs into ‘SVD associated with CAA’ and ‘arteriolosclerosis-
associated SVD’ may be too simplistic, as they may share some risk factors and 
pathological/radiological/clinical markers. Identifying genetic associations with SVD 
may be further improved if methods to assess the total SVD load on imaging are 
developed and used to avoid over-reliance on just one feature, as has occurred in 
most studies so far (Staals et al. 2014, Wardlaw et al. 2013a).   
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Finally, ongoing and future research efforts should be informed and directed by up-
to-date systematic and unbiased assessments of the body of evidence in the form of 
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Ovid Embase search strategy (1980 to October 2014) 
1. cerebrovascular disease/ 
2. basal ganglion hemorrhage/ or cerebrovascular accident/ or stroke/ or exp brain 
hematoma/ or exp brain hemorrhage/ 
3. ((brain or cerebr$ or cerebell$ or intracerebr$ or intracran$ or parenchyma$ or 
intraventricular or infratentorial or supratentorial or basal gang$ or ganglion$ or 
putaminal or putamen or posterior fossa or brain?stem or intra?axial or lobar or deep or 
thalam$ or cortical or superficial or vertebrobasil$ or front$ or tempor$ or pariet$ or 
occipit$ or subarachn$) adj5 (haemorrhage$ or hemorrhage$ or haematoma$ or 
hematoma$ or bleed$)).tw. 
4. ((h?emorrhag$ or aneurysm$) adj6 (stroke$ or cerebrovasc$ or cerebr?vasc$ or cerebral 
vasc$ or brain vasc$ or cva$ or apoplex$ or attack$ or event$ or insult$ or 
intracranial)).tw. 
5. 1 or 2 or 3 or 4 
6. (type$ or subtype$ or classification$ or categor$ or SMASH-U).tw. 
7. 5 and 6 
8. interrater reliability/ or intrarater reliability/ or observer variation/ or reproducibility/ or 
predictive value/ 
9. ((observer or interobserver or inter-observer or intra-observer or intraobserver or 
interrater or rater or inter-rater or intra-rater or intrarater) adj5 (variation$ or variabilit$ 
or bias or reliability or agreement or comparison$ or error$ or concordance or 
feasib$)).tw. 
10. 8 or 9 
11. 7 and 10 
Ovid Medline search strategy (1946 to October 2014) 
1. Stroke/ 
2. Cerebrovascular Disorders/ 
3. exp intracranial hemorrhages/ 
4. ((brain$ or cerebr$ or cerebell$ or intracerebr$ or intracran$ or parenchyma$ or 
intraventricular or infratentorial or supratentorial or basal gang$ or ganglion$ or 
putaminal or putamen or posterior fossa or brain?stem or intra?axial or lobar or deep or 
thalam$ or cortical or superficial or vertebrobasil$ or front$ or tempor$ or pariet$ or 
occipit$ or subarachn$) adj5 (haemorrhage$ or hemorrhage$ or haematoma$ or 
hematoma$ or bleed$)).tw. 
5. ((h?emorrhag$ or aneurysm$) adj6 (stroke$ or cerebrovasc$ or cerebr?vasc$ or cerebral 
vasc$ or brain vasc$ or cva$ or apoplex$ or attack$ or event$ or insult$ or 
intracranial)).tw. 
6. 1 or 2 or 3 or 4 or 5 
7. (type$ or subtype$ or classification$ or categor$ or SMASH-U).tw. 
8. "reproducibility of results"/ 
9. Observer Variation/ 
10. "Predictive Value of Tests"/ 
11. ((observer or interobserver or inter-observer or intra-observer or intraobserver or 
interrater or rater or inter-rater or intra-rater or intrarater) adj5 (variation$ or variabilit$ 
or bias or reliability or agreement or comparison$ or error$ or concordance or 
feasib$)).tw. 
12. 6 and 7 
13. 8 or 9 or 10 or 11 









Dear Dr Palm, 
Reliability of spontaneous ICH classification systems – invitation to 
join a collaborative systematic review 
“Intracerebral haemorrhage in a population-based stroke registry (LuSSt): incidence, 
aetiology, functional outcome and mortality.” F. Palm, N. Henschke, J. Wolf, K. Zimmer et 
al.; J Neurol 2013;  Oct;260(10):2541-50.  
We would like to invite you to join a collaborative systematic review of the reliability of 
spontaneous intracerebral haemorrhage (sICH) classification systems. We have recently 
undertaken a thorough systematic literature search aiming to identify existing studies of 
the reliability of various sICH classification systems but were able to identify only four 
relevant publications. These published studies have found the inter-rater reliability to be 
good, but we want to avoid publication bias by including studies such as yours (above), if 
you have some additional unpublished data about inter- and/or intrarater reliability of the 
classification system you used.  
We plan to include the relevant person/people from any contributing group as co-authors 
on any publication arising from this work. If you are interested in collaborating and could 
provide the relevant data, all you need to do is simply fill in the attached summary tables 
with data from your study above. 
We are circulating this invitation by both email and post, so please contact us by whichever 
means is most convenient for you. Please respond by filling in and returning the attached 
forms by 9th December 2013. We will be delighted to discuss any aspect of this proposal 
with you by email or telephone.  
                                                              
Yours sincerely,  
Professor Cathie Sudlow  
Professor of Neurology and Clinical Epidemiology 
Honorary Consultant Neurologist 
Chief Scientist & Senior Epidemiologist, UK Biobank 
Division of Clinical Neurosciences 
University of Edinburgh, WGH, Crewe Road,  
Edinburgh EH4 2XU, UK 
Email: cathie.sudlow@ed.ac.uk 
 
Dr Kristiina Rannikmäe 
Clinical Research Training Fellow 
Division of Clinical Neurosciences 
University of Edinburgh 
Western General Hospital 
Crewe Road, Edinburgh EH4 2XU, UK 
Tel: +44 (0)7 808 664 850 






Collaborative systematic review of the reliability of spontaneous ICH classification 
systems – data collection tables 
 
Please complete as much of these summary tables A - D as you can (we do not 
expect you to be able to fill in all the boxes). Please fill in or tick the box with the 
appropriate answer in the grey-shaded cells. Please amend or supplement the 
information in the prefilled unshaded cells as appropriate.  
 
Please return the completed tables to the following address:  
Email: kristiina.rannikmae@ed.ac.uk   
and / or 
Address: 
Dr Kristiina Rannikmäe  
Clinical Research Training Fellow 
Bramwell Dott Building 
Division of Clinical Neurosciences 
University of Edinburgh 
Western General Hospital 
Crewe Road, Edinburgh EH4 2XU, UK 
and / or  














TABLE A: Study characteristics.  
TABLE A 
1. First author and publication 
title 
F. Palm: Intracerebral haemorrhage in a population-based 
stroke registry (LuSSt): incidence, aetiology, functional 
outcome and mortality. 
2. Publication year 2013 
3. Country where study conducted Germany 
4. Primary study aim To assess incidence, mortality, functional outcome and 
mortality of ICH based on a prospective population based 
stroke registry (the Ludwigshafen Stroke Study).  
5. Inclusion/exclusion criteria Excluded recurrent strokes, primary subdural and epidural 
haematomas, traumatic ICHs, tumour-related ICH, 
haemorrhagic transformation of an ischaemic stroke. Included 
cases with first-ever primary ICH over 5 years (between 2006-
2010). 
6. Number of included ICH cases 152 ICH cases  
7. Gender of ICH cases 50.7% male 
8. Ethnicity of ICH cases  
9. Mean age ± standard deviation 
of ICH cases 
71.3 ± 13.5 
10. Completeness of investigations 
for ICH 
CT for all; MRI for 20.4%; CTA/MRA/DSA for 26.3% 
11. Classification of ICH used in 
study 
All ICH cases divided into the following mutually exclusive 




And based on the underlying aetiology of the ICH (aetiological 
classification): 





12. Definitions of the classification 
categories 
Anatomical: 
1) lobar: cortical or subcortical bleeds   
2) deep: basal ganglia, infratentorial.             
 
Aetiological:  
1) Structural vascular pathology: AVM or 
cavernoma 
2) OAK-related: on warfarin with INR >2      
3) CAA: older than 54 years with lobar haematoma 
site                       
4) Hypertension: deep ICH with pre-ICH 
hypertension diagnosis (on medication, BP 
>140/90 on 2 or more measurements > 3 days 
after stroke) 
5) Undetermined 
13. Did more than 1 rater1 classify 
the ICH cases into one of the 
above mentioned categories? 
 Yes 
 No 
14. Did any one rater classify the 








15. Was the inter-rater reliability of 
the anatomical ICH 
classification system assessed?  
 Yes 
 No 
16. Was the inter-rater reliability of 
the aetiological ICH 
classification system assessed?  
 Yes 
 No 
17. Was the intra-rater reliability of 
the anatomical ICH 
classification system assessed? 
 Yes 
 No 
18. Was the intra-rater reliability of 
the aetiological ICH 
classification system assessed? 
 Yes 
 No 
Questions regarding assessing inter-rater reliability  





19. What statistical measure was used to assess 
reliability?  
  
20. Please provide the relevant value(s) of the 
statistical measure used (e.g. the kappa value 
with 95% confidence intervals where available) 
  
21. How many raters classified the cases?   
22. What was the experience and qualification of the 
raters? 
  
23. What institution(s) were the raters from?   
24. What was the information available to the raters 
(clinical information and information regarding 
investigations)? 
  
25. Was the same information available to each 
rater? 
  
26. What (if any) were the decision rules provided 
to the raters for classifying the cases? 
  
27. What format was the information provided in? 
(i.e. clinical notes, extracted information from 
clinical notes, computerised format etc) 
  
28. How long from symptom onset was 
classification done? 
  





30. Was there blinding between raters? (i.e.was each 
rater unaware of the other rater’s decisions?) 
  
31. Was each rater aware of being compared to 
other rater(s)? 
  
Questions regarding assessing intra-rater reliability
2 





32. What statistical measure was used to assess 
reliability? 
  
33. Please provide the relevant value(s) of the 
statistical measure used (e.g. the kappa value 
with 95% confidence intervals where available) 
  
34. How many times did the rater classify cases?   
35. What was the experience and qualification of the 
rater? 
  
36. What institution was the rater from?   
37. What information was available to the rater 






38. Was the same information available to the rater 
each time? 
  
39. What (if any) were the decision rules provided 
to the rater for classifying the cases? 
  
40. What format was the information provided in? 
(i.e. clinical notes, extracted information from 
clinical notes, computerised format etc) 
  
41. How long from symptom onset where the 
classifications done? 
  
42. What was the time interval between the ratings?   





44. Was there blinding? (i.e., was the rater unaware 
of his/her own previous decision and other 
raters’ decisions) 
  
45. Was the rater aware that intra-rater reliability 
was assessed (i.e., was he/she aware that his/her 




1 For the purposes of this study a “rater” is defined as a person assigning an ICH case into 
one of the two anatomical or five aetiological categories based on the classification of 
intracerebral haemorrhage used here. 2 If there are data for intra-observer reliability for 
more than one rater, please fill in this table for each rater separately. 3Prospective: i.e. 
patients were classified at the time or shortly after presenting and being recruited to the 
study. Retrospective: i.e. cases were classified some time after initial presentation, usually 
through retrieving and reviewing medical records 
 
TABLE B: Information regarding the proportions of cases classified to each 
category.  
Please insert the number of cases classified into each category (if more than one rater 
classified the cases please explain briefly in the space below the table how consensus was 




TABLE B_1 (anatomical classification) 
 Total Lobar Deep 
Number of cases in each  
category 
152   
TABLE B_2 (aetiological classification) 
 









in each  
category 




TABLE C: Numeric data to enable calculation of inter-rater reliability. Please complete a similar table to “example table C” for the 
152 ICH cases in your study (for example in an Excel spreadsheet or in Microsoft word). You are also very welcome to provide us with 
the relevant information in any other format you may have. We are interested in both the anatomical and aetiological classification 
system used.  
Please insert to each cell the number of raters that assigned case X to category Y. Please see an example table below: this table has been populated based on the 
following assumptions: there were 3 raters assigning 2 ICH cases to one of 2 categories. For example rater number 1 thought that case number 1 was a lobar bleed, 
but raters 2 and 3 thought that case number 1 was deep. Raters 1 and 3 thought that case number 2 was deep but rater number 2 thought that it was lobar. Etc. 
EXAMPLE TABLE C 
Categories → Lobar 
Deep 
  
2 ICH cases 
↓ 
  
Case 1  1 2 












TABLE D: Numeric data to enable calculation of intra-rater reliability. Please complete a similar table to “example table D” for the 
152 ICH cases in your study (for example in an Excel spreadsheet or in Microsoft word). You are also very welcome to provide us with 
the relevant information in any other format you may have. We are interested in both the anatomical and aetiological classification 
system used. 
Please insert to each cell the number of times a rater assigned case X to category Y. Please see an example table below: this table has been populated based on the 
following assumptions: one rater assigned 2 ICH cases to one of 2 categories, the rater did that twice with a 1 month interval. For example on first assessment the 
rater thought that case number 1 was a lobar bleed, but on the second assessment a month later classified it as deep. The rater thought that case number 2 was a 
deep bleed on both occasions. Etc. 
EXAMPLE TABLE D
4 
Categories → Lobar 
Deep 
  
2 ICH cases 
↓ 
  
Case 1  1 1 
Case 2 0 2 





Ovid Embase search strategy (1980 to March 2012) 
 
1. exp vascular amyloidosis/ 
2. exp Congo Red/ or exp amyloid/ or exp amyloid beta protein/ or exp amyloid 
precursor protein/  
3. exp cerebrovascular disease/ 
4. 2 and 3 
5. (amyloid angiopath$ or congophil$ angiopath$ or cerebral amyloid$ or 
cerebral congo?red or cerebral A?beta or cerebral beta?amyloid).tw. 
6. 1 or 4 or 5 
7. exp genetics/ or exp genetic disorder/ or genetic epidemiology/ or exp genetic 
analysis/ or exp population genetic parameters/ or quantitative trait/ or exp 
molecular genetics/ or exp genetic parameters/ or exp gene mapping/ or exp 
APOLIPOPROTEIN E2/ or exp APOLIPOPROTEIN/ or exp 
APOLIPOPROTEIN E3/ or exp APOLIPOPROTEIN E/ or exp 
APOLIPOPROTEIN E4/ 
8. (polymorphi$ or genotype$ or gene or genes or genetic$ or allele$ or mutat$ 
or apolipoprotein$ or apoprotein$ or APO?E$).tw. 
9. 7 or 8 
10. 6 and 9 
11. limit 10 to human 
 
Ovid Medline search strategy (1950 to March 2012) 
 
1. exp Cerebral Amyloid Angiopathy/ 
2. amyloidosis/ or  amyloidosis, familial/ or exp Amyloid beta-Protein/ or exp 
Amyloid/ or exp Congo Red/ 
3. exp cerebrovascular disorders/ 
4. 2 and 3 
5. (amyloid angiopath$ or congophil$ angiopath$ or cerebral amyloid$ or 
cerebral congo?red or cerebral A?beta or cerebral beta?amyloid).tw. 
6. 1 or 4 or 5 
7. exp genetics/ or exp genotype/ or exp inheritance patterns/ or exp linkage 
genetics/ or exp genes/ or exp genome/ or apolipoproteins/ or exp 
apolipoproteins e/ 
8. (polymorphi$ or genotype$ or gene or genes or genetic$ or allele$ or mutat$ 
or apolipoprotein$ or apoprotein$ or APO?E$).tw. 
9. Cerebral Amyloid Angiopathy/ge [Genetics] 
10. 7 or 8 
11. 6 and 10 
12. 9 or 11 








I am currently undergoing discussion with the editors of JNNP with regards to the 
necessity to make corrections to the published article (Rannikmäe et al. 2013). The 
published data in the article includes an error in the calculations for the fixed-effects 
meta-analysis of associations of APOE ɛ2+ versus ɛ2- genotypes with presence 
versus absence of CAA. The published overall pooled odds ratio for this analysis was 
0.73 (95% confidence intervals 0.53 to 1.00) and the p-value for this analysis was 
0.05. The corrected overall pooled odds ratio for this analysis is 0.64 (95% 
confidence intervals 0.47 to 0.86) and the p-value is 0.003. The error resulted from a 
mistake in the Microsoft Excel formula (omission of number 1) when calculating the 
standard error of the logarithm of the odds ratio (SE[logOR]) for the Premkumar 
study. This error resulted in entering the incorrect SE(logOR) to the Review Manager 
meta-analysis programme (incorrect value 4.1557; correct value 0.5734) which then 
assigned an incorrect weight to the study when meta-analysing the data across all 
included studies (incorrect weight 0.1%; correct weight 7.2%). The meta-analyses 
included in the thesis for the effects of APOE ɛ4 dose on presence versus absence of 
CAA also demonstrate different overall odds ratios compared to the published results 
(Rannikmäe et al. 2013) because since publishing the data, further statistical 
manipulations have enabled additional data to be included. The overall conclusions 
remain unchanged.  
 
Appendix 5 
Vonsattel scale for grading CAA:  
 
 Mild: amyloid is restricted to a congophilic rim around normal or atrophic 
smooth muscle fibers in the media of otherwise normal vessels 
 Moderate: media is replaced by amyloid and is thicker than normal, with no 
evidence of remote or recent blood leakage.  
 Severe: extensive amyloid deposition with focal wall fragmentation and at least 
one focus of paravascular leakage evidenced by the presence of erythrocytes or 














Appendix 6  





Dear Dr Chui,  
 
 
Re: Collaborative meta-analysis of APOE ε2 and CAA related vasculopathic changes 
 
We would like to invite you to join a collaborative meta-analysis of the association between 
APOE genotype and cerebral amyloid angiopathy related vasculopathic changes that lead to 
CAA-haemorrhage. We propose including as co-authors on any publication arising from this 
the relevant person/people from each contributing group. All that is required is for you to 
simply fill in the attached summary tables with data from your study described in: Chui HC, 
Zarow C, Mack WJ et al. Cognitive impact of subcortical vascular and Alzheimer's disease 
pathology. Ann Neurol 2006;60:677-687.  
 
Our interest in this topic has arisen after our recently completed systematic review and 
series of meta-analyses looking at the genetic associations of CAA (please find a brief 
summary of the results and the scientific background for this work attached).  
 
We are circulating this invitation by both email and post, so please contact us by whichever 
means is most convenient for you. Please respond by filling in and returning the attached 
forms by July 9th 2012. We will be delighted to discuss any aspect of this proposal with you 
by email or telephone.  
 
 
Yours sincerely,  
Dr Cathie Sudlow  
Clinical Reader & Honorary Consultant 
Neurologist, 
Chief Scientist & Senior Epidemiologist, UK 
Biobank 
Division of Clinical Neurosciences 
University of Edinburgh 
Western General Hospital 
Crewe Road, Edinburgh EH4 2XU, UK 
Email: cathie.sudlow@ed.ac.uk 
Dr Kristiina Rannikmäe 
Clinical Research Training Fellow 
Division of Clinical Neurosciences 
University of Edinburgh 
Western General Hospital 
Crewe Road, Edinburgh EH4 2XU, UK 







Collaborative meta-analysis of APOE ε2 and CAA related vasculopathic changes - 
data collection tables 
 
Please complete as much of these summary tables as you can (we do not expect 
you to be able to fill in all the boxes). Please fill in or mark the appropriate answer in 
the grey-shaded cells. If the information in the prefilled unshaded cells is incorrect, 
please amend as appropriate. We would also like to once more draw you attention 
to the fact that we are only collecting data about participants without CAA related 
haemorrhage.  
 
Please return the completed tables to the following address:  
 
Address: 
Dr Kristiina Rannikmäe  
Clinical Research Training Fellow 
Bramwell Dott Building 
Division of Clinical Neurosciences 
University of Edinburgh 
Western General Hospital 
Crewe Road, Edinburgh EH4 2XU, UK 
and / or  























Table 1 – study characteristics and methods  
First author and year of publication Chui 2006 
Country USA 
Brief description of participants People from the Ischaemic Vascular Dementia 
Programme (longitudinal study of subcortical 
ischaemic vascular dementia, AD and cognitively 
normal elderly people) 
No. of participants clinically demented  
No. of participants not clinically demented  
No. of participants for whom dementia status not 
known  
 
No. of participants with clinical and 
neuropathological diagnosis of AD 
 
No. of participants genotyped & assessed for CAA  
Mean age of participants at death  
Ethnicity of participants 86 % Caucasian 
% participants male  
Source of DNA Blood 
Were genotypes assigned using all data 
simultaneously or in batches? 
 
No. in whom genotyping attempted/in whom 
successful 
 
Genotyping method - PCR 
- Other (please specify) 
Were genotypers blinded to pathology data? - Yes 
- No 
Method for assessing CAA on Vonsattel scale Congo Red and/or H&E for all participants, IHC for 
some 
Method for assessing double-barrelling  
Method for assessing blood vessel dilatation and 
microaneurysms 
 
Method for assessing fibrinoid necrosis  
Qualification of the person who rated CAA and 
vasculopathic changes 
Neuropathologist 
Locations examined for CAA severity Frontal-, temporal-, parietal-, occipital cortex
 
Locations examined for CAA related vasculopathic 
changes 
 
Were pathologists blinded to genotype? Yes 
Were pathologists blinded to relevant clinical 








Table 2 – study data  
Please enter the number of participants with each genotype/phenotype feature in the grey cells.  




ε2/ε4 ε4/ε4 ε4/ε3 ε3/ε3 
Severity of CAA on the Vonsattel scale* 
Severe CAA        
Moderate CAA        
Mild CAA        
No CAA       
Total no. of participants       
CAA related changes 
Any severity of CAA 
Present       
Absent       
Total no. of participants       
Vasculopathic CAA: fibrinoid necrosis# 
Present       
Absent       
Total no. of participants       
Vasculopathic CAA: blood vessel dilatation and/or microaneurysm formation 
Present       
Absent       
Total no. of participants       
Vasculopathic CAA: double-barrelling of the vessel wall (“vessel within a vessel” appearance) 
Present        
Absent       
Total no. of participants       
*The Vonsattel scale is defined as follows: “Mild”- amyloid is restricted to a congophilic rim around 
normal or atrophic smooth muscle fibres in the media of otherwise normal vessels. “Moderate” - media 
is replaced by amyloid and is thicker than normal, with no evidence of remote or recent blood leakage. 
“Severe” - extensive amyloid deposition with focal wall fragmentation and at least one focus of 
paravascular leakage evidenced by the presence of erythrocytes or hemosiderin or both. Each 
participant should be graded according to the most advanced degree of CAA present among all vessels 
examined. If a different scoring method has been used, please explain. #Fibrinoid necrosis is defined as 
homogeneous discrete foci or segments of vascular wall with smudgy eosinophilic material that stain 
dark blue with PTAH (posphotungstic acid hematoxylin stain) or red with MSB (Martius Scarlett blue 






The overall number of participants for the other polymorphisms part varies slightly between 
the published manuscript (4703 participants) (Rannikmäe et al, 2013) and the thesis data 
(4617 participants). This is because for the Chapuis et al 2006 paper, different number of 
cases who have been genotyped and had pathological CAA assessment is reported in text and 
in table 2 (114 and 76 respectively). After further discussions, I have decided to use the 
smaller number for the purposes of the thesis, to make sure I do not overestimate the effect 
of this study. For the Durany et al 2000 paper, similarly it is unclear which groups of 
participants have been included in various parts of the analyses and after further discussions 
and review of the paper, I have decided that it is more appropriate for the purposes of the 
thesis to use the smaller number of AD cases (32) compared to the overall number of 80 
participants that include CAA-related ICH cases and controls. The overall conclusions remain 
unchanged.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
